

Effects of Intensive Blood-Pressure Control in Type 2 D

New England Journal of Medicine

362, 1575-1585

DOI: [10.1056/nejmoa1001286](https://doi.org/10.1056/nejmoa1001286)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Chick-Embryo Deaths Traced to Tincture of Iodine. <i>Journal of Infectious Diseases</i> , 1973, 127, 581-581.	1.9	0
4	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) <i>Tj ETQq1 1 0.784314 rgBT /Ove</i>	1.9	2,331
5	Emphasizing the Burden of Proof. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 565-567.	0.9	11
6	Editorial [Hot topic: Controversies in Hypertension Treatment (Guest Editors: Maciej Banach, Sverre E.) <i>Tj ETQq1 1 0.784314 rgBT /Ove</i>	0.8	18
7	Should regression or prevention of development of the electrocardiographic strain pattern be an indication for more aggressive treatment in hypertensive patients?. <i>Journal of Hypertension</i> , 2010, 28, 1617-1619.	0.3	0
8	Bringing Hypertension Under Control. <i>Nephrology Times</i> , 2010, 3, 2.	0.0	0
9	Editorial comment. <i>Current Opinion in Cardiology</i> , 2010, 25, 340-341.	0.8	0
10	A practical approach to the metabolic syndrome: review of current concepts and management. <i>Current Opinion in Cardiology</i> , 2010, 25, 502-512.	0.8	30
11	Diabetic Nephropathy: Eye on the Targets. <i>Nephrology Times</i> , 2010, 3, 12.	0.0	0
12	Ambulatory blood pressure monitoring: its time to move on!. <i>Journal of Hypertension</i> , 2010, 28, 2000-2002.	0.3	6
13	Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. <i>Current Opinion in Lipidology</i> , 2010, 21, 352-358.	1.2	34
14	Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish national diabetes register. <i>Journal of Hypertension</i> , 2010, 28, 2026-2035.	0.3	40
15	Crucial role of kidney function in resistance to antihypertensive therapy in patients with diabetes mellitus. <i>Journal of Hypertension</i> , 2010, 28, 2323-2328.	0.3	11
16	When Clinical Practice Guidelines Meet the Black Box. <i>Archives of Internal Medicine</i> , 2010, 170, 1013.	4.3	5
20	Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more. <i>Clinical Research in Cardiology</i> , 2010, 99, 337-344.	1.5	4
22	Diabetes in the Elderly. <i>Current Cardiovascular Risk Reports</i> , 2010, 4, 347-353.	0.8	0
23	Blood Pressure and Cognitive Outcome. <i>Current Cardiovascular Risk Reports</i> , 2010, 4, 369-375.	0.8	4
24	Establishing Targets for Hypertension Control in Patients with Comorbidities. <i>Current Hypertension Reports</i> , 2010, 12, 465-473.	1.5	2

#	ARTICLE	IF	CITATIONS
25	Are There Benefits of Antihypertensive Therapy Beyond Blood Pressure Lowering?. Current Hypertension Reports, 2010, 12, 440-447.	1.5	5
26	Blood Pressure Target in Individuals Without Diabetes: What Is the Evidence?. American Journal of Kidney Diseases, 2010, 56, 434-438.	2.1	4
27	Blood Pressure Control in Type 2 Diabetes Mellitus. American Journal of Kidney Diseases, 2010, 56, 1029-1031.	2.1	4
28	Reducing cardiovascular risk in type 2 diabetes mellitus. Medicine, 2010, 38, 632-637.	0.2	0
29	Cardiovascular Disease Risk Factors, Type 2 Diabetes Mellitus, and the Framingham Heart Study. Trends in Cardiovascular Medicine, 2010, 20, 90-95.	2.3	135
30	Effectiveness of Lowering Blood Pressure to Prevent Stroke Versus to Prevent Coronary Events. American Journal of Cardiology, 2010, 106, 825-829.	0.7	46
31	Is There Accord in ACCORD? Lower Blood Pressure Targets in Type 2 Diabetes Does Not Lead to Fewer Cardiovascular Events Except for Reductions in Stroke. Journal of Clinical Hypertension, 2010, 12, 472-477.	1.0	5
32	Are the Recommended Blood Pressure Goals in High-Risk Patients Based on Outcome Data or Opinion?. Journal of Clinical Hypertension, 2010, 12, 879-880.	1.0	0
33	Metabolic syndrome predicts vascular changes in whole body magnetic resonance imaging in patients with long standing diabetes mellitus. Cardiovascular Diabetology, 2010, 9, 44.	2.7	7
34	Renal protection in diabetes: lessons from ONTARGET®. Cardiovascular Diabetology, 2010, 9, 60.	2.7	26
35	Multiple uncontrolled conditions and blood pressure medication intensification: an observational study. Implementation Science, 2010, 5, 55.	2.5	1
36	Half full, half empty, or negative? Results of recent clinical trials. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2010, 27, 174-175.	0.2	0
37	The glucose triad and its role in comprehensive glycaemic control: current status, future management. International Journal of Clinical Practice, 2010, 64, 1705-1711.	0.8	59
38	Hypertension in patients with diabetes: questions. Journal of Diabetes, 2010, 2, 128-129.	0.8	2
39	The Avandia debate: An unhappy conclusion. Journal of Diabetes, 2010, 2, 221-222.	0.8	3
40	Optimal management of hypertension in elderly patients. Integrated Blood Pressure Control, 2010, 3, 145.	0.4	3
41	Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vascular Health and Risk Management, 2010, 6, 749.	1.0	45
42	Diabetic microvascular complications: possible targets for improved macrovascular outcomes. International Journal of Nephrology and Renovascular Disease, 2011, 4, 1.	0.8	9

#	ARTICLE	IF	CITATIONS
43	Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1085-1088.	1.8	25
44	The Goal Blood Pressure in Type 2 Diabetes: Do We Have an ACCORD?. <i>The Consultant Pharmacist</i> , 2010, 25, 686-688.	0.4	1
46	US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension, 1988-2008. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 2043.	3.8	1,689
47	Effects of Intensive Blood Pressure Control in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>Circulation</i> , 2010, 122, 847-849.	1.6	55
48	What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes?. <i>Circulation</i> , 2010, 122, 2142-2151.	1.6	207
49	Management of High Blood Pressure in Blacks. <i>Hypertension</i> , 2010, 56, 780-800.	1.3	398
50	ACCORD(ing) to a Trialist. <i>Circulation</i> , 2010, 122, 841-843.	1.6	5
51	Secular Trends in Treatment and Control of Type 2 Diabetes in an American Indian Population: A 30-Year Longitudinal Study. <i>Diabetes Care</i> , 2010, 33, 2383-2389.	4.3	10
52	Intensive lowering of systolic blood pressure to a target of less than 120 mm Hg has no effect on the rate of fatal and non-fatal major cardiovascular events in high-risk patients with type 2 diabetes. <i>Evidence-Based Medicine</i> , 2010, 15, 142-143.	0.6	1
53	Counterpoint: Intensive Glucose Control and Mortality in ACCORD--Still Looking for Clues. <i>Diabetes Care</i> , 2010, 33, 2722-2724.	4.3	34
54	Blood Pressure Control in Diabetes: Where Is the Ownership?. <i>Clinical Diabetes</i> , 2010, 28, 97-98.	1.2	2
55	Trends in Diabetes Medication Use and Prevalence of Geriatric Syndromes in Older Mexican Americans from 1993/1994 to 2004/2005. <i>Annals of Pharmacotherapy</i> , 2010, 44, 1376-1383.	0.9	13
56	Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. <i>Annals of the New York Academy of Sciences</i> , 2010, 1212, 29-40.	1.8	22
57	Strategies and Goals for Hypertension Control in Patients With Diabetes Mellitus. <i>Hypertension</i> , 2010, 56, 24-25.	1.3	0
58	Pharmacologic Treatment of Hypertension. , 2010, , 430-444.		0
59	Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 61.	3.8	578
60	Risk of Diabetes and Cardiovascular Disease: Best to Return Back to the Basics. <i>Archives of Internal Medicine</i> , 2010, 170, 1575-7.	4.3	4
61	New Recommendations for Treating Hypertension in Black Patients. <i>Hypertension</i> , 2010, 56, 801-803.	1.3	16

#	ARTICLE	IF	CITATIONS
62	Improving blood pressure control rates by optimizing combination antihypertensive therapy. Expert Opinion on Pharmacotherapy, 2010, 11, 2011-2026.	0.9	11
63	BP reduction in patients with diabetes—uncertainties remain. Nature Reviews Cardiology, 2010, 7, 609-611.	6.1	0
64	J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. European Heart Journal, 2010, 31, 2897-2908.	1.0	318
65	Clinical trials update from the American College of Cardiology meeting 2010: DOSE, ASPIRE, CONNECT, STICH, STOP-AF, CABANA, RACE II, EVEREST II, ACCORD, and NAVIGATOR. European Journal of Heart Failure, 2010, 12, 623-629.	2.9	60
66	Blood Pressure Control in Chronic Kidney Disease: Is Less Really More?. Journal of the American Society of Nephrology: JASN, 2010, 21, 1086-1092.	3.0	91
67	Risk-Factor Medicine: An Industry out of Control?. Cardiology, 2010, 117, 64-67.	0.6	6
68	Debate: PRO Position. People with Chronic Kidney Disease Should Have a Blood Pressure Lower than 130/80 mm Hg. American Journal of Nephrology, 2010, 32, 370-373.	1.4	5
69	Rethinking targets of blood pressure and guidelines for hypertension clinical management. Nephrology Dialysis Transplantation, 2010, 25, 3465-3471.	0.4	6
72	Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. European Heart Journal, 2010, 31, 2837-2840.	1.0	62
73	Dietary Therapy in Hypertension. New England Journal of Medicine, 2010, 363, 1580-1583.	13.9	0
74	ACCORD and Risk-Factor Control in Type 2 Diabetes. New England Journal of Medicine, 2010, 362, 1628-1630.	13.9	57
75	Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. New England Journal of Medicine, 2010, 363, 233-244.	13.9	1,091
76	Blood Pressure Control in Type 2 Diabetes. New England Journal of Medicine, 2010, 363, 695-697.	13.9	3
77	ACCORD Blood Pressure and ACCORD Lipid: how low can we go?. Nature Reviews Endocrinology, 2010, 6, 483-484.	4.3	1
78	Cardiovascular Disease and Glycemic Treatment. Diabetes Care, 2010, 33, e134-e139.	4.3	5
79	Efficacy and Safety of Olmesartan Medoxomil in Patients with Stage 1 Hypertension: Blood Pressure Lowering and Goal Achievement. Postgraduate Medicine, 2010, 122, 57-67.	0.9	1
80	National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney International, 2010, 78, 726-736.	2.6	48
82	The combined impact of blood pressure category and glucose abnormality on the incidence of cardiovascular diseases in a Japanese urban cohort: the Suita Study. Hypertension Research, 2010, 33, 1238-1243.	1.5	49

#	ARTICLE	IF	CITATIONS
84	The doctor needs to see you now: accelerating the care of patients with uncontrolled hypertension. Expert Review of Cardiovascular Therapy, 2010, 8, 1501-1503.	0.6	3
85	Lower Blood Pressure Goals in High-Risk Cardiovascular Patients: Are They Defensible?. Cardiology Clinics, 2010, 28, 447-452.	0.9	2
86	Risque cardiovasculaire résiduel dans l'hypertension artérielle traitée. Medecine Des Maladies Metaboliques, 2010, 4, 371-376.	0.1	0
87	Respuesta del Dr. Marcos Lahera Vargas. Avances En Diabetología, 2010, 26, 366-369.	0.1	0
88	Maladie coronaire du diabétique. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2010, 2010, 23-28.	0.0	0
89	Respuesta del Dr. Juan José Chillarín Jordán. Avances En Diabetología, 2010, 26, 265-267.	0.1	0
90	Secondary stroke prevention. Nature Reviews Neurology, 2010, 6, 477-486.	4.9	27
91	Novel therapeutic targets for hypertension. Nature Reviews Cardiology, 2010, 7, 431-441.	6.1	101
93	Hypertension 2010: what was new for the cardiologist?. Expert Opinion on Pharmacotherapy, 2010, 11, 2579-2597.	0.9	6
94	Treating high blood pressure: Is reaching the target more important than the means? No, the means are important. European Journal of Internal Medicine, 2010, 21, 478-483.	1.0	0
95	Treating high blood pressure: Is reaching the target more important than the means? Yes, the target is more important. European Journal of Internal Medicine, 2010, 21, 473-477.	1.0	0
96	Dislipemia aterogénica: una llamada de atención sobre su papel en el riesgo residual. Clínica E Investigación En Arteriosclerosis, 2010, 22, 162-166.	0.4	0
97	ASH Hypertension Community Outreach Program: taking action to address a "neglected disease". Journal of the American Society of Hypertension, 2010, 4, 157-162.	2.3	0
98	Mixed messages on systemic therapies for diabetic retinopathy " Authors' reply. Lancet, The, 2010, 376, 1462.	6.3	3
99	The Polypill in the Prevention of Cardiovascular Diseases. Circulation, 2010, 122, 2078-2088.	1.6	152
100	Polypharmacy and Combination Therapy in the Management of Hypertension in Elderly Patients with Co-Morbid Diabetes Mellitus. Drugs and Aging, 2010, 27, 871-883.	1.3	41
101	Effect of an Olmesartan Medoxomil-Based Treatment Algorithm on Systolic Blood Pressure in Patients with Stage 1 or 2 Hypertension. American Journal of Cardiovascular Drugs, 2010, 10, 239-246.	1.0	4
102	Therapeutic Potential of Alogliptin, a New Dual PPAR- α/δ Agonist. American Journal of Cardiovascular Drugs, 2010, 10, 209-216.	1.0	38

#	ARTICLE	IF	CITATIONS
103	Management of high blood pressure in type 2 diabetes: perindopril/indapamide fixed-dose combination and the ADVANCE trial. Expert Opinion on Pharmacotherapy, 2010, 11, 1647-1657.	0.9	6
104	An Evaluation of Diabetes-Related Measures of Control After 6 Months of Clinical Pharmacy Specialist Intervention. Journal of Pharmacy Practice, 2011, 24, 332-338.	0.5	23
105	Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patients. Current Medical Research and Opinion, 2011, 27, 1995-2008.	0.9	12
106	Impact of new clinical trials on recent guidelines on hypertension management. Annals of Medicine, 2011, 43, 124-132.	1.5	7
107	The ACCORD Study: The Devil Is in the Details. Metabolic Syndrome and Related Disorders, 2011, 9, 81-84.	0.5	3
108	The ROADMAP trial: olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. Expert Opinion on Pharmacotherapy, 2011, 12, 2421-2424.	0.9	5
109	Blood pressure lowering in patients with diabetes—“one level might not fit all. Nature Reviews Cardiology, 2011, 8, 42-49.	6.1	16
110	Controversies in the cardiovascular management of type 2 diabetes. Heart, 2011, 97, 6-14.	1.2	24
111	Management issues in hypertensive diabetics. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2011, 53, 144-148.	0.2	1
112	Peripheral artery disease. Part 2: medical and endovascular treatment. Nature Reviews Cardiology, 2011, 8, 429-441.	6.1	32
113	Treatment and Landmark Clinical Trials for Renoprotection. Contributions To Nephrology, 2011, 170, 184-195.	1.1	10
114	Fenofibrate. American Journal of Cardiovascular Drugs, 2011, 11, 227-247.	1.0	71
115	HTA et diabète: nouveaux niveaux de preuves et prise en charge. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2011, 2011, 24-30.	0.0	0
116	Analogues du GLP-1 et éducation du patient diabétique de type 2. Pharmacien Hospitalier, 2011, 46, 3.	0.1	1
117	Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus. Mayo Clinic Proceedings, 2011, 86, 444-456.	1.4	104
119	Influence of Time of Day of Blood Pressure-Lowering Treatment on Cardiovascular Risk in Hypertensive Patients With Type 2 Diabetes. Diabetes Care, 2011, 34, 1270-1276.	4.3	196
120	Overall Mortality in Diabetes Mellitus: Where Do We Stand Today?. Diabetes Technology and Therapeutics, 2011, 13, S-65-S-74.	2.4	42
121	Hypertension artérielle et diabète: nouvelles données apportées par l'étude ACCORD-Blood Pressure (ACCORD-BP). Médecine Des Maladies Metaboliques, 2011, 5, 312-316.	0.1	0

#	ARTICLE	IF	CITATIONS
122	Le risque cardiovasculaire. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2011, 2011, 9-15.	0.0	0
123	Predicting the Future Burden of Diabetes in Alberta from 2008 to 2035. Canadian Journal of Diabetes, 2011, 35, 274-281.	0.4	10
124	¿Es posible prevenir la nefropatía diabética? El estudio ROADMAP. Hipertension Y Riesgo Vascular, 2011, 28, 24-29.	0.3	0
125	Blood Pressure and Stroke. Journal of the American College of Cardiology, 2011, 57, 114-115.	1.2	3
126	FAME and Coronary Stent Investigations. Journal of the American College of Cardiology, 2011, 57, 115-116.	1.2	4
127	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American College of Cardiology, 2011, 57, 2037-2114.	1.2	419
128	The Year in Atherothrombosis. Journal of the American College of Cardiology, 2011, 58, 779-791.	1.2	7
129	Decreasing Sleep-Time Blood Pressure Determined by Ambulatory Monitoring Reduces Cardiovascular Risk. Journal of the American College of Cardiology, 2011, 58, 1165-1173.	1.2	270
130	ACCF/AHA/AMA-PCPI 2011 Performance Measures for Adults With Coronary Artery Disease and Hypertension. Journal of the American College of Cardiology, 2011, 58, 316-336.	1.2	58
131	Sleep-Time Blood Pressure. Journal of the American College of Cardiology, 2011, 58, 1174-1175.	1.2	16
132	INCREASE IN TREATMENT-REFRACTORY HYPERTENSION: PROGRESS IN CURRENT TREATMENT BY PRIMARY CARE. Hipertension Y Riesgo Vascular, 2011, 28, 196-203.	0.3	0
133	Telmisartan for the management of patients at high cardiovascular risk. Current Medical Research and Opinion, 2011, 27, 1673-1682.	0.9	23
134	Special considerations on the management of Latino patients with type 2 diabetes mellitus. Current Medical Research and Opinion, 2011, 27, 969-979.	0.9	16
135	Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. , 2011, , CD008143.		57
136	AGE restriction in diabetes mellitus: a paradigm shift. Nature Reviews Endocrinology, 2011, 7, 526-539.	4.3	209
140	Features of Mobile Diabetes Applications: Review of the Literature and Analysis of Current Applications Compared Against Evidence-Based Guidelines. Journal of Medical Internet Research, 2011, 13, e65.	2.1	397
141	Individualizing treatment targets in diabetes care. Nature Reviews Endocrinology, 2011, 7, 67-68.	4.3	16
142	Manipine for Hypertension not Controlled by Dual Therapy in Patients with Diabetes Mellitus. Clinical Drug Investigation, 2011, 31, 427-434.	1.1	9

#	ARTICLE	IF	CITATIONS
143	Heart Disease and Stroke Statistics—2011 Update. <i>Circulation</i> , 2011, 123, e18-e209.	1.6	4,379
144	Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. <i>New England Journal of Medicine</i> , 2011, 364, 818-828.	13.9	901
145	Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations. <i>Hypertension Research</i> , 2011, 34, 714-721.	1.5	28
146	Choosing Targets for Glycaemia, Blood Pressure and Low-Density Lipoprotein Cholesterol in Elderly Individuals with Diabetes Mellitus. <i>Drugs and Aging</i> , 2011, 28, 945-960.	1.3	15
147	Medical Management of the Patient with Intermittent Claudication. <i>Cardiology Clinics</i> , 2011, 29, 363-379.	0.9	10
148	Guidelines for the Primary Prevention of Stroke. <i>Stroke</i> , 2011, 42, 517-584.	1.0	1,289
149	Hypertension in Diabetic Nephropathy: Epidemiology, Mechanisms, and Management. <i>Advances in Chronic Kidney Disease</i> , 2011, 18, 28-41.	0.6	159
150	Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. , 2011, , .		11
151	Clinical Inertia as a Clinical Safeguard. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1591.	3.8	74
152	Cardiometabolic Risk in Canada: A Detailed Analysis and Position Paper by the Cardiometabolic Risk Working Group. <i>Canadian Journal of Cardiology</i> , 2011, 27, e1-e33.	0.8	138
153	Canadian Hypertension Education Program: The Science Supporting New 2011 CHEP Recommendations With an Emphasis on Health Advocacy and Knowledge Translation. <i>Canadian Journal of Cardiology</i> , 2011, 27, 407-414.	0.8	18
154	The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. <i>Canadian Journal of Cardiology</i> , 2011, 27, 415-433.e2.	0.8	127
155	The combination of amlodipine and angiotensin receptor blocker or diuretics in high risk hypertensive patients. <i>International Journal of Cardiology</i> , 2011, 152, S24.	0.8	0
156	I. Stroke in General. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2011, 20, S7-S30.	0.7	22
158	Primary and Secondary Prevention Strategy for Cardiovascular Disease in Diabetes Mellitus. <i>Cardiology Clinics</i> , 2011, 29, 47-70.	0.9	19
159	Initial hypertension treatment: one combination fits most?. <i>Journal of the American Society of Hypertension</i> , 2011, 5, 66-75.	2.3	7
160	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. <i>Journal of the American Society of Hypertension</i> , 2011, 5, 259-352.	2.3	125
163	Why Hypotheses Informed by Observation Are Often Wrong: Results of Randomized Controlled Trials Challenge Chronic Disease Management Strategies Based on Epidemiological Evidence. <i>Journal of Managed Care Pharmacy</i> , 2011, 17, 224-231.	2.2	4

#	ARTICLE	IF	CITATIONS
164	Clinical utility of fixed-combination telmisartan–amlodipine in the treatment of hypertension. <i>Integrated Blood Pressure Control</i> , 2011, 4, 27.	0.4	3
165	Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination. <i>Integrated Blood Pressure Control</i> , 2011, 4, 73.	0.4	7
166	The Potential for Increasing Quality and Reducing Costs. <i>Annals of Internal Medicine</i> , 2011, 155, 564.	2.0	0
167	Measuring Blood Pressure for Decision Making and Quality Reporting. <i>Annals of Internal Medicine</i> , 2011, 155, 565.	2.0	2
168	Measuring Blood Pressure for Decision Making and Quality Reporting. <i>Annals of Internal Medicine</i> , 2011, 155, 565.	2.0	1
169	Ambulatory Blood Pressure Monitoring in Diabetes and Obesityâ€™A Review. <i>International Journal of Hypertension</i> , 2011, 2011, 1-8.	0.5	20
170	Prevalence, Awareness, and Control of Hypertension among Diabetic Koreans. <i>Diabetes and Metabolism Journal</i> , 2011, 35, 337.	1.8	6
171	Prevention for Micro- and Macro-Vascular Complications in Diabetic Patients. , 0, , .		0
172	Glycaemic Control and Protection of the Vasculature from Glucose Toxicity. , 2011, , .		0
173	The Significance of the J-Curve in Hypertension and Coronary Artery Diseases. <i>Korean Circulation Journal</i> , 2011, 41, 349.	0.7	6
174	Treatment options for hypertension in high-risk patients. <i>Vascular Health and Risk Management</i> , 2011, 7, 137.	1.0	7
175	Inhaled Long-Acting Î²-Agonists Versus Anticholinergics in Older Patients With Chronic Obstructive Pulmonary Disease. <i>Annals of Internal Medicine</i> , 2011, 155, 561.	2.0	0
176	Hypertension in Chronic Kidney Disease: Navigating the Evidence. <i>International Journal of Hypertension</i> , 2011, 2011, 1-9.	0.5	98
177	Is it possible to prevent cardiovascular diseases with comprehensive health screening and evaluation program?. <i>Health Evaluation and Promotion</i> , 2011, 38, 600-606.	0.0	0
178	Olmesartan/amlodipine: a review of its use in the management of hypertension. <i>Vascular Health and Risk Management</i> , 2011, 7, 183.	1.0	27
179	Prognosis after Stroke. , 2011, , 219-241.		5
180	Comparative Effectiveness of Guidelines for the Management of Hyperlipidemia and Hypertension for Type 2 Diabetes Patients. <i>PLoS ONE</i> , 2011, 6, e16170.	1.1	12
181	Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective. <i>Current Opinion in Lipidology</i> , 2011, 22, 55-61.	1.2	41

#	ARTICLE	IF	CITATIONS
182	Is blood pressure control to less than 140/less than 90 mmHg in 50% of all hypertensive patients as good as we can do in the USA: or is this as good as it gets?. <i>Current Opinion in Cardiology</i> , 2011, 26, 300-307.	0.8	16
183	Clinical practice and implications of recent diabetes trials. <i>Current Opinion in Cardiology</i> , 2011, 26, 288-293.	0.8	8
184	What should be the blood pressure target for diabetic patients?. <i>Current Opinion in Cardiology</i> , 2011, 26, 308-313.	0.8	9
186	Pathogenesis and management of hypertension after kidney transplantation. <i>Journal of Hypertension</i> , 2011, 29, 2283-2294.	0.3	39
187	Immune-related effects in hypertension and target-organ damage. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 113-117.	1.0	51
188	Which patients with diabetes should undergo ambulatory blood pressure monitoring?. <i>Journal of Hypertension</i> , 2011, 29, 236-241.	0.3	10
189	The Wrong Tool for the Job: Diabetes Public Health Programs and Practice Guidelines. <i>American Journal of Public Health</i> , 2011, 101, 1871-1873.	1.5	0
190	A new dimension in hypertension management with the amlodipine/perindopril combination. <i>Journal of Hypertension</i> , 2011, 29, S15-S21.	0.3	3
191	The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the Diabetic REtinopathy Candesartan Trials-Protect 2 study. <i>Journal of Hypertension</i> , 2011, 29, 1457-1462.	0.3	17
192	Diagnosis of diabetes mellitus as a cardiovascular risk equivalent or risk factor and implications in drug therapy management. <i>Diabetes Management</i> , 2011, 1, 615-626.	0.5	0
193	Choice of Antihypertensive Treatment in Subjects with Pre-Diabetes. Is There a Dream After the Navigator. <i>Current Vascular Pharmacology</i> , 2011, 9, 715-722.	0.8	6
194	Reduced Progression of Diabetic Microvascular Complications With Islet Cell Transplantation Compared With Intensive Medical Therapy. <i>Transplantation</i> , 2011, 91, 373-378.	0.5	185
195	Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. <i>Yearbook of Cardiology</i> , 2011, 2011, 80-82.	0.0	1
196	Masked Hypertension and Diabetes. <i>Current Hypertension Reviews</i> , 2011, 7, 1-4.	0.5	0
197	Target Blood Pressure for Treatment of Isolated Systolic Hypertension in the Elderly: Valsartan in Elderly Isolated Systolic Hypertension Study. <i>Yearbook of Cardiology</i> , 2011, 2011, 71-73.	0.0	0
198	Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. <i>Yearbook of Cardiology</i> , 2011, 2011, 76-78.	0.0	0
199	Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. <i>Yearbook of Medicine</i> , 2011, 2011, 209-210.	0.1	0
200	Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease. <i>Yearbook of Cardiology</i> , 2011, 2011, 50-52.	0.0	0

#	ARTICLE	IF	CITATIONS
201	Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. Yearbook of Cardiology, 2011, 2011, 67-69.	0.0	0
202	Target Blood Pressure for Treatment of Isolated Systolic Hypertension in the Elderly: Valsartan in Elderly Isolated Systolic Hypertension Study. Yearbook of Medicine, 2011, 2011, 377-379.	0.1	0
203	Reducing cardiovascular risk factors in patients with prediabetes. Diabetes Management, 2011, 1, 423-438.	0.5	1
204	Measuring Blood Pressure for Decision Making and Quality Reporting: Where and How Many Measures?. Annals of Internal Medicine, 2011, 154, 781.	2.0	164
205	Systematic Review: Blood Pressure Target in Chronic Kidney Disease and Proteinuria as an Effect Modifier. Annals of Internal Medicine, 2011, 154, 541.	2.0	292
206	Blood Pressure Target in Chronic Kidney Disease and Proteinuria as an Effect Modifier. Annals of Internal Medicine, 2011, 155, 208.	2.0	0
207	Impact of recent landmark clinical trials on hypertension treatment. Clinical Investigation, 2011, 1, 1141-1154.	0.0	3
208	ACCORD microvascular and Eye substudy: should the results change our practice?. Diabetes Management, 2011, 1, 389-396.	0.5	0
209	Age and Effectiveness of Implantable Cardioverter-Defibrillators. Annals of Internal Medicine, 2011, 155, 201.	2.0	0
210	Routine Sterile Gloving and Contamination Rates in Blood Culture. Annals of Internal Medicine, 2011, 155, 203.	2.0	0
211	Review: Lowering systolic BP to ≤ 135 mm Hg reduces CV events in type 2 diabetes/IFG/IGT. Annals of Internal Medicine, 2011, 155, JC5.	2.0	0
212	The challenge of managing hypertension in chronic renal disease. Journal of Renal Nursing, 2011, 3, 58-62.	0.1	0
214	Music Lessons. Annals of Internal Medicine, 2011, 155, 206.	2.0	0
215	The Effect on Surrogates of Making Treatment Decisions for Others. Annals of Internal Medicine, 2011, 155, 206.	2.0	0
216	Blood Pressure Target in Chronic Kidney Disease and Proteinuria as an Effect Modifier. Annals of Internal Medicine, 2011, 155, 207.	2.0	0
217	The Effect on Surrogates of Making Treatment Decisions for Others. Annals of Internal Medicine, 2011, 155, 206.	2.0	0
218	Music Lessons. Annals of Internal Medicine, 2011, 155, 207.	2.0	0
219	Tripping Over the HIPAA Hurdle. Annals of Internal Medicine, 2011, 155, 203.	2.0	0

#	ARTICLE	IF	CITATIONS
220	The Effect on Surrogates of Making Treatment Decisions for Others. <i>Annals of Internal Medicine</i> , 2011, 155, 206.	2.0	10
221	Analysis of Health Benefits and Cost-Effectiveness of Mammography for Breast Cancer. <i>Annals of Internal Medicine</i> , 2011, 155, 566.	2.0	4
222	Age and Effectiveness of Implantable Cardioverter-Defibrillators. <i>Annals of Internal Medicine</i> , 2011, 155, 201.	2.0	0
223	The Potential for Increasing Quality and Reducing Costs. <i>Annals of Internal Medicine</i> , 2011, 155, 563.	2.0	0
224	An Update on the Comparative Effectiveness and Safety of Medications for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2011, 155, 562.	2.0	0
225	Update in Endocrinology: Evidence Published in 2010. <i>Annals of Internal Medicine</i> , 2011, 154, 684.	2.0	0
226	Addressing Cardiovascular Risk in Patients With Type 2 Diabetes: Focus on Primary Care. <i>American Journal of the Medical Sciences</i> , 2011, 341, 132-140.	0.4	6
227	Hepatitis B Virus in the United States. <i>Annals of Internal Medicine</i> , 2011, 155, 204.	2.0	4
228	Hepatitis B Virus in the United States. <i>Annals of Internal Medicine</i> , 2011, 155, 205.	2.0	0
229	Hospital Volume and Processes, Outcomes, and Costs of Care for Congestive Heart Failure. <i>Annals of Internal Medicine</i> , 2011, 155, 202.	2.0	1
230	Low incidence of cardiovascular events in Japanese patients with Type 2 diabetes in primary care settings: a prospective cohort study (JDDM 20). <i>Diabetic Medicine</i> , 2011, 28, 1221-1228.	1.2	38
231	Remission of diabetic nephropathy in type 2 diabetic Asian population: role of tight glucose and blood pressure control. <i>European Journal of Clinical Investigation</i> , 2011, 41, 870-878.	1.7	16
232	Repeat measurements of glycated haemoglobin A _{1c} and N-terminal pro-BNP type natriuretic peptide: divergent behaviour in diabetes mellitus. <i>European Journal of Clinical Investigation</i> , 2011, 41, 1292-1298.	1.7	14
233	The Management of Hypertension for Primary Stroke Prevention: A Proposed Approach. <i>International Journal of Stroke</i> , 2011, 6, 144-149.	2.9	8
234	The Secondary Prevention of Small Subcortical Strokes (SPS3) Study. <i>International Journal of Stroke</i> , 2011, 6, 164-175.	2.9	136
235	Stratifying and tailoring HbA _{1c} control targets for adults with Type 2 diabetes: Interpretation of the consensus proposed by the Chinese Society of Endocrinology. <i>Journal of Diabetes</i> , 2011, 3, 201-207.	0.8	4
236	Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids. <i>Journal of Diabetes</i> , 2011, 3, 257-260.	0.8	3
237	Barriers to Blood Pressure Control: A STITCH Substudy. <i>Journal of Clinical Hypertension</i> , 2011, 13, 73-80.	1.0	33

#	ARTICLE	IF	CITATIONS
238	Treating the Black Hypertensive in 2010: Achieve Lower Targets While Awaiting More Definitive Evidence. <i>Journal of Clinical Hypertension</i> , 2011, 13, 1-4.	1.0	5
239	CON: Blood Pressure Treatment Goal for Patients With Diabetes Should Be $\leq 130/80\text{ mm Hg}$. <i>Journal of Clinical Hypertension</i> , 2011, 13, 263-265.	1.0	5
240	Efficacy of Amlodipine and Olmesartan Medoxomil in Hypertensive Patients With Diabetes and Obesity. <i>Journal of Clinical Hypertension</i> , 2011, 13, 422-430.	1.0	9
241	Blood Pressure Targets in Diabetes: Is This the Time for Change?â€”PRO (Rebuttal). <i>Journal of Clinical Hypertension</i> , 2011, 13, 266-267.	1.0	0
242	Blood Pressure Targets in Diabetes: Is This the Time for Change?. <i>Journal of Clinical Hypertension</i> , 2011, 13, 258-262.	1.0	5
243	The Role of Antiplatelets in Hypertension and Diabetes Mellitus. <i>Journal of Clinical Hypertension</i> , 2011, 13, 305-313.	1.0	9
244	Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection. <i>Journal of Clinical Hypertension</i> , 2011, 13, 244-251.	1.0	333
245	Blood Pressure Targets in Diabetes: Is This the Time for Change?â€”CON (Rebuttal). <i>Journal of Clinical Hypertension</i> , 2011, 13, 268-269.	1.0	1
246	Hypertension in Diabetes: Treatment Considerations. <i>Journal of Clinical Hypertension</i> , 2011, 13, 314-318.	1.0	5
247	Pathophysiology, Prevention and Management of Chronic Kidney Disease in the Hypertensive Patient With Diabetes Mellitus. <i>Journal of Clinical Hypertension</i> , 2011, 13, 252-257.	1.0	12
248	Value of Angiotensin Receptor Blocker Therapy in Diabetes. <i>Journal of Clinical Hypertension</i> , 2011, 13, 290-295.	1.0	6
249	Reninâ€”Angiotensinâ€”Aldosterone System in Diabetes and Hypertension. <i>Journal of Clinical Hypertension</i> , 2011, 13, 224-237.	1.0	106
250	Are There Pleiotropic Effects of Antihypertensive Medications or Is It All About the Blood Pressure in the Patient With Diabetes and Hypertension?. <i>Journal of Clinical Hypertension</i> , 2011, 13, 301-304.	1.0	8
251	Hypertension and Lipid Management in Prediabetic States. <i>Journal of Clinical Hypertension</i> , 2011, 13, 270-274.	1.0	4
252	Diabetes and Hypertension: A Comprehensive Report on Management and the Prevention of Cardiovascular and Renal Complications. <i>Journal of Clinical Hypertension</i> , 2011, 13, 221-223.	1.0	2
253	Thiazide Diuretics and β -Blockers in the Treatment of Hypertension in Diabetes Mellitus. <i>Journal of Clinical Hypertension</i> , 2011, 13, 296-300.	1.0	11
254	â€œROADMAPâ€”Controversies. <i>Journal of Clinical Hypertension</i> , 2011, 13, 628-628.	1.0	1
255	PROGRESS: Prevention of Recurrent Stroke. <i>Journal of Clinical Hypertension</i> , 2011, 13, 693-702.	1.0	41

#	ARTICLE	IF	CITATIONS
256	Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy and Amlodipine Monotherapy in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus. <i>Journal of Clinical Hypertension</i> , 2011, 13, 889-897.	1.0	6
257	Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 1-23.	1.5	253
258	Management of chronic kidney disease. <i>Medicine</i> , 2011, 39, 407-413.	0.2	7
260	Hypertension After Kidney Transplant. <i>American Journal of Kidney Diseases</i> , 2011, 57, 331-341.	2.1	132
261	Olmesartan to Prevent the Development of Microalbuminuria: Is It New? Is It True? Is It Important?. <i>American Journal of Kidney Diseases</i> , 2011, 58, 700-703.	2.1	0
263	Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. <i>Vascular Pharmacology</i> , 2011, 55, 2-9.	1.0	137
264	Blood Pressure Level Attainment Among Patients with Coronary Artery Disease and Uncontrolled Blood Pressure. <i>Pharmacotherapy</i> , 2011, 31, 1063-1072.	1.2	0
266	Cold Pressor Test Safety—The Incidence of Vasovagal Reactions. <i>American Journal of Cardiology</i> , 2011, 107, 492-493.	0.7	0
267	Relation of Baseline Systolic Blood Pressure and Long-Term Outcomes in Ambulatory Patients With Chronic Mild to Moderate Heart Failure. <i>American Journal of Cardiology</i> , 2011, 107, 1208-1214.	0.7	92
268	Current Status of Aggressive Blood Glucose and Blood Pressure Control in Diabetic Hypertensive Subjects. <i>American Journal of Cardiology</i> , 2011, 107, 1856-1861.	0.7	15
269	Best Clinical Trials Reported in 2010. <i>American Journal of Cardiology</i> , 2011, 108, 162-168.	0.7	0
270	Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose. <i>American Journal of Cardiology</i> , 2011, 108, 3B-24B.	0.7	254
271	Target blood pressure in diabetes patients with hypertension —What is the accumulated evidence in 2011?. <i>Journal of Zhejiang University: Science B</i> , 2011, 12, 611-623.	1.3	12
272	Irbesartan in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 364, 928-938.	13.9	220
273	Management of hypertension in diabetic patients: outstanding issues. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 721-728.	0.6	2
275	Cardiovascular risk stratification and antihypertensive therapy according to guidelines in the outpatient setting. <i>Wiener Medizinische Wochenschrift</i> , 2011, 161, 557-564.	0.5	0
277	What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?. <i>Advances in Therapy</i> , 2011, 28, 716-727.	1.3	4
278	Treatment of Risk Factors to Prevent Stroke. <i>Neurotherapeutics</i> , 2011, 8, 463-474.	2.1	20

#	ARTICLE	IF	CITATIONS
280	Examining the Evidence: A Systematic Review of the Inclusion and Analysis of Older Adults in Randomized Controlled Trials. <i>Journal of General Internal Medicine</i> , 2011, 26, 783-790.	1.3	324
281	Residual cardiovascular risk in secondary prevention. <i>Internal and Emergency Medicine</i> , 2011, 6, 61-68.	1.0	6
282	Optimal Therapy in Hypertensive Subjects with Diabetes Mellitus. <i>Current Atherosclerosis Reports</i> , 2011, 13, 176-185.	2.0	16
283	Optimal Medical Therapy, Lifestyle Intervention, and Secondary Prevention Strategies for Cardiovascular Event Reduction in Ischemic Heart Disease. <i>Current Cardiology Reports</i> , 2011, 13, 287-295.	1.3	10
284	Can Treating the Diastolic Blood Pressure Below a Certain Value Increase Cardiovascular Risk?. <i>Current Cardiology Reports</i> , 2011, 13, 517-519.	1.3	2
285	What is the Ideal Blood Pressure Goal for Patients with Stage III or Higher Chronic Kidney Disease?. <i>Current Cardiology Reports</i> , 2011, 13, 492-501.	1.3	13
286	What Is the Blood Pressure Goal for the Elder Patient 75 Years of Age or Older?. <i>Current Cardiology Reports</i> , 2011, 13, 485-491.	1.3	2
287	Which Combination Therapy Is Superior at Reducing Cardiovascular Events in Diabetic Patients with Hypertension?. <i>Current Diabetes Reports</i> , 2011, 11, 151-153.	1.7	0
288	The Goal of Blood Pressure Control for Prevention of Early Diabetic Microvascular Complications. <i>Current Diabetes Reports</i> , 2011, 11, 323-329.	1.7	8
289	Antihypertensive Therapy in Diabetes: The Legacy Effect and RAAS Blockade. <i>Current Hypertension Reports</i> , 2011, 13, 318-324.	1.5	31
290	Is Nocturnal Blood Pressure Reduction the Secret to Reducing the Rate of Progression of Hypertensive Chronic Kidney Disease?. <i>Current Hypertension Reports</i> , 2011, 13, 378-385.	1.5	27
291	Blood Pressure Targets for Patients with Diabetes or Kidney Disease. <i>Current Hypertension Reports</i> , 2011, 13, 452-455.	1.5	17
292	Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008. <i>Cardiovascular Diabetology</i> , 2011, 10, 31.	2.7	54
293	Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy. <i>Proteomics - Clinical Applications</i> , 2011, 5, 354-366.	0.8	35
294	Medical care of type 2 diabetes in German Disease Management Programmes: a population-based evaluation. <i>Diabetes/Metabolism Research and Reviews</i> , 2011, 27, 383-391.	1.7	31
295	Endothelin-Converting Enzyme/Neutral Endopeptidase Inhibitor SLV338 Prevents Hypertensive Cardiac Remodeling in a Blood Pressure-Independent Manner. <i>Hypertension</i> , 2011, 57, 755-763.	1.3	39
296	Should the blood pressure or the blood vessel be the target of therapy?. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1397-1401.	0.6	2
297	The (pre)hypertension limbo. <i>Neurology</i> , 2011, 77, 1322-1323.	1.5	3

#	ARTICLE	IF	CITATIONS
298	Reducing Cardiovascular Events and End-Organ Damage in Patients with Hypertension: New Considerations. <i>Postgraduate Medicine</i> , 2011, 123, 7-17.	0.9	3
299	Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. <i>European Heart Journal</i> , 2011, 32, 1500-1508.	1.0	116
301	Effects of Multiple Factorial Intervention on Ambulatory BP Profile and Renal Function in Hypertensive Type 2 Diabetic Patients with Overt Nephropathy – A Pilot Study. <i>Clinical and Experimental Hypertension</i> , 2011, 33, 255-263.	0.5	12
302	Evolution of Treatment for Diabetic Nephropathy: Historical Progression from RAAS Inhibition and Onward. <i>Postgraduate Medicine</i> , 2011, 123, 166-179.	0.9	13
303	The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. <i>Clinical Lipidology</i> , 2011, 6, 9-20.	0.4	52
304	Intensive Glucose Lowering and Cardiovascular Outcomes. <i>New England Journal of Medicine</i> , 2011, 364, 2263-2264.	13.9	3
305	Olmesartan, Microalbuminuria, and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2011, 364, 2260-2263.	13.9	6
306	New challenges in blood pressure goals and assessment. <i>Nature Reviews Cardiology</i> , 2011, 8, 73-75.	6.1	11
307	Insights from the extended follow-up of the ACCORD trial. <i>Nature Reviews Cardiology</i> , 2011, 8, 308-310.	6.1	0
308	Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. <i>Eye</i> , 2011, 25, 843-849.	1.1	58
309	Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008. <i>Circulation</i> , 2011, 124, 1046-1058.	1.6	519
310	Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1429-1438.	0.9	16
311	Prevalence of Resistant Hypertension in the United States, 2003–2008. <i>Hypertension</i> , 2011, 57, 1076-1080.	1.3	670
312	A call for wider use of ambulatory blood pressure monitoring in patients with diabetes. <i>Hypertension Research</i> , 2011, 34, 1171-1172.	1.5	2
313	Predictors of Blood Pressure Control Among Hypertensives in Community Health Centers. <i>American Journal of Hypertension</i> , 2011, 24, 1318-1323.	1.0	48
314	Blood Pressure Goals in CKD: Where Are We Going, and How Do We Get There?. <i>Nephrology Times</i> , 2011, 4, 11-13.	0.0	0
315	Introduction to the Third World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). <i>Diabetes Care</i> , 2011, 34, S99-S100.	4.3	1
316	Blood Pressure Trajectories Prior to Death in Patients With Diabetes. <i>Diabetes Care</i> , 2011, 34, 1534-1539.	4.3	17

#	ARTICLE	IF	CITATIONS
317	Isolated Diastolic Hypotension and Incident Heart Failure in Older Adults. <i>Hypertension</i> , 2011, 58, 895-901.	1.3	44
318	Systolic blood pressure and incident heart failure in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study. <i>Heart</i> , 2011, 97, 1304-1311.	1.2	65
319	Guidelines, Inertia, and Judgment. <i>Hypertension</i> , 2011, 58, 544-545.	1.3	3
320	Management of Blood Pressure in Patients With Diabetes. <i>American Journal of Hypertension</i> , 2011, 24, 863-875.	1.0	33
321	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. <i>Circulation</i> , 2011, 123, 2434-2506.	1.6	381
322	Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial—Clinical Implications. <i>Clinical Chemistry</i> , 2011, 57, 261-263.	1.5	8
323	Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. <i>BMJ: British Medical Journal</i> , 2011, 343, d6898-d6898.	2.4	312
324	Antiplatelet Therapy for Every Diabetic Person?. <i>Diabetes Care</i> , 2011, 34, S150-S154.	4.3	17
325	Redefining Blood Pressure Targets in High-Risk Patients?: Lessons From Coronary Endpoints in Recent Randomized Clinical Trials. <i>American Journal of Hypertension</i> , 2011, 24, 1060-1068.	1.0	14
326	Disparities in Blood Pressure Control Within a Community-Based Provider Network: An Exploratory Analysis. <i>Annals of Pharmacotherapy</i> , 2011, 45, 1473-1482.	0.9	25
327	Predialysis Nephrology Care of Older Patients Approaching End-stage Renal Disease. <i>Archives of Internal Medicine</i> , 2011, 171, 1371.	4.3	62
328	Near-normalization of glucose and microvascular diabetes complications: data from ACCORD and ADVANCE. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2011, 2, 17-26.	1.4	28
329	Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. <i>Journal of Hypertension</i> , 2011, 29, 1253-1269.	0.3	235
330	Antihypertensive Treatment and Secondary Prevention of Cardiovascular Disease Events Among Persons Without Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 913.	3.8	189
331	Observation on Renal Outcomes in the Veterans Affairs Diabetes Trial. <i>Diabetes Care</i> , 2011, 34, 2090-2094.	4.3	34
332	Diabetes Performance Measures: Current Status and Future Directions. <i>Diabetes Care</i> , 2011, 34, 1651-1659.	4.3	121
333	Relationship between Blood Pressure and Incident Chronic Kidney Disease in Hypertensive Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2605-2611.	2.2	65
334	Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. <i>Therapeutic Advances in Chronic Disease</i> , 2011, 2, 265-278.	1.1	25

#	ARTICLE	IF	CITATIONS
335	Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. <i>Cmaj</i> , 2011, 183, 1007-1013.	0.9	220
336	Renal Association Clinical Practice Guideline on Detection, Monitoring and Management of Patients with CKD. <i>Nephron Clinical Practice</i> , 2011, 118, c71-c100.	2.3	23
337	Control of Blood Pressure in Chronic Kidney Disease: How Low to Go. <i>Nephron Clinical Practice</i> , 2011, 119, c324-c332.	2.3	6
338	ACCF/AHA/AMAâ€œPCPI 2011 Performance Measures for Adults With Coronary Artery Disease and Hypertension. <i>Circulation</i> , 2011, 124, 248-270.	1.6	123
339	Response to Letter Regarding Article, â€œAcetaminophen Increases Blood Pressure in Patients With Coronary Artery Diseaseâ€• <i>Circulation</i> , 2011, 123, .	1.6	0
340	Intensive Blood Pressure Control Affects Cerebral Blood Flow in Type 2 Diabetes Mellitus Patients. <i>Hypertension</i> , 2011, 57, 738-745.	1.3	48
341	The Diastolic J Curve. <i>Hypertension</i> , 2011, 58, 751-753.	1.3	21
342	Blood Pressure: The Lower, the Better: The con side. <i>Diabetes Care</i> , 2011, 34, S308-S312.	4.3	24
343	A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients. <i>Blood Pressure</i> , 2011, 20, 322-334.	0.7	9
344	What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist?. Expert Opinion on Pharmacotherapy, 2011, 12, 1835-1844.	0.9	31
345	Lowering systolic blood pressure below 130 mm Hg does not improve cardiovascular outcomes in hypertensive patients with diabetes and coronary artery disease. <i>Evidence-Based Medicine</i> , 2011, 16, 24-26.	0.6	4
346	Combined Effect of High-Normal Blood Pressure and Low HDL Cholesterol on Mortality in an Elderly Korean Population: The South-West Seoul (SWS) Study. <i>American Journal of Hypertension</i> , 2011, 24, 918-923.	1.0	18
347	Sudden Acceleration of Diabetes Quality Measures. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 709.	3.8	40
348	Level of Systolic Blood Pressure Within the Normal Range and Risk of Recurrent Stroke. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2137-44.	3.8	215
350	NINDS Halts the Aspirin-Clopidogrel Arm of Stroke Trial. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2011, 11, 1.	0.0	0
351	High â€” and Low â€” Blood Pressure May Raise Risk of Recurrent Stroke. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2011, 11, 23-24.	0.0	0
352	Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. <i>European Heart Journal</i> , 2011, 32, 2247-2255.	1.0	39
353	What's new in hypertension 2010?. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 50-55.	0.4	4

#	ARTICLE	IF	CITATIONS
354	Kidney disease in diabetology: lessons from 2010. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 454-457.	0.4	8
355	Ambulatory blood pressure monitoring in diabetic patients: new data, new questions. <i>Journal of Hypertension</i> , 2011, 29, 198-200.	0.3	5
356	Blood pressure management in diabetes: a path forward?. <i>Journal of Hypertension</i> , 2011, 29, 1283-1284.	0.3	2
357	Standards of Medical Care in Diabetes—2011. <i>Diabetes Care</i> , 2011, 34, S11-S61.	4.3	2,448
358	Is a Blood Pressure Target of $130/80$ mm Hg Still Appropriate for High-Risk Patients?. <i>Circulation</i> , 2011, 124, 1700-1702.	1.6	16
359	Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose. <i>Circulation</i> , 2011, 123, 2799-2810.	1.6	397
360	Treatment Intensification in a Hypertension Telemanagement Trial. <i>Hypertension</i> , 2011, 58, 552-558.	1.3	44
361	Letter by Nguyen Regarding Article, "Acetaminophen Increases Blood Pressure in Patients With Coronary Artery Disease"; <i>Circulation</i> , 2011, 123, e645; author reply e646.	1.6	1
362	Mixed Messages on Blood Pressure Goals. <i>Hypertension</i> , 2011, 57, 1039-1040.	1.3	22
363	Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). <i>Circulation</i> , 2011, 124, 1727-1736.	1.6	156
364	Antihypertensive Treatment and Blood Pressure in Diabetic and Nondiabetic Patients: The lower, the better?. <i>Diabetes Care</i> , 2011, 34, S304-S307.	4.3	24
365	Cardiovascular Outcomes in Framingham Participants With Diabetes. <i>Hypertension</i> , 2011, 57, 891-897.	1.3	217
366	Hypertension Guidelines. <i>Hypertension</i> , 2011, 58, 347-348.	1.3	32
367	Limitations of Analyses Based on Achieved Blood Pressure. <i>Hypertension</i> , 2011, 57, 1061-1068.	1.3	42
368	Blood pressure and the kidney. <i>Nature Reviews Nephrology</i> , 2011, 7, 73-74.	4.1	8
369	Diabetes, Hypertension, and Outcome Studies: Overview 2010. <i>Diabetes Care</i> , 2011, 34, S109-S113.	4.3	16
370	Glycemic Control in HIV-Infected Patients with Diabetes Mellitus and Rates of Meeting American Diabetes Association Management Guidelines. <i>AIDS Patient Care and STDs</i> , 2011, 25, 5-12.	1.1	23
371	Hypertension in aging patients. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 113-120.	0.6	26

#	ARTICLE	IF	CITATIONS
372	Home blood pressure for the management of hypertension: will it become the new standard of practice?. Expert Review of Cardiovascular Therapy, 2011, 9, 745-751.	0.6	5
373	Response to Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703-709. Diabetes Care, 2011, 34, e125-125.	4.3	2
374	Renin-angiotensin system blockade and reduction of cardiovascular risk: future perspectives. Expert Review of Cardiovascular Therapy, 2011, 9, 1585-1591.	0.6	7
375	Management of patients with type 2 diabetes. Current Medical Research and Opinion, 2011, 27, 1931-1947.	0.9	12
376	New clinical concepts after the ONTARGET trial. Expert Review of Cardiovascular Therapy, 2011, 9, 685-689.	0.6	10
377	Bedtime Dosing of Antihypertensive Medications Reduces Cardiovascular Risk in CKD. Journal of the American Society of Nephrology: JASN, 2011, 22, 2313-2321.	3.0	239
378	Systematic kidney disease management in a population with diabetes mellitus: turning the tide of kidney failure. BMJ Quality and Safety, 2011, 20, 903-910.	1.8	31
379	Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 13-26.	0.2	68
380	Chronobiology Impacts Response to Antihypertensive Drug Regimen in Type 2 Diabetes. Diabetes Care, 2011, 34, 1438-1439.	4.3	4
381	Primary prevention of stroke: blood pressure, lipids, and heart failure. European Heart Journal, 2011, 32, 545-552.	1.0	76
382	Screening for Type 2 Diabetes and Dysglycemia. Epidemiologic Reviews, 2011, 33, 63-87.	1.3	70
383	Interactions between CKD and MetS and the Development of CVD. Cardiology Research and Practice, 2011, 2011, 1-2.	0.5	3
384	Blood Pressure Control in Diabetes Mellitus. Circulation, 2011, 123, 2776-2778.	1.6	28
385	Trends in blood pressure control in patients with type 2 diabetes - Data from the Swedish National Diabetes Register (NDR). Blood Pressure, 2011, 20, 348-354.	0.7	57
386	Consensus Report: Diabetes Performance Measures: Current Status and Future Directions. Clinical Diabetes, 2011, 29, 102-112.	1.2	2
387	Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease: A Dynamic and Life-Threatening Triad. Cardiology Research and Practice, 2011, 2011, 1-16.	0.5	29
388	Adiponectin and All-Cause Mortality in Elderly People With Type 2 Diabetes. Diabetes Care, 2012, 35, 1858-1863.	4.3	33
389	Hypertension in women: latest findings and clinical implications. Therapeutic Advances in Chronic Disease, 2012, 3, 137-146.	1.1	53

#	ARTICLE	IF	CITATIONS
390	Effects of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis. PLoS Medicine, 2012, 9, e1001293.	3.9	389
391	Diabetic nephropathy. Clinical Medicine, 2012, 12, 480-482.	0.8	2
392	Stroke Prevention: Managing Modifiable Risk Factors. Stroke Research and Treatment, 2012, 2012, 1-15.	0.5	22
393	Intensive Blood Pressure Treatment Does Not Improve Cardiovascular Outcomes in Centrally Obese Hypertensive Individuals With Diabetes. Diabetes Care, 2012, 35, 1401-1405.	4.3	31
394	Type 2 diabetes and cardiovascular diseases: do they share a common soil? The Asian Indian experience. Heart Asia, 2012, 4, 69-76.	1.1	4
396	Monitoring Performance for Blood Pressure Management Among Patients With Diabetes Mellitus. Archives of Internal Medicine, 2012, 172, 938.	4.3	56
397	The J-Shaped Curve in Secondary Prevention. Hypertension, 2012, 59, 8-9.	1.3	13
398	Glucose control and cardiovascular outcomes: reorienting approach. Frontiers in Endocrinology, 2012, 3, 110.	1.5	11
399	Occurrence of Hypotension in Older Participants. Which 24-hour ABPM Parameter Better Correlate With?. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2012, 67, 804-810.	1.7	44
400	Angina Pectoris and Stable Ischemic Heart Disease. , 2012, , 412-425.		2
401	Some Aspects of Preventing Coronary Heart Disease. Angiology, 2012, 63, 17-23.	0.8	5
402	Relation Between Blood Pressure and Vascular Events and Mortality in Patients With Manifest Vascular Disease. Hypertension, 2012, 59, 14-21.	1.3	117
403	Blockade of the renin-angiotensin system for the primary prevention of diabetic nephropathy. Diabetes Management, 2012, 2, 55-64.	0.5	1
404	Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus. Archives of Internal Medicine, 2012, 172, 1296.	4.3	118
405	“Hot topics” in hypertension. Current Opinion in Cardiology, 2012, 27, 368-369.	0.8	0
406	Revascularization in Renal Artery Stenosis. Cardiology in Review, 2012, 20, 189-193.	0.6	7
407	Is the lower blood pressure target for patients with chronic kidney disease supported by evidence?. Current Opinion in Cardiology, 2012, 27, 370-373.	0.8	5
408	The J-Curve Revisited. Cardiology in Review, 2012, 20, 253-258.	0.6	6

#	ARTICLE	IF	CITATIONS
409	Improving Blood Pressure Control Through a Clinical Pharmacist Outreach Program in Patients With Diabetes Mellitus in 2 High-Performing Health Systems. <i>Circulation</i> , 2012, 125, 2863-2872.	1.6	105
410	Antihypertensive therapy versus alternative therapeutic options for prehypertension: an evidence-based approach. <i>Future Cardiology</i> , 2012, 8, 115-122.	0.5	6
411	Use of a Single Target Blood Pressure Level in Type 2 Diabetes Mellitus for All Cardiovascular Risk Reduction. <i>Archives of Internal Medicine</i> , 2012, 172, 1304.	4.3	6
412	Blood Pressure Targets with Antihypertensive Treatment. , 2012, , 267-277.		0
413	J-Curve Phenomenon: Does It Exist?. , 2012, , 295-308.		2
414	Hypertension in the Very Old: Special Features, Therapeutic Approaches, and Problems. , 2012, , 45-56.		0
415	Global cardiovascular disease risk assessment in United States adults with diabetes. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 146-152.	0.9	59
416	Blood pressure target attainment in the background of guidelines: the very elderly in Swiss primary care. <i>Family Practice</i> , 2012, 29, 511-520.	0.8	3
417	Optimizing Care in Diabetes: a Quixotic Challenge. <i>Diabetes Care</i> , 2012, 35, 1204-1205.	4.3	1
420	Multifactorial intervention with nurse practitioners does not change cardiovascular outcomes in patients with chronic kidney disease. <i>Kidney International</i> , 2012, 82, 710-717.	2.6	77
421	Hyaline Cartilage Tissue Is Formed through the Co-culture of Passaged Human Chondrocytes and Primary Bovine Chondrocytes. <i>Journal of Histochemistry and Cytochemistry</i> , 2012, 60, 576-587.	1.3	10
422	What Should the Blood Pressure Goal Be in Patients with Hypertension Who Are at High Risk for Cardiovascular Disease?. <i>Hospital Practice (1995)</i> , 2012, 40, 28-32.	0.5	0
423	Blood pressure treatment target in patients with diabetes mellitus—current evidence. <i>Annals of Medicine</i> , 2012, 44, S36-S42.	1.5	8
424	Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study. <i>BMJ, The</i> , 2012, 345, e5567-e5567.	3.0	76
425	Glycemic and blood-pressure control—lower is not better. <i>Nature Reviews Nephrology</i> , 2012, 8, 199-200.	4.1	0
427	Current Approaches to the Treatment of Hypertension in Older Persons. <i>Postgraduate Medicine</i> , 2012, 124, 50-59.	0.9	3
428	A change in paradigm: Lowering blood pressure in everyone over a certain age. <i>Annals of Medicine</i> , 2012, 44, S30-S35.	1.5	2
429	Very-low-energy diets and morbidity: a systematic review of longer-term evidence. <i>British Journal of Nutrition</i> , 2012, 108, 832-851.	1.2	43

#	ARTICLE	IF	CITATIONS
430	Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. <i>European Heart Journal</i> , 2012, 33, 2804-2812.	1.0	102
431	Beta-blockers for hypertension. , 2012, , CD002003.		24
432	Chapter 3: Blood pressure management in CKD ND patients without diabetes mellitus. <i>Kidney International Supplements</i> , 2012, 2, 357-362.	4.6	20
433	Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2012, 14, 341-343.	2.9	737
434	Blood pressure control status and effects of pravastatin on cardiovascular events occurrence in patients with dyslipidaemia. <i>Journal of Human Hypertension</i> , 2012, 26, 388-395.	1.0	4
436	Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus. <i>Kidney International Supplements</i> , 2012, 2, 363-369.	4.6	24
438	An observational study to evaluate factors responsible and actions taken for hypertensive patients who are not at blood pressure goal: i-target Goal Study. <i>Hypertension Research</i> , 2012, 35, 624-632.	1.5	2
439	Thresholds of Ambulatory Blood Pressure Associated With Chronic Complications in Type 2 Diabetes. <i>American Journal of Hypertension</i> , 2012, 25, 82-88.	1.0	19
440	Effect of Intensive Versus Standard Blood Pressure Control on Depression and Health-Related Quality of Life in Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1479-1481.	4.3	20
441	National Surveillance Definitions for Hypertension Prevalence and Control Among Adults. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 343-351.	0.9	92
442	Diabetes in Older Adults. <i>Diabetes Care</i> , 2012, 35, 2650-2664.	4.3	961
443	Angiotensin II receptor blocker combinations: From guidelines to clinical practice. <i>Blood Pressure</i> , 2012, 21, 73-81.	0.7	4
444	Intensive blood pressure control in obese diabetic patients: clinical relevance of stroke prevention in the ACCORD trial. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1467-1470.	0.6	6
445	Cardiology in Family Practice. , 2012, , .		3
446	Comparable short-term prognosis in diabetic and non-diabetic patients with acute coronary syndrome after cardiac rehabilitation. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 15-22.	0.8	15
447	Evening dosing of antihypertensive medications results in better blood pressure control and decreases cardiovascular morbidity and mortality in patients with Type 2 diabetes. <i>Evidence-Based Medicine</i> , 2012, 17, 116-117.	0.6	0
448	Cerebrovascular Complications of Diabetes: Focus on Stroke. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2012, 12, 148-158.	0.6	149
449	Initial Choice of Antihypertensive on Long-Term Cardiovascular Outcomes in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 884-886.	2.2	0

#	ARTICLE	IF	CITATIONS
450	Diabetes and Stroke Prevention: A Review. <i>Stroke Research and Treatment</i> , 2012, 2012, 1-6.	0.5	29
451	Genetic Predisposition to High Blood Pressure Associates With Cardiovascular Complications Among Patients With Type 2 Diabetes. <i>Diabetes</i> , 2012, 61, 3026-3032.	0.3	12
452	Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). <i>Hypertension</i> , 2012, 60, 1400-1406.	1.3	54
454	Care Guides. <i>Journal of Ambulatory Care Management</i> , 2012, 35, 27-37.	0.5	16
455	Review of Olmesartan Medoxomil in Achieving Guideline-Recommended Target BP Goals and Implications for Managed Care. <i>Current Hypertension Reviews</i> , 2012, 8, 190-195.	0.5	2
456	Torcetrapib impairs endothelial function in hypertension. <i>European Heart Journal</i> , 2012, 33, 1615-1624.	1.0	75
457	Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression. <i>Journal of Hypertension</i> , 2012, 30, 204-209.	0.3	39
458	Blood pressure lowering in diabetic patients. <i>Journal of Hypertension</i> , 2012, 30, 438-439.	0.3	7
460	A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications. <i>Current Hypertension Reviews</i> , 2012, 8, 196-226.	0.5	2
461	Cardiovascular outcomes in hypertensive patients. <i>Journal of Hypertension</i> , 2012, 30, 2213-2222.	0.3	25
462	Pros and Cons of Aggressive Blood Pressure Lowering in Patients with Type 2 Diabetes. <i>Current Vascular Pharmacology</i> , 2012, 10, 156-161.	0.8	16
463	Impact of lower achieved blood pressure on outcomes in hypertensive patients. <i>Journal of Hypertension</i> , 2012, 30, 802-810.	0.3	49
464	Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). <i>Yearbook of Cardiology</i> , 2012, 2012, 53-55.	0.0	0
465	Advancing Cardiovascular Research. <i>Chest</i> , 2012, 141, 500-505.	0.4	25
466	Effective Management of the Type 2 Diabetes Patient with Cardiovascular and Renal Disease: Secondary Prevention Strategies after a Myocardial Infarction. <i>Current Diabetes Reviews</i> , 2012, 8, 219-228.	0.6	4
467	Pulse wave encephalopathy. <i>Journal of Hypertension</i> , 2012, 30, 429.	0.3	8
468	Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. <i>Journal of Hypertension</i> , 2012, 30, 811-818.	0.3	28
469	Validation of carotid blood pressure assessment by tonometry. <i>Journal of Hypertension</i> , 2012, 30, 429-432.	0.3	8

#	ARTICLE	IF	CITATIONS
470	Meta-analysis supports ACCORD blood pressure but effect of excessive DBP lowering uncertain. <i>Journal of Hypertension</i> , 2012, 30, 436-438.	0.3	1
471	The history of primary hyperaldosteronism with simultaneous hypercortisolism. <i>Journal of Hypertension</i> , 2012, 30, 432-433.	0.3	1
472	Response to "Validation of carotid blood pressure assessment by tonometry"™. <i>Journal of Hypertension</i> , 2012, 30, 432.	0.3	0
473	Blood pressure and risk of cardiovascular diseases in type 2 diabetes. <i>Journal of Hypertension</i> , 2012, 30, 2020-2030.	0.3	51
474	Different methods to present the effect of blood pressure on cardiovascular diseases by Cox regression. <i>Journal of Hypertension</i> , 2012, 30, 235-237.	0.3	6
475	Adrenal venous sampling crucial in primary aldosteronism?. <i>Journal of Hypertension</i> , 2012, 30, 433-435.	0.3	0
476	Supracentrimetric nodule on computed tomography does not exclude adrenal venous sampling before surgery for primary aldosteronism. <i>Journal of Hypertension</i> , 2012, 30, 435-436.	0.3	1
477	The metabolic syndrome and dyslipidemia in primary and secondary prevention: examining the implications of recent trials. <i>Clinical Lipidology</i> , 2012, 7, 223-239.	0.4	4
478	Ambulatory blood pressure monitoring in Australia. <i>Journal of Hypertension</i> , 2012, 30, 253-266.	0.3	109
479	Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73%913 patients. <i>Yearbook of Cardiology</i> , 2012, 2012, 57-59.	0.0	0
480	Treatment of hypercholesterolemia and hypertension in diabetics with coronary artery disease. <i>Clinical Lipidology</i> , 2012, 7, 689-695.	0.4	2
481	Diabetes and hypertension: the bad companions. <i>Lancet, The</i> , 2012, 380, 601-610.	6.3	498
482	Hypertension: treatments, diabetes, and developing regions. <i>Lancet, The</i> , 2012, 380, 539-541.	6.3	8
483	Discrepancy Between Tonometric Ambulatory and Cuff-Based Office Blood Pressure Measurements in Patients With Type 1 Diabetes. <i>Journal of Clinical Hypertension</i> , 2012, 14, 686-693.	1.0	3
484	Editorial Commentary on Dilemmas in Treating Hypertension in Octogenarians. <i>Journal of Clinical Hypertension</i> , 2012, 14, 665-667.	1.0	1
485	Proteinuria modifies the effect of systolic blood pressure on total and cardiovascular disease mortality in patients with type 2 diabetes. <i>Journal of Internal Medicine</i> , 2012, 272, 611-619.	2.7	8
486	Blood pressure control among patients with hypertension and newly diagnosed diabetes. <i>Diabetic Medicine</i> , 2012, 29, 1126-1133.	1.2	4
487	Management of Hypertension in People with Diabetes Mellitus: Translating the 2012 Canadian Hypertension Education Program Recommendations into Practice. <i>Canadian Journal of Diabetes</i> , 2012, 36, 345-353.	0.4	4

#	ARTICLE	IF	CITATIONS
488	Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. <i>Kidney International</i> , 2012, 82, 570-580.	2.6	120
489	Treatment of isolated systolic hypertension in the elderly. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1367-1373.	0.6	20
490	Management of Hyperglycemia, Dyslipidemia, and Albuminuria in Patients With Diabetes and CKD: A Systematic Review for a KDOQI Clinical Practice Guideline. <i>American Journal of Kidney Diseases</i> , 2012, 60, 747-769.	2.1	87
491	Should we change the target blood pressure in diabetic patients?. <i>Diabetes/Metabolism Research and Reviews</i> , 2012, 28, 1-7.	1.7	1
492	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). <i>Atherosclerosis</i> , 2012, 223, 1-68.	0.4	414
493	Extended longitudinal analysis of arterial pressure and heart rate control in unanesthetized rats with type 1 diabetes. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2012, 170, 20-29.	1.4	1
494	The effects of blood pressure control levels on the renoprotection of type 2 diabetic patients without overt proteinuria. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 124-131.	2.3	11
495	Diabetes and the Risk of Heart Failure. <i>Heart Failure Clinics</i> , 2012, 8, 125-133.	1.0	55
496	Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 7-22.	1.0	65
499	Clinical Update on Nursing Home Medicine: 2012. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 581-594.	1.2	6
500	Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance. <i>Mayo Clinic Proceedings</i> , 2012, 87, 561-570.	1.4	15
501	Concepto y componentes del riesgo residual. <i>Clínica E Investigación En Arteriosclerosis</i> , 2012, 24, 8-13.	0.4	0
503	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). <i>European Heart Journal</i> , 2012, 33, 1635-1701.	1.0	5,247
504	Effect of Antihypertensive Therapy on Incident Stroke in Cohorts With Prehypertensive Blood Pressure Levels. <i>Stroke</i> , 2012, 43, 432-440.	1.0	74
505	Combination of Amlodipine plus Angiotensin Receptor Blocker or Diuretics in High-Risk Hypertensive Patients. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 137-142.	1.0	16
506	Current challenges in the clinical management of hypertension. <i>Nature Reviews Cardiology</i> , 2012, 9, 267-275.	6.1	54
507	Standards of Medical Care in Diabetes—2012. <i>Diabetes Care</i> , 2012, 35, S11-S63.	4.3	1,956
508	Aggressive blood pressure reduction in patients at high vascular risk: is it dangerous?. <i>Italian Journal of Medicine</i> , 2012, 6, 302-306.	0.2	0

#	ARTICLE	IF	CITATIONS
509	Improved Identification and Antihypertension Pharmacotherapy in Cardiorenal Metabolic Syndrome: Focus on Racial/Ethnic Minorities, Olmesartan Medoxomil, and Combination Therapy. <i>CardioRenal Medicine</i> , 2012, 2, 256-267.	0.7	1
510	Alpha-glucosidase inhibitors 2012 – cardiovascular considerations and trial evaluation. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 163-169.	0.9	115
511	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). <i>European Journal of Preventive Cardiology</i> , 2012, 19, 585-667.	0.8	359
512	Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. <i>Kidney International</i> , 2012, 81, 586-594.	2.6	53
513	Treatment of hypertension in diabetes: what is the best therapeutic option?. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 727-734.	0.6	10
514	Epidemiology and prevention of stroke: a worldwide perspective. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 199-208.	1.4	105
515	Treatment of Hypertension. <i>Hypertension</i> , 2012, 60, 281-282.	1.3	1
516	Renal endpoints in renal and cardiovascular randomized clinical trials: time for a consensus?. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 771-782.	1.0	13
517	Management of hypertension in the elderly. <i>Nature Reviews Cardiology</i> , 2012, 9, 286-296.	6.1	54
518	Authors' response to – need, also, for transformative innovation in the definition of hypertension. <i>American Heart Journal</i> , 2012, 163, e17.	1.2	0
519	Rationale and design of a randomized study to determine the value of central Blood Pressure for GUIDing management of hypertension: The BP GUIDE study. <i>American Heart Journal</i> , 2012, 163, 761-767.	1.2	13
520	Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 132-141.	2.3	31
521	Long-Term Tolerability and Efficacy of Single-Pill Combinations of Telmisartan 40–80 mg Plus Amlodipine 5 or 10 mg in Patients Whose Blood Pressure Was Not Initially Controlled by Amlodipine 5–10 mg: Open-Label, Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 Studies. <i>Current Therapeutic Research</i> , 2012, 73, 65-84.	0.5	8
522	The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. <i>Diabetes Research and Clinical Practice</i> , 2012, 95, 389-398.	1.1	16
523	Long-term changes of the prevalence and control rate of hypertension among Korean adults with diagnosed diabetes: 1998–2008 Korean National Health and Nutrition Examination Survey. <i>Diabetes Research and Clinical Practice</i> , 2012, 97, 151-157.	1.1	13
524	Prevalence, Awareness, Treatment, and Control of Hypertension Among Canadian Adults With Diabetes, 2007 to 2009. <i>Canadian Journal of Cardiology</i> , 2012, 28, 367-374.	0.8	23
525	Gender-Related Differences in Left Ventricular Mass in Nonhypertensive Young Adults: It's Not All About Size. <i>Canadian Journal of Cardiology</i> , 2012, 28, 411-412.	0.8	0
526	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. <i>Canadian Journal of Cardiology</i> , 2012, 28, 270-287.	0.8	173

#	ARTICLE	IF	CITATIONS
527	Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. <i>BMC Endocrine Disorders</i> , 2012, 12, 5.	0.9	58
528	Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure. <i>Cardiovascular Diabetology</i> , 2012, 11, 118.	2.7	7
529	Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. <i>Cardiovascular Diabetology</i> , 2012, 11, 134.	2.7	29
530	Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies. <i>Cardiovascular Diabetology</i> , 2012, 11, 50.	2.7	31
531	Determinants of uncontrolled hypertension in adult type 2 diabetes mellitus: an analysis of the Malaysian diabetes registry 2009. <i>Cardiovascular Diabetology</i> , 2012, 11, 54.	2.7	35
532	Beta-blockers for hypertension. , 2012, 11, CD002003.		80
535	Progression of Subclinical Myocardial Dysfunction in Type 2 Diabetes after 5 years Despite Improved Glycemic Control. <i>Echocardiography</i> , 2012, 29, 1045-1053.	0.3	17
536	Diabetes in Older Adults: A Consensus Report. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 2342-2356.	1.3	417
537	Heart Failure in Hypertension. <i>Drugs</i> , 2012, 72, 1373-1398.	4.9	16
538	Hypertension and Kidney Disease: What Do the Data Really Show?. <i>Current Hypertension Reports</i> , 2012, 14, 462-467.	1.5	6
539	Safety and Efficacy of Low Blood Pressures Among Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 74-83.	1.2	164
540	Cardiovascular Risk Factors in a Patient with Diabetes Mellitus and Coronary Artery Disease: Therapeutic Approaches to Improve Outcomes: Perspectives of a Preventive Cardiologist. <i>American Journal of Cardiology</i> , 2012, 110, 43B-49B.	0.7	29
541	Diabetes and Cardiovascular Disease: Changing the Focus from Glycemic Control to Improving Long-Term Survival. <i>American Journal of Cardiology</i> , 2012, 110, 58B-68B.	0.7	64
542	Hypertension and Chronic Kidney Disease Progression: Why the Suboptimal Outcomes?. <i>American Journal of Medicine</i> , 2012, 125, 1057-1062.	0.6	27
543	Hypertension in cancer patients. <i>Community Oncology</i> , 2012, 9, 324-330.	0.2	2
544	Hypertension and ischemic heart disease. <i>Cor Et Vasa</i> , 2012, 54, e433-e438.	0.1	22
545	Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus – natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature. <i>European Journal of Internal Medicine</i> , 2012, 23, 628-632.	1.0	53
546	The treatment of hypertension in very old persons: Benefits and limitations. <i>European Geriatric Medicine</i> , 2012, 3, 33-36.	1.2	1

#	ARTICLE	IF	CITATIONS
547	Complicaciones macrovasculares del paciente diabético. <i>Medicine</i> , 2012, 11, 1011-1020.	0.0	0
548	Paciente de 65 años con diabetes no conocida. <i>Medicine</i> , 2012, 11, 1059.e1-1059.e4.	0.0	0
549	Epidemiology of Hypertension in Diabetes. , 2012, , 1-14.		1
550	Hypertension in African Americans. , 2012, , 25-34.		0
554	Management of the unholy trinity diabetes-obesity-hypertension (diabesotension). <i>Diabetes/Metabolism Research and Reviews</i> , 2012, , n/a-n/a.	1.7	0
556	European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). <i>International Journal of Behavioral Medicine</i> , 2012, 19, 403-488.	0.8	224
557	Guía europea sobre prevención de la enfermedad cardiovascular en la práctica clínica (versión 2012). <i>Revista Española De Cardiología</i> , 2012, 65, 937.e1-937.e66.	0.6	30
559	What Is the Ideal Blood Pressure Goal for Patients with Diabetes Mellitus and Nephropathy?. <i>Current Cardiology Reports</i> , 2012, 14, 651-659.	1.3	14
560	Should African Americans Have a Lower Blood Pressure Goal than Other Ethnic Groups to Prevent Organ Damage?. <i>Current Cardiology Reports</i> , 2012, 14, 660-666.	1.3	9
561	Hypertensive Goals in Patients with Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2012, 14, 667-672.	1.3	0
562	Blood Pressure J-Curve: Current Concepts. <i>Current Hypertension Reports</i> , 2012, 14, 556-566.	1.5	90
563	Therapeutic Modalities in Diabetic Nephropathy: <i>Future Approaches</i>. <i>Open Journal of Nephrology</i> , 2012, 02, 5-18.	0.0	11
564	Manual of Outpatient Cardiology. , 2012, , .		1
565	Management of hypertension in women. <i>Hypertension Research</i> , 2012, 35, 251-260.	1.5	33
569	Treatment of chronic kidney disease. <i>Kidney International</i> , 2012, 81, 351-362.	2.6	141
570	Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2012, 6, 81-91.	1.0	39
573	An eicosanoid-centric view of atherothrombotic risk factors. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 3361-3380.	2.4	34
574	Longitudinal analysis of cardiovascular parameters after gastric bypass surgery. <i>Surgery for Obesity and Related Diseases</i> , 2012, 8, 703-709.	1.0	15

#	ARTICLE	IF	CITATIONS
575	Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy. <i>BMC Medical Research Methodology</i> , 2012, 12, 119.	1.4	19
576	Type 2 Diabetes Mellitus. , 2012, , e95-e108.		2
578	Arterial Hypertension. , 2012, , 373-389.		0
579	Diabetes mellitus, insulin, oral antidiabetes agents, obesity. , 2012, , 572-586.		0
580	Aggressive blood pressure reduction in patients at high vascular risk: is it dangerous?. <i>Italian Journal of Medicine</i> , 0, , .	0.2	0
581	Co-existing disease in vascular surgery patients. , 0, , 22-31.		0
582	EFFICACY OF COMBINED ANTIHYPERTENSIVE THERAPY IN ACHIEVEMENT OF TARGET BLOOD PRESSURE IN DIABETIC PATIENTS. <i>Rational Pharmacotherapy in Cardiology</i> , 2012, 8, 667-674.	0.3	0
583	Treatment of Hypertension. <i>Cardiovascular Pharmacology: Open Access</i> , 2012, 1, .	0.1	0
584	Editorial What should the optimal blood pressure goal be in patients with diabetes mellitus or chronic kidney disease?. <i>Archives of Medical Science</i> , 2012, 3, 399-402.	0.4	16
585	Prevention and Treatment of Diabetic Retinopathy: Evidence from Large, Randomized Trials. The Emerging Role of Fenofibrate. <i>Reviews on Recent Clinical Trials</i> , 2012, 7, 71-80.	0.4	24
586	Heart Disease and Stroke Statistics—2012 Update. <i>Circulation</i> , 2012, 125, e2-e220.	1.6	4,096
587	Diabetic renal disease in older people. <i>Practical Diabetes</i> , 2012, 29, 109-112.	0.1	0
588	Clinical Implications of the ACCORD Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 41-48.	1.8	52
591	Screening for diabetes: hope and despair. <i>Diabetologia</i> , 2012, 55, 1568-1571.	2.9	2
593	Effect of a Physician Uncertainty Reduction Intervention on Blood Pressure in Uncontrolled Hypertensives—A Cluster Randomized Trial. <i>Journal of General Internal Medicine</i> , 2012, 27, 413-419.	1.3	24
594	Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches. <i>Journal of General Internal Medicine</i> , 2012, 27, 458-468.	1.3	46
595	Impact of Delaying Blood Pressure Control in Patients with Type 2 Diabetes: Results of a Decision Analysis. <i>Journal of General Internal Medicine</i> , 2012, 27, 640-646.	1.3	6
596	Is It Time to Screen for the Haptoglobin Genotype to Assess the Cardiovascular Risk Profile and Vitamin E Therapy Responsiveness in Patients with Diabetes?. <i>Current Diabetes Reports</i> , 2012, 12, 274-279.	1.7	12

#	ARTICLE	IF	CITATIONS
597	The Diagnosis and Management of Cerebrovascular Disease in Diabetes. <i>Current Diabetes Reports</i> , 2012, 12, 314-323.	1.7	26
598	Should Two-Drug Initial Therapy for Hypertension Be Recommended for All Patients?. <i>Current Hypertension Reports</i> , 2012, 14, 324-332.	1.5	8
599	Approach to Cardiovascular Disease Prevention in Patients With Chronic Kidney Disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2012, 14, 391-413.	0.4	10
600	J Curve in Hypertension. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 281-290.	0.8	7
601	Combination Therapy in Hypertension. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 291-298.	0.8	1
602	Prehypertension: how low to go and do drugs have a role?. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 187-193.	1.1	8
603	Single-Pill Combination of Telmisartan/Amlodipine Versus Amlodipine Monotherapy in Diabetic Hypertensive Patients: An 8-Week Randomized, Parallel-Group, Double-Blind Trial. <i>Clinical Therapeutics</i> , 2012, 34, 537-551.	1.1	17
604	¿Hasta qué valores debemos bajar la presión arterial sistólica para reducir el riesgo de recurrencia del ictus?. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2012, 19, 201.	0.0	0
605	Diabetes, hyperglycaemia, and acute ischaemic stroke. <i>Lancet Neurology</i> , The, 2012, 11, 261-271.	4.9	377
606	Kidney Disease in People With Diabetes: The Expanding Epidemic. <i>American Journal of Kidney Diseases</i> , 2012, 59, 340-342.	2.1	3
607	A 48-week study of amlodipine plus amiloride/hydrochlorothiazide vs. amlodipine plus telmisartan in the treatment of hypertension. <i>International Journal of Clinical Practice</i> , 2012, 66, 792-799.	0.8	6
608	Controversies in blood pressure goal guidelines and masked hypertension. <i>Annals of the New York Academy of Sciences</i> , 2012, 1254, 115-122.	1.8	4
609	Evidence-Based Hypertension Treatment in Patients With Diabetes. <i>Journal of Clinical Hypertension</i> , 2012, 14, 97-102.	1.0	20
610	Single-Pill Combination of Telmisartan/Amlodipine in Patients With Severe Hypertension: Results From the TEAMSTA Severe HTN Study. <i>Journal of Clinical Hypertension</i> , 2012, 14, 206-215.	1.0	31
611	Prognostic Impact of Baseline Low Blood Pressure in Hypertensive Patients With Stable Coronary Artery Disease of Daily Clinical Practice. <i>Journal of Clinical Hypertension</i> , 2012, 14, 537-546.	1.0	7
612	Aggressive Blood Pressure Lowering Therapy Guided by Home Blood Pressure Monitoring Improves Target Organ Damage in Hypertensive Patients With Type 2 Diabetes/Prediabetes. <i>Journal of Clinical Hypertension</i> , 2012, 14, 422-428.	1.0	22
613	Trends in Hypertension Prevalence, Awareness, Treatment, and Control Rates in Shandong Province of China. <i>Journal of Clinical Hypertension</i> , 2012, 14, 637-643.	1.0	24
614	Blood Pressure in Renal Disease: How to Accomplish the Goal?. <i>Cardiovascular Therapeutics</i> , 2012, 30, 193-198.	1.1	14

#	ARTICLE	IF	CITATIONS
616	Prevalence and predictors of abnormal arterial function in statin-treated type 2 diabetes mellitus patients. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 349-357.	1.5	5
617	Comparison of demographic factors and cardiovascular risk factor control among U.S. adults with type 2 diabetes by insulin treatment classification. <i>Journal of Diabetes and Its Complications</i> , 2012, 26, 169-174.	1.2	53
618	Visit-to-visit variability in blood pressure strongly predicts all-cause mortality in patients with type 2 diabetes: a 5-year prospective analysis. <i>European Journal of Clinical Investigation</i> , 2012, 42, 245-253.	1.7	101
619	Are there new threshold and goals in the treatment of arterial hypertension?. <i>European Journal of Clinical Investigation</i> , 2012, 42, 914-920.	1.7	5
620	Does achieving an intensive versus usual blood pressure level prevent stroke?. <i>Annals of Neurology</i> , 2012, 71, 133-140.	2.8	44
621	Tight Blood Pressure Control in Diabetes: Evidence-Based Review of Treatment Targets in Patients with Diabetes. <i>Current Cardiology Reports</i> , 2012, 14, 89-96.	1.3	21
623	Diabetes Mellitus Prevention and Treatment. , 2013, , 63-79.		0
624	Management of Hypertension in Patients with Diabetes. <i>Critical Care Nursing Clinics of North America</i> , 2013, 25, 71-91.	0.4	3
625	Hypertension and Vascular Dynamics in Men and Women With Metabolic Syndrome. <i>Journal of the American College of Cardiology</i> , 2013, 61, 12-19.	1.2	104
626	Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2013, 165, 477-488.	1.2	30
627	Pharmacological primary and secondary cardiovascular prevention among diabetic patients in a multiethnic general practice population: still room for improvements. <i>BMC Health Services Research</i> , 2013, 13, 182.	0.9	7
628	Blood Pressure and Mortality in U.S. Veterans With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2013, 159, 233.	2.0	182
629	Genetics of Stroke. , 2013, , 1-20.		1
630	Independent Contribution of A1C, Systolic Blood Pressure, and LDL Cholesterol Control to Risk of Cardiovascular Disease Hospitalizations in Type 2 Diabetes: An Observational Cohort Study. <i>Journal of General Internal Medicine</i> , 2013, 28, 691-697.	1.3	42
631	Role of Ambulatory Blood Pressure Monitoring in Hypertension and Diabetes. <i>Current Hypertension Reports</i> , 2013, 15, 137-142.	1.5	3
632	Type 2 Diabetes in Older People; The Importance of Blood Pressure Control. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 233-237.	0.8	8
633	Effectiveness and Safety of Aliskiren and Aliskiren Hydrochlorothiazide (HCT) in a Multiethnic, Real-World Setting. <i>Advances in Therapy</i> , 2013, 30, 176-189.	1.3	2
634	Bringing prevention in geriatrics: Evidences from cardiovascular medicine supporting the new challenge. <i>Experimental Gerontology</i> , 2013, 48, 64-68.	1.2	25

#	ARTICLE	IF	CITATIONS
635	Hypertension in the Elderly. Clinics in Geriatric Medicine, 2013, 29, 593-609.	1.0	17
639	Traitement de l'hypertension. Canadian Journal of Diabetes, 2013, 37, S492-S493.	0.4	0
640	Hypertension in the elderly: A reappraisal. Clinical Queries Nephrology, 2013, 2, 71-77.	0.2	2
641	Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension. American Journal of Medicine, 2013, 126, 501-508.	0.6	56
642	Strategies for preventing type 2 diabetes: an update for clinicians. Therapeutic Advances in Chronic Disease, 2013, 4, 242-261.	1.1	45
643	Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis. American Heart Journal, 2013, 166, 199-207.e15.	1.2	347
645	How useful are hypertension guidelines for diabetes?. Diabetes Management, 2013, 3, 115-121.	0.5	0
646	Blood pressure targets for hypertension in people with diabetes mellitus. The Cochrane Library, 2013, , CD008277.	1.5	68
647	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. European Heart Journal, 2013, 34, 2444-2452.	1.0	282
648	Changing Impact of Modifiable Risk Factors on the Incidence of Major Outcomes of Type 1 Diabetes. Diabetes Care, 2013, 36, 3999-4006.	4.3	38
649	American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. Endocrine Practice, 2013, 19, 1-48.	1.1	132
650	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	1.0	1,758
651	Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: Potential applications to cardiovascular disease and diabetes. Proteomics - Clinical Applications, 2013, 7, 528-540.	0.8	48
652	Hypertension management algorithm for type 2 diabetic patients applied in primary care. Diabetology and Metabolic Syndrome, 2013, 5, 52.	1.2	5
653	Pharmacologic Treatment of Hypertension in Patients With Chronic Kidney Disease. American Journal of Cardiovascular Drugs, 2013, 13, 177-188.	1.0	7
654	Hypertension-Related Stroke Prevention in the Elderly. Current Hypertension Reports, 2013, 15, 582-589.	1.5	12
655	Blood Pressure Control and Primary Prevention of Stroke: Summary of the Recent Clinical Trial Data and Meta-Analyses. Current Hypertension Reports, 2013, 15, 559-574.	1.5	78
656	Blood Pressure Levels and Stroke: J-curve Phenomenon?. Current Hypertension Reports, 2013, 15, 575-581.	1.5	26

#	ARTICLE	IF	CITATIONS
657	Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes Mellitus. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 706-721.	0.4	0
658	Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1115-1124.	0.6	7
660	Antihypertensive Response to Combination of Olmesartan and Amlodipine Does Not Depend on Method and Time of Drug Administration. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013, 20, 25-32.	1.0	3
661	Antihypertensive therapy: from 2003 to 2013 and beyond. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1443-1446.	0.6	1
662	Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. <i>Annals of the New York Academy of Sciences</i> , 2013, 1281, 36-50.	1.8	85
663	Taking small steps towards targets - perspectives for clinical practice in diabetes, cardiometabolic disorders and beyond. <i>International Journal of Clinical Practice</i> , 2013, 67, 322-332.	0.8	28
664	Pharmacologic Management of Hypertension. , 2013, , 474-489.		4
665	Albuminuria in relation to the single and combined effects of systolic and diastolic blood pressure in Chinese. <i>Blood Pressure</i> , 2013, 22, 158-164.	0.7	6
666	Heart Disease and Stroke Statistics—2013 Update. <i>Circulation</i> , 2013, 127, e6-e245.	1.6	4,387
667	Classification of Hypertension. , 2013, , 471-478.		1
668	U.S. and Canadian Hypertension Guidelines. , 2013, , 425-432.		0
669	European and British Guidelines on Hypertension. , 2013, , 433-440.		0
670	Hypertension and Diabetes Mellitus. , 2013, , 313-319.		0
671	Sleep-Time Blood Pressure: Prognostic Value and Relevance as a Therapeutic Target for Cardiovascular Risk Reduction. <i>Chronobiology International</i> , 2013, 30, 68-86.	0.9	79
672	Cardiovascular Risk of Resistant Hypertension: Dependence on Treatment-Time Regimen of Blood Pressure—Lowering Medications. <i>Chronobiology International</i> , 2013, 30, 340-352.	0.9	67
673	Role of Time-of-Day of Hypertension Treatment on the J-Shaped Relationship Between Blood Pressure and Cardiovascular Risk. <i>Chronobiology International</i> , 2013, 30, 328-339.	0.9	25
674	Ambulatory Blood Pressure Thresholds for Diagnosis of Hypertension in Patients With and Without Type 2 Diabetes Based on Cardiovascular Outcomes. <i>Chronobiology International</i> , 2013, 30, 132-144.	0.9	13
675	Le diabète chez les personnes âgées. <i>Canadian Journal of Diabetes</i> , 2013, 37, S567-S574.	0.4	0

#	ARTICLE	IF	CITATIONS
677	Diabetes in the Elderly. Canadian Journal of Diabetes, 2013, 37, S184-S190.	0.4	68
680	Treatment of Hypertension. Canadian Journal of Diabetes, 2013, 37, S117-S118.	0.4	10
681	The association of blood pressure with survival rate and cardiovascular events in Chinese patients with type 2 diabetes. International Journal of Cardiology, 2013, 168, 4514-4515.	0.8	2
683	Hypertension in renal transplantation. Clinical Queries Nephrology, 2013, 2, 131-135.	0.2	0
684	Hypertension. Primary Care - Clinics in Office Practice, 2013, 40, 179-194.	0.7	18
685	Hypertension, coronary heart disease and stroke: Should the blood pressure J-curve be a concern?. Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 139-144.	0.2	5
686	Telmisartan plus amlodipine single-pill combination for the management of hypertensive patients with a metabolic risk profile (added-risk patients). Current Medical Research and Opinion, 2013, 29, 41-53.	0.9	6
687	American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary. Endocrine Practice, 2013, 19, 536-557.	1.1	230
688	Lowering blood pressure limits in patients with type 2 diabetes: Is it still warranted?. Journal of Diabetes and Its Complications, 2013, 27, 415-416.	1.2	0
689	Obesity, blood pressure, and cardiovascular outcomes – Authors' reply. Lancet, The, 2013, 381, 1982-1983.	6.3	0
692	Diabetes and kidney disease. Apollo Medicine, 2013, 10, 118-125.	0.0	2
693	Delayed Diagnosis of Hypertension in Diabetic Patients Monitored in Primary Care. Revista Espanola De Cardiologia (English Ed), 2013, 66, 700-706.	0.4	7
694	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). Revista Espanola De Cardiologia, 2013, 66, 880.e1-880.e64.	0.6	24
695	Retraso diagnóstico de la hipertensión arterial en pacientes diabéticos atendidos en atención primaria. Revista Espanola De Cardiologia, 2013, 66, 700-706.	0.6	6
696	High-density lipoprotein cholesterol and the risk of nephropathy in type 2 diabetic patients. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 751-757.	1.1	44
697	Detection of cardiovascular autonomic neuropathy using exercise testing in patients with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2013, 27, 64-69.	1.2	19
698	Longitudinal changes in dietary fat intake and associated changes in cardiovascular risk factors in adults with type 2 diabetes: The ACCORD trial. Diabetes Research and Clinical Practice, 2013, 100, 61-68.	1.1	3
699	Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabetic Medicine, 2013, 30, 46-55.	1.2	166

#	ARTICLE	IF	CITATIONS
701	The Pathogenesis and Management of Hypertension in Diabetic Kidney Disease. Medical Clinics of North America, 2013, 97, 31-51.	1.1	15
702	Antihypertensive treatment in diabetic patients. Review of current data. Maturitas, 2013, 75, 142-147.	1.0	2
703	Standards of Medical Care in Diabetes—2013. Diabetes Care, 2013, 36, S11-S66.	4.3	3,076
704	KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD. American Journal of Kidney Diseases, 2013, 62, 201-213.	2.1	174
705	Aggressive Blood Pressure Control Increases Coronary Heart Disease Risk Among Diabetic Patients. Diabetes Care, 2013, 36, 3287-3296.	4.3	47
706	Cardiovascular Complications in Patients with Renal Disease. , 2013, , 687-700.		0
707	2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2013, 22, 193-278.	0.7	355
708	To <scp>RAS</scp> or Not to <scp>RAS</scp>? The Evidence for and Cautions with Renin—Angiotensin System Inhibition in Patients with Diabetic Kidney Disease. Pharmacotherapy, 2013, 33, 496-514.	1.2	23
709	2013 Ambulatory Blood Pressure Monitoring Recommendations for the Diagnosis of Adult Hypertension, Assessment of Cardiovascular and other Hypertension-associated Risk, and Attainment of Therapeutic Goals. Chronobiology International, 2013, 30, 355-410.	0.9	168
710	Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet, The, 2013, 382, 507-515.	6.3	606
711	Blood Pressure and Stroke Risk Among Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3653-3662.	1.8	37
712	Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. , 2013, , CD008143.		130
713	Identifiable Hypertension: A New Spectrum. Journal of Clinical Hypertension, 2013, 15, 705-709.	1.0	2
714	Masked Hypertension in Diabetes Mellitus. Hypertension, 2013, 61, 964-971.	1.3	142
715	2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219.	1.0	5,681
716	Blood pressure and diabetes: vicious twins. Heart, 2013, 99, 577-585.	1.2	27
718	Renin Inhibitors and Cardiovascular and Renal Protection: An Endless Quest?. Cardiovascular Drugs and Therapy, 2013, 27, 145-153.	1.3	24
719	Blood pressure targets in patients with coronary artery disease: observations from traditional and Bayesian random effects meta-analysis of randomised trials. Heart, 2013, 99, 601-613.	1.2	58

#	ARTICLE	IF	CITATIONS
720	Computer Modeling of Diabetes and Its Complications: A Report on the Fifth Mount Hood Challenge Meeting. <i>Value in Health</i> , 2013, 16, 453-454.	0.1	7
721	Hypertension after Kidney Transplantation: A Pathophysiologic Approach. <i>Current Hypertension Reports</i> , 2013, 15, 458-469.	1.5	22
722	Randomized Trial of Guiding Hypertension Management Using Central Aortic Blood Pressure Compared With Best-Practice Care. <i>Hypertension</i> , 2013, 62, 1138-1145.	1.3	132
723	Salt intake and cardiovascular disease: why are the data inconsistent?. <i>European Heart Journal</i> , 2013, 34, 1034-1040.	1.0	103
724	Calcium and phosphate impact cardiovascular risk. <i>European Heart Journal</i> , 2013, 34, 1112-1121.	1.0	40
725	Utility of a Post-Hospitalization Stroke Prevention Program Managed by Nurses. <i>Hospital Practice (1995)</i> , 2013, 41, 70-79.	0.5	24
728	The J-Curve Limbo: How Low Can You Go?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3588-3591.	1.8	1
729	Blood pressure goals in T2DM: a Latin American perspective. <i>Nature Reviews Endocrinology</i> , 2013, 9, 138-139.	4.3	1
730	Systematic Review and Meta-Analysis of 16 Randomized Clinical Trials of Radix Astragali and Its Prescriptions for Diabetic Retinopathy. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-13.	0.5	2
731	Effect of Aliskiren on Progression of Coronary Disease in Patients With Prehypertension. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1135.	3.8	67
732	Humanism in the time of metrics--an essay by David Loxterkamp. <i>BMJ, The</i> , 2013, 347, f5539-f5539.	3.0	12
733	Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy. <i>International Journal of Hypertension</i> , 2013, 2013, 1-8.	0.5	1
734	Low Diastolic Blood Pressure as a Risk for All-Cause Mortality in VA Patients. <i>International Journal of Hypertension</i> , 2013, 2013, 1-5.	0.5	22
735	Treat to Goal: Impact of Clinical Pharmacist Referral Service Primarily in Diabetes Management. <i>Hospital Pharmacy</i> , 2013, 48, 656-661.	0.4	4
736	Prognostic impact of clinic and ambulatory blood pressure components in high-risk type 2 diabetic patients. <i>Journal of Hypertension</i> , 2013, 31, 2176-2186.	0.3	37
737	Myths in the Treatment of Type 2 Diabetes. <i>American Journal of Therapeutics</i> , 2013, 20, 543-548.	0.5	3
738	Extreme Sodium Reductions for the Entire Population: Zealotry or Evidence Based?. <i>American Journal of Hypertension</i> , 2013, 26, 1187-1190.	1.0	9
739	Statins and beyond: Concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 99-114.	0.9	7

#	ARTICLE	IF	CITATIONS
740	Is it AKI or Nonrecovery of Renal Function That Is Important for Long-Term Outcomes?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 173-176.	2.2	22
741	Current issues in the management and monitoring of hypertension in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 599-606.	1.0	13
742	Predictive power of home blood pressure and clinic blood pressure in hypertensive patients with impaired glucose metabolism and diabetes. <i>Journal of Hypertension</i> , 2013, 31, 1593-1602.	0.3	45
743	Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes. <i>Journal of Hypertension</i> , 2013, 31, 1603-1610.	0.3	38
744	The unappreciated importance of blood pressure in recent and older atrial fibrillation trials. <i>Journal of Hypertension</i> , 2013, 31, 2109-2117.	0.3	19
745	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Journal of Hypertension</i> , 2013, 31, 1281-1357.	0.3	4,251
746	Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus. <i>Journal of Hypertension</i> , 2013, 31, 2094-2102.	0.3	120
747	What should be the blood pressure target for patients with chronic kidney disease?. <i>Current Opinion in Cardiology</i> , 2013, 28, 439-445.	0.8	6
748	Establishing Normal Reference Values in Quantitative Computed Tomography of Emphysema. <i>Journal of Thoracic Imaging</i> , 2013, 28, 280-283.	0.8	16
749	Are Serial BNP Measurements Useful in Heart Failure Management?. <i>Circulation</i> , 2013, 127, 509-516.	1.6	54
750	Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes. <i>Cmaj</i> , 2013, 185, 963-967.	0.9	15
751	Most Important Outcomes Research Papers on Hypertension. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, e26-35.	0.9	4
752	Albuminuria and Cognitive Decline in People with Diabetes and Normal Renal Function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1907-1914.	2.2	47
753	Plasma Renin Activity Testing to Guide Triple Antirenin System Drug Therapy in a Patient With Difficult-to-Treat Hypertension. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1562-1568.	0.9	2
754	Meta-analysis shows limited benefit of lowering blood pressure below 130/80 mmHg in patients with type 2 diabetes. <i>Evidence-Based Medicine</i> , 2013, 18, 222-223.	0.6	0
755	Generic Medications and Blood Pressure Control in Diabetic Hypertensive Subjects: Results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. <i>Diabetes Care</i> , 2013, 36, 591-597.	4.3	11
756	The Impact of Blood Pressure on Kidney Function in the Elderly: A Cross-Sectional Study. <i>Kidney and Blood Pressure Research</i> , 2013, 38, 205-216.	0.9	12
757	Prevalence of Optimal Treatment Regimens in Patients With Apparent Treatment-Resistant Hypertension Based on Office Blood Pressure in a Community-Based Practice Network. <i>Hypertension</i> , 2013, 62, 691-697.	1.3	137

#	ARTICLE	IF	CITATIONS
758	A New Approach to Residual Risk in Treated Hypertensionâ€”3P Screening. Hypertension, 2013, 62, 236-239.	1.3	15
759	Cardiovascular protection in type 2 diabetes: time to ADVANCE management ACCORDing to the evidence. Research Reports in Clinical Cardiology, 2013, , 1.	0.2	0
760	Impact of Diabetes on Cardiovascular Disease: An Update. International Journal of Hypertension, 2013, 2013, 1-15.	0.5	321
763	Blood Pressure and Cholesterol Control in Hypertensive Hypercholesterolemic Patients. Circulation, 2013, 128, 29-41.	1.6	123
764	Pharmacologic Options for Treatment of Ischemic Disease. , 2013, , 83-130.		4
765	Management of Cardiovascular Disease Risk Factors in Older Adults with Type 2 Diabetes Mellitus: 2002â€”2012 Literature Review. Journal of the American Geriatrics Society, 2013, 61, 2027-2037.	1.3	56
766	Prevalence of Apparent Treatment-Resistant Hypertension among Individuals with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1583-1590.	2.2	130
767	Association among blood pressure control in elderly patients with hypertension, left atrial structure and function and new-onset atrial fibrillation: a prospective 2-year study in 234 patients. Hypertension Research, 2013, 36, 799-806.	1.5	17
768	Combining Risk Difference and Risk Ratio in Noninferiority Trials of Safety. Journal of Biopharmaceutical Statistics, 2013, 23, 261-271.	0.4	3
769	Interpretation of Chinese Society of Endocrinology consensus statement on hyperglycemia management target in adult inpatients in China (â€”). Diabetes, 2013, 5, 416-420.		
770	Exploring Issues in Difficultâ€”toâ€”Treat Hypertension. Journal of Clinical Hypertension, 2013, 15, 859-864.	1.0	2
771	Lower, faster, better: the delusions of surrogate markers in hypertension. International Journal of Clinical Practice, 2013, 67, 822-824.	0.8	0
772	Different Definitions of Prevalent Hypertension Impact: The Clinical Epidemiology of Hypertension and Attainment of Healthy People Goals. Journal of Clinical Hypertension, 2013, 15, 154-161.	1.0	29
773	New approaches to assessing cardiovascular risk. Trends in Urology & Men's Health, 2013, 4, 37-42.	0.2	0
774	Assessment of Target Organ Damage in the Evaluation and Followâ€”Up of Hypertensive Patients: Where Do We Stand?. Journal of Clinical Hypertension, 2013, 15, 742-747.	1.0	28
775	Blood pressure targets for patients with chronic kidney disease. Blood Pressure, 2013, 22, 395-396.	0.7	2
776	Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus. European Journal of Preventive Cardiology, 2013, 20, 209-217.	0.8	26
777	Isolated Nocturnal Hypertension. Hypertension, 2013, 61, 278-283.	1.3	97

#	ARTICLE	IF	CITATIONS
778	Diabetic Retinopathy, Its Progression, and Incident Cardiovascular Events in the ACCORD Trial. <i>Diabetes Care</i> , 2013, 36, 1266-1271.	4.3	86
779	Early-Adulthood Cardiovascular Disease Risk Factor Profiles Among Individuals With and Without Diabetes in the Framingham Heart Study. <i>Diabetes Care</i> , 2013, 36, 1590-1596.	4.3	25
780	Management of the patient with diabetes and coronary artery disease: a contemporary review. <i>Future Cardiology</i> , 2013, 9, 387-403.	0.5	8
781	Simple Integer Risk Score to Determine Prognosis of Patients With Hypertension and Chronic Stable Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2013, 2, e000205.	1.6	11
782	Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring. <i>Journal of Human Hypertension</i> , 2013, 27, 715-720.	1.0	18
783	Diastolic blood pressure reduction contributes more to the regression of left ventricular hypertrophy: a meta-analysis of randomized controlled trials. <i>Journal of Human Hypertension</i> , 2013, 27, 698-706.	1.0	14
784	Significance of estimating the glomerular filtration rate for the management of hypertension in type 2 diabetes with microalbuminuria. <i>Hypertension Research</i> , 2013, 36, 705-710.	1.5	21
785	Hypertension and the J-curve phenomenon: implications for tight blood pressure control. <i>Hypertension Research</i> , 2013, 36, 109-111.	1.5	21
786	A Clinician's Guide to the <scp>ABCs</scp> of Cardiovascular Disease Prevention: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. <i>Clinical Cardiology</i> , 2013, 36, 383-393.	0.7	45
787	Benefits of Early Hypertension Control on Cardiovascular Outcomes in Patients With Diabetes. <i>Diabetes Care</i> , 2013, 36, 322-327.	4.3	20
788	Are Observational Studies More Informative Than Randomized Controlled Trials in Hypertension?. <i>Hypertension</i> , 2013, 62, 470-476.	1.3	13
789	Higher Accuracy of Self-Monitoring of Blood Glucose in Insulin-Treated Patients in Germany: Clinical and Economical Aspects. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 904-912.	1.3	11
790	Treatment-resistant hypertension: another Cinderella story. <i>European Heart Journal</i> , 2013, 34, 1175-1177.	1.0	12
791	New blood pressure control goals, more rational but facilitating therapeutic inertia?. <i>Journal of Hypertension</i> , 2013, 31, 2463.	0.3	5
792	Aortic, but not brachial blood pressure category enhances the ability to identify target organ changes in normotensives. <i>Journal of Hypertension</i> , 2013, 31, 1124-1130.	0.3	14
794	Contributions to management of hypertension from papers in the current issue. <i>Journal of Hypertension</i> , 2013, 31, 845-847.	0.3	0
795	Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes. <i>Journal of Hypertension</i> , 2013, 31, 414-421.	0.3	72
796	Guidelines for the management of hypertension and target organ damage. <i>Journal of Hypertension</i> , 2013, 31, 2464-2465.	0.3	23

#	ARTICLE	IF	CITATIONS
797	Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome. <i>Journal of Hypertension</i> , 2013, 31, 223-238.	0.3	61
798	Should diabetic blood pressure targets be the same in elderly compared with younger patients?. <i>Diabetes Management</i> , 2013, 3, 315-321.	0.5	0
799	Hypertension and stable coronary artery disease. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 545-552.	0.6	5
800	New blood pressure control goals, more rational but facilitating therapeutic inertia?. <i>Journal of Hypertension</i> , 2013, 31, 2462.	0.3	9
801	Guidelines for the management of hypertension and target organ damage. <i>Journal of Hypertension</i> , 2013, 31, 2463-2464.	0.3	5
802	Myocardial perfusion pressure in patients with hypertension and coronary artery disease. <i>Journal of Hypertension</i> , 2013, 31, 975-982.	0.3	31
803	Social Impacts, (3) Guideline for Managements of Hypertension -Concept and Social Significance. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2013, 102, 117b-118a.	0.0	0
807	O acometimento renal na hipertensão arterial e diabetes mellitus tipo 2: como identificar e prevenir “A visão do nefrologista. <i>Revista Hospital Universitário Pedro Ernesto</i> , 2013, 12, .	0.1	2
808	Diabetes in Women. , 2013, , 873-882.		0
809	Can Transient Drop in Blood Pressure in High-Risk Hypertensive Patients Cause Small Cerebral Infarcts?. <i>ISRN Stroke</i> , 2013, 2013, 1-8.	0.8	0
810	New Aspects on Arterial Hypertension. <i>Conference Papers in Medicine</i> , 2013, 2013, 1-3.	0.6	0
811	A comprehensive management of hypertension among patients with metabolic syndrome: an evidence-based update. <i>Medical Journal of Indonesia</i> , 2013, , 189.	0.2	1
812	Ischemic Heart Disease in Hypertension. , 2013, , 253-261.		0
813	Diabetes mellitus e cora��o: um continuum de risco Quais os alvos contempor��neos de tratamento e como alcan��-los?. <i>Revista Hospital Universit��rio Pedro Ernesto</i> , 2013, 12, .	0.1	1
814	Diabetes mellitus and stroke. <i>Nosotchu</i> , 2014, 36, 105-112.	0.0	0
815	Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression. <i>Current Vascular Pharmacology</i> , 2014, 12, 155-167.	0.8	7
816	All-Cause Mortality in Patients with Type 2 Diabetes in Association with Achieved Hemoglobin A1c, Systolic Blood Pressure, and Low-Density Lipoprotein Cholesterol Levels. <i>PLoS ONE</i> , 2014, 9, e109501.	1.1	18
817	Perspective on Combination RAS Blocking Therapy: Off-TARGET, Dis-CORD, MAP-to-Nowhere, Low ALTITUDE, and NEPHRON-D. <i>American Journal of Nephrology</i> , 2014, 39, 46-49.	1.4	9

#	ARTICLE	IF	CITATIONS
818	Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis. <i>Vascular Health and Risk Management</i> , 2014, 10, 651.	1.0	6
819	Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?. <i>World Journal of Diabetes</i> , 2014, 5, 444.	1.3	588
820	Efficacy of treatment for hyperglycemic crisis in elderly diabetic patients in a day hospital. <i>Clinical Interventions in Aging</i> , 2014, 9, 843.	1.3	3
821	Health outcomes in diabetics measured with Minnesota Community Measurement quality metrics. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2015, 8, 1.	1.1	6
822	Revisiting the J-curve Phenomenon. An Old New Concept?. <i>Current Hypertension Reviews</i> , 2014, 10, 14-19.	0.5	1
823	Program Participation and Blood Pressure Improvement in the Heart of New Ulm Project, Minnesota, 2009-2011. <i>Preventing Chronic Disease</i> , 2014, 11, E48.	1.7	10
824	Blood Pressure Control in Diabetic Nephropathy. <i>Journal of Nephrology & Therapeutics</i> , 2014, 04, .	0.1	0
825	Stage A: Can Heart Failure Be Prevented?. <i>Current Cardiology Reviews</i> , 2014, 11, 4-9.	0.6	4
826	African Americans, hypertension and the renin angiotensin system. <i>World Journal of Cardiology</i> , 2014, 6, 878.	0.5	51
828	Mobile health applications to support diabetic patient and doctor. , 2014, , .		2
829	Factors Influencing the Decline in Stroke Mortality. <i>Stroke</i> , 2014, 45, 315-353.	1.0	655
831	Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2014, 129, 999-1008.	1.6	197
833	Evidence Relating Sodium Intake to Blood Pressure and CVD. <i>Current Cardiology Reports</i> , 2014, 16, 529.	1.3	18
834	Revisiting the J shaped curve, exploring the association between cardiovascular risk factors and concurrent depressive symptoms in patients with cardiometabolic disease: Findings from a large cross-sectional study. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 139.	0.7	10
835	Association of physical function with predialysis blood pressure in patients on hemodialysis. <i>BMC Nephrology</i> , 2014, 15, 177.	0.8	11
837	How many clinic BP readings are needed to predict cardiovascular events as accurately as ambulatory BP monitoring?. <i>Journal of Human Hypertension</i> , 2014, 28, 731-735.	1.0	1
838	Chapter 3. Principles of treatment. <i>Hypertension Research</i> , 2014, 37, 279-285.	1.5	1
841	Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?. <i>Kidney International</i> , 2014, 85, 536-546.	2.6	64

#	ARTICLE	IF	CITATIONS
842	Blood pressure targets in the treatment of high blood pressure: a reappraisal of the J-shaped phenomenon. <i>Journal of Human Hypertension</i> , 2014, 28, 80-84.	1.0	12
843	Chapter 7. Hypertension complicated by other diseases. <i>Hypertension Research</i> , 2014, 37, 315-324.	1.5	2
844	The Association Between Patient-Reported Self-management Behavior, Intermediate Clinical Outcomes, and Mortality in Patients With Type 2 Diabetes: Results From the KORA-A Study. <i>Diabetes Care</i> , 2014, 37, 1604-1612.	4.3	32
845	In search for the "sweet spot" for blood pressure level in diabetes: Table 1. <i>Heart</i> , 2014, 100, 1404-1405.	1.2	3
846	Mitigation of experimental radiation nephropathy by renin-equivalent doses of angiotensin converting enzyme inhibitors. <i>International Journal of Radiation Biology</i> , 2014, 90, 762-768.	1.0	30
847	Cumulative Systolic BP and Changes in Urine Albumin-to-Creatinine Ratios in Nondiabetic Participants of the Multi-Ethnic Study of Atherosclerosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1922-1929.	2.2	37
848	Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive treatment. <i>Blood Pressure</i> , 2014, 23, 71-80.	0.7	14
849	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention. <i>Journal of the American Heart Association</i> , 2014, 3, e001098.	1.6	24
854	Treatment targets in patients with type 2 diabetes set by primary care physicians from Central and Eastern Europe. <i>European Journal of General Practice</i> , 2014, 20, 253-259.	0.9	4
855	Physiological Changes in Older Adults and Their Effect on Diabetes Treatment. <i>Diabetes Spectrum</i> , 2014, 27, 20-29.	0.4	11
856	Antithrombotic selection and risk factor management in ischemic stroke and transient ischemic attack. <i>Neurosurgical Focus</i> , 2014, 36, E10.	1.0	2
859	Ocular perfusion pressure in glaucoma. <i>Acta Ophthalmologica</i> , 2014, 92, e252-66.	0.6	183
860	Systemic Therapies for Diabetic Retinopathy. <i>Ophthalmology</i> , 2014, 121, 2295-2296.	2.5	13
861	Heart Disease and Stroke Statistics—2014 Update. <i>Circulation</i> , 2014, 129, e28-e292.	1.6	4,522
862	Clinical Practice Guidelines for the Management of Hypertension in the Community. <i>Journal of Clinical Hypertension</i> , 2014, 16, 14-26.	1.0	768
863	The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). <i>Clinical Trials</i> , 2014, 11, 532-546.	0.7	408
864	Validation of the IMS CORE Diabetes Model. <i>Value in Health</i> , 2014, 17, 714-724.	0.1	163
865	Comparing treatment goals for psoriasis with treatment decisions in daily practice: results from a prospective cohort of patients with psoriasis treated with biologics: Bio CAPTURE. <i>British Journal of Dermatology</i> , 2014, 171, 1091-1098.	1.4	20

#	ARTICLE	IF	CITATIONS
866	BP, Cardiovascular Disease, and Death in the Folic Acid for Vascular Outcome Reduction in Transplantation Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1554-1562.	3.0	60
867	Aggressive Blood Pressure Lowering Is Dangerous: The J-Curve. <i>Hypertension</i> , 2014, 63, 29-36.	1.3	101
868	Association of Glycemic Control With Mortality in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 503-509.	1.4	26
869	Cardiovascular disease prevention in diabetes: uncertainties and ethics. <i>Diabetes Management</i> , 2014, 4, 285-292.	0.5	0
870	Impact of a Reduced Error Range of SMBG in Insulin-treated Patients in Germany. <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 479-482.	1.3	8
871	Intensive Blood Pressure Control, Falls, and Fractures in Patients with Type 2 Diabetes: The ACCORD Trial. <i>Journal of General Internal Medicine</i> , 2014, 29, 1599-1606.	1.3	69
872	Potential Overtreatment and Undertreatment of Diabetes in Different Patient Age Groups in Primary Care After the Introduction of Performance Measures. <i>Diabetes Care</i> , 2014, 37, 1312-1320.	4.3	15
873	Contemporary treatment strategies for Type 2 diabetes-related macrovascular disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 641-658.	1.2	1
874	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline. <i>Journal of Hypertension</i> , 2014, 32, 1741-1750.	0.3	39
875	Cardiovascular disease risk in an aging HIV population. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 346-354.	1.5	38
876	How far to lower blood pressure in the long term, after a stroke?. <i>Journal of Hypertension</i> , 2014, 32, 746-748.	0.3	1
877	Optimal Medical Therapy vs CT Angiography Screening for Patients With Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2219.	3.8	8
878	Update on Transient Ischemic Attack Nursing Care. <i>Stroke</i> , 2014, 45, e71-3.	1.0	3
879	Diagnosis and Treatment of Diabetic Kidney Disease. <i>American Journal of the Medical Sciences</i> , 2014, 347, 406-413.	0.4	33
880	Staying up to date with the JNC 8 hypertension guideline. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2014, 27, 44-49.	0.1	8
881	Clinical Practice Guidelines for the Management of Hypertension in the Community. <i>Journal of Hypertension</i> , 2014, 32, 3-15.	0.3	498
882	Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. <i>Journal of Hypertension</i> , 2014, 32, 2285-2295.	0.3	267
883	Relationships of different types of event to cardiovascular death in trials of antihypertensive treatment. <i>Journal of Hypertension</i> , 2014, 32, 495-508.	0.3	12

#	ARTICLE	IF	CITATIONS
884	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 133-173.	0.9	173
885	Understanding the Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Paradox. <i>Postgraduate Medicine</i> , 2014, 126, 190-204.	0.9	11
886	Cognitive Function and Brain Structure in Persons With Type 2 Diabetes Mellitus After Intensive Lowering of Blood Pressure and Lipid Levels. <i>JAMA Internal Medicine</i> , 2014, 174, 324.	2.6	142
887	Combination Pill for Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 92.	3.8	0
888	Systolic Blood Pressure Levels Among Adults With Hypertension and Incident Cardiovascular Events. <i>JAMA Internal Medicine</i> , 2014, 174, 1252.	2.6	50
889	Observational Modeling of Strict vs Conventional Blood Pressure Control in Patients With Chronic Kidney Disease. <i>JAMA Internal Medicine</i> , 2014, 174, 1442.	2.6	83
891	Management of Diabetic Nephropathy in Older Patients: A Need for Flexible Guidelines. <i>Postgraduate Medicine</i> , 2014, 126, 171-177.	0.9	7
892	Gamma-glutamyltransferase predicts increased risk of mortality: A systematic review and meta-analysis of prospective observational studies. <i>Free Radical Research</i> , 2014, 48, 716-728.	1.5	30
893	Hyperglycemia and Blood Pressure Treatment Goal: A Cross Sectional Survey of 18350 Patients with Type 2 Diabetes in 77 Tertiary Hospitals in China. <i>PLoS ONE</i> , 2014, 9, e103507.	1.1	2
894	Non-proliferative Diabetic Retinopathy. , 2014, , 19-63.		3
895	Let's Prioritize the Right Care for the Right Patients With Hypertension. <i>JAMA Internal Medicine</i> , 2014, 174, 1261.	2.6	2
896	Self-titration of Antihypertensive Therapy in High-Risk Patients. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 795.	3.8	3
897	Tight Versus Standard Blood Pressure Control in Patients With Hypertension With and Without Cardiovascular Disease. <i>Hypertension</i> , 2014, 63, 475-482.	1.3	31
898	Insulin-Regulated Protein Palmitoylation Impacts Endothelial Cell Function. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 346-354.	1.1	65
899	Left-ventricular hypertrophy is associated better with 24-h aortic pressure than 24-h brachial pressure in hypertensive patients. <i>Journal of Hypertension</i> , 2014, 32, 1805-1814.	0.3	102
900	Type 2 diabetes and cardiovascular disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2014, 21, 109-120.	1.2	42
901	Pathophysiology of Chronic Kidney Disease. , 2014, , 448-457.		1
902	Evaluation and Management of Hypertension. , 2014, , 590-600.		0

#	ARTICLE	IF	CITATIONS
903	Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease. <i>American Journal of Medicine</i> , 2014, 127, 71-81.e1.	0.6	77
904	The Egyptian Hypertension Society. <i>Egyptian Heart Journal</i> , 2014, 66, 79-132.	0.4	21
905	The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: A neutral viewpoint. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 577-584.	1.1	4
906	Blood Pressure Goals: How Low Is Safe in CKD?. <i>American Journal of Kidney Diseases</i> , 2014, 63, 892-894.	2.1	1
907	Effects of antihypertensive treatment in Asian populations: A meta-analysis of prospective randomized controlled studies (CARDiovascular protectioN group in Asia: CARNA). <i>Journal of the American Society of Hypertension</i> , 2014, 8, 103-116.	2.3	22
908	Role of Aldosterone Blockade in Resistant Hypertension. <i>Seminars in Nephrology</i> , 2014, 34, 273-284.	0.6	25
909	Characteristics associated with informed consent for genetic studies in the ACCORD trial. <i>Contemporary Clinical Trials</i> , 2014, 37, 155-164.	0.8	4
910	Status of hypertension and coronary stenosis in asymptomatic type 2 diabetic patients: Analysis from Coronary Computed Tomographic Angiography Registry. <i>International Journal of Cardiology</i> , 2014, 174, 282-287.	0.8	8
911	Quantitative imaging biomarkers for the evaluation of cardiovascular complications in type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 234-242.	1.2	7
912	Lowering Blood Pressure to Lower the Risk of Cardiovascular Events in CKD. <i>American Journal of Kidney Diseases</i> , 2014, 63, 900-902.	2.1	1
913	Characteristics of hypertension subtypes and treatment outcome among elderly Korean hypertensives. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 246-253.	2.3	6
914	The screening of potential α -glucosidase inhibitors from the <i>Polygonum multiflorum</i> extract using ultrafiltration combined with liquid chromatography-tandem mass spectrometry. <i>Analytical Methods</i> , 2014, 6, 3353-3359.	1.3	29
915	U-shaped Relationship of Blood Pressure to CVD Risk and Relevance to Treatment Goals in Diabetes. <i>Current Cardiovascular Risk Reports</i> , 2014, 8, 1.	0.8	1
916	Should African Americans with Hypertension Be Treated Differently than Non-African Americans?. <i>Current Hypertension Reports</i> , 2014, 16, 409.	1.5	10
918	Joint British Societies [™] consensus recommendations for the prevention of cardiovascular disease (JBS3). <i>Heart</i> , 2014, 100, ii1-ii67.	1.2	441
919	A Canadian Perspective on the Eighth Joint National Committee (<sc>JNC</sc> 8) Hypertension Guidelines. <i>Journal of Clinical Hypertension</i> , 2014, 16, 246-248.	1.0	6
920	The gut [™] renal axis: do incretin-based agents confer renoprotection in diabetes?. <i>Nature Reviews Nephrology</i> , 2014, 10, 88-103.	4.1	155
921	Changes in blood pressure classification, blood pressure goals and pharmacological treatment of essential hypertension in medical guidelines from 2003 to 2013. <i>IJC Metabolic & Endocrine</i> , 2014, 2, 1-10.	0.5	3

#	ARTICLE	IF	CITATIONS
922	Pathogenesis, Pathophysiology, and Treatment of Diabetic Nephropathy. , 2014, , 222-234.		1
923	A guide for easy- and difficult-to-treat hypertension. International Journal of Cardiology, 2014, 172, 17-22.	0.8	19
924	Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. International Journal of Obesity, 2014, 38, 1165-1171.	1.6	23
925	Cardiovascular disease in chronic kidney disease. Clinical Queries Nephrology, 2014, 3, 20-29.	0.2	3
926	GuÃa de prÃctica clÃnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboraciÃn con la European Association for the Study of Diabetes. Revista Espanola De Cardiologia, 2014, 67, 136.e1-136.e56.	0.6	15
927	Integrative Weight Management. , 2014, , .		2
928	Screening, Early Diagnosis, Genetic Markers, and Predictors of Diabetic Nephropathy. , 2014, , 79-89.		0
929	Hypertension in Diabetes Mellitus. , 2014, , 119-134.		0
930	Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial. Diabetes Care, 2014, 37, 1721-1728.	4.3	217
931	Therapeutic approaches to diabetic nephropathyâ€”beyond the RAS. Nature Reviews Nephrology, 2014, 10, 325-346.	4.1	152
932	Plasma Renin Activity Testing to Guide Triple Antirenin System Drug Therapy in a Patient With Difficult-to-Treat Hypertension. Annals of Pharmacotherapy, 2014, 48, 279-285.	0.9	2
933	Closing the Gap in Hypertension Control Between Younger and Older Adults. Circulation, 2014, 129, 2052-2061.	1.6	34
935	Diabetic Kidney Disease: An ACEI (or an ARB) in the Hole. Advances in Chronic Kidney Disease, 2014, 21, 251-255.	0.6	3
936	Systolic Blood Pressure and Outcomes in Stage 3â€“4 Chronic Kidney Disease Patients: Evidence from a Taiwanese Cohort. American Journal of Hypertension, 2014, 27, 1396-1407.	1.0	15
937	Optimum Blood Pressure Target After Lacunar Stroke. Hypertension, 2014, 63, 923-924.	1.3	2
938	Optimum Blood Pressure Target After Lacunar Stroke. Hypertension, 2014, 63, 918-922.	1.3	3
939	Cognitive decline and T2DMâ€™a disconnect in the evidence?. Nature Reviews Endocrinology, 2014, 10, 258-260.	4.3	15
940	Diabesity: The Causes of Our Modern Plague. , 2014, , 187-200.		2

#	ARTICLE	IF	CITATIONS
942	Vitamin Eâ€™ gene interactions in aging and inflammatory age-related diseases: Implications for treatment. A systematic review. <i>Ageing Research Reviews</i> , 2014, 14, 81-101.	5.0	110
943	Identifying Common Genetic Variants in Blood Pressure Due to Polygenic Pleiotropy With Associated Phenotypes. <i>Hypertension</i> , 2014, 63, 819-826.	1.3	83
944	Exclusion of â€™nonRCT evidenceâ€™™ in guidelines for chronic diseases â€™ is it always appropriate? The Look AHEAD study. <i>Current Medical Research and Opinion</i> , 2014, 30, 2009-2019.	0.9	12
945	Guidelines for the Primary Prevention of Stroke. <i>Stroke</i> , 2014, 45, 3754-3832.	1.0	1,621
946	Effects of fasting blood glucose levels and blood pressure and treatment of diabetes and hypertension on the incidence of cardiovascular disease: a study of 740 patients with incident Type 2 diabetes with up to 30 years' followâ€™up. <i>Diabetic Medicine</i> , 2014, 31, 1055-1063.	1.2	11
947	The Ageâ€™Related Hemodynamic Changes of Blood Pressure and Their Impact on the Incidence of Cardiovascular Disease and Stroke: New Evidence. <i>Journal of Clinical Hypertension</i> , 2014, 16, 87-90.	1.0	26
948	Achieved Blood Pressures in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study: Challenges and Lessons Learned. <i>American Journal of Hypertension</i> , 2014, 27, 1052-1060.	1.0	22
949	Current Therapeutic Approaches to Cardio-Protection in Hypertension. <i>Current Hypertension Reports</i> , 2014, 16, 457.	1.5	1
950	Treatment. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 770-774.	2.3	0
951	Blood Pressure and Pulse Pressure Effects on Renal Outcomes in the Veterans Affairs Diabetes Trial (VADT). <i>Diabetes Care</i> , 2014, 37, 2782-2788.	4.3	23
952	Assessment of Central Blood Pressure in Patients With Type 2 Diabetes: A Comparison Between Sphygmocor and Invasively Measured Values. <i>American Journal of Hypertension</i> , 2014, 27, 169-176.	1.0	40
953	Stroke and diabetes mellitus. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 126, 167-174.	1.0	77
954	Updated National and International Hypertension Guidelines: A Review of Current Recommendations. <i>Drugs</i> , 2014, 74, 2033-2051.	4.9	95
955	Combined Angiotensin Inhibition in Diabetic Nephropathy. <i>New England Journal of Medicine</i> , 2014, 370, 777-779.	13.9	10
956	New hypertension guidelines: One size fits most?. <i>Cleveland Clinic Journal of Medicine</i> , 2014, 81, 178-188.	0.6	8
957	Coronary triglyceride deposition in contemporary advanced diabetics. <i>Pathology International</i> , 2014, 64, 325-335.	0.6	26
959	Secondary Prevention of Stroke in the Elderly: Focus on Drug Therapy. <i>Drugs and Aging</i> , 2014, 31, 721-730.	1.3	16
960	The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 Diabetes. <i>Ophthalmology</i> , 2014, 121, 2443-2451.	2.5	239

#	ARTICLE	IF	CITATIONS
961	Renin-Angiotensin-Aldosterone System Inhibition. Primary Care - Clinics in Office Practice, 2014, 41, 765-778.	0.7	24
962	Commentary on the 2014 BP Guidelines from the Panel Appointed to the Eighth Joint National Committee (JNC 8). Journal of the American Society of Nephrology: JASN, 2014, 25, 2419-2424.	3.0	30
964	Treating hypertension in type 2 diabetes. Expert Opinion on Pharmacotherapy, 2014, 15, 2131-2140.	0.9	9
965	The cardiovascular effects of insulin. Expert Opinion on Drug Safety, 2014, 13, 955-966.	1.0	17
966	Blood pressure and heart failure risk among diabetic patients. International Journal of Cardiology, 2014, 176, 125-132.	0.8	14
967	2014 Eighth Joint National Committee Panel Recommendation for Blood Pressure Targets Revisited. Journal of the American College of Cardiology, 2014, 64, 784-793.	1.2	67
968	Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet, The, 2014, 384, 1936-1941.	6.3	134
969	Impact of Achieved Blood Pressures on Mortality Risk and End-Stage Renal Disease Among a Large, Diverse Hypertension Population. Journal of the American College of Cardiology, 2014, 64, 588-597.	1.2	138
970	Association between blood pressure and risk of cardiovascular hospital admissions among people with type 2 diabetes. Heart, 2014, 100, 1444-1449.	1.2	19
971	Principles of Primary and Secondary Prevention of Cardiovascular Disease. , 2014, , 1-44.		0
973	Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke, 2014, 45, 2160-2236.	1.0	3,891
974	The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice. Diabetology and Metabolic Syndrome, 2014, 6, 31.	1.2	28
975	Diabetes and cardiovascular disease: from evidence to clinical practice – position statement 2014 of Brazilian Diabetes Society. Diabetology and Metabolic Syndrome, 2014, 6, 58.	1.2	19
976	The Population Risks of Dietary Salt Excess Are Exaggerated. Canadian Journal of Cardiology, 2014, 30, 507-512.	0.8	11
977	Standards of Medical Care in Diabetes – 2014. Diabetes Care, 2014, 37, S14-S80.	4.3	3,893
979	What Level of Sodium Intake Worsens Renal Outcomes?. American Journal of Hypertension, 2014, 27, 1243-1244.	1.0	6
980	Rational Use of Electronic Health Records for Diabetes Population Management. Current Diabetes Reports, 2014, 14, 479.	1.7	24
982	What Should the Systolic Blood Pressure Treatment Goal Be in Patients Aged 60 Years and Older with Hypertension?. Current Geriatrics Reports, 2014, 3, 299-305.	1.1	0

#	ARTICLE	IF	CITATIONS
983	Clinical Implications of the 2013 ESH/ESC Hypertension Guidelines: Targets, Choice of Therapy, and Blood Pressure Monitoring. <i>Drugs in R and D</i> , 2014, 14, 31-43.	1.1	14
984	Primary prevention for risk factors of ischemic stroke with Baduanjin exercise intervention in the community elder population: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 113.	0.7	25
985	Markers of and Risk Factors for the Development and Progression of Diabetic Kidney Disease. <i>American Journal of Kidney Diseases</i> , 2014, 63, S39-S62.	2.1	247
986	Mid-Adulthood Risk Factor Profiles for CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2633-2641.	3.0	48
987	Comprehensive approach to diabetic nephropathy. <i>Kidney Research and Clinical Practice</i> , 2014, 33, 121-131.	0.9	78
988	Association between Physical Activity Advice Only or Structured Exercise Training with Blood Pressure Levels in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Sports Medicine</i> , 2014, 44, 1557-1572.	3.1	49
989	Lowering of Blood Pressure for Recurrent Stroke Prevention. <i>Stroke</i> , 2014, 45, 2506-2513.	1.0	45
990	Clinical Challenges in Diagnosis and Management of Diabetic Kidney Disease. <i>American Journal of Kidney Diseases</i> , 2014, 63, S3-S21.	2.1	85
993	Quality of Diabetes Care in the Canadian Forces. <i>Canadian Journal of Diabetes</i> , 2014, 38, 11-16.	0.4	3
994	Guidelines and Straitjackets: Blood Pressure Targets in the Era of the Eighth Joint National Committee. <i>American Journal of Kidney Diseases</i> , 2014, 63, 895-899.	2.1	2
995	Differences in Health Services Utilization and Costs between Antihypertensive Medication Users Versus Nonusers in Adults with Diabetes and Concomitant Hypertension from Medical Expenditure Panel Survey Pooled Years 2006 to 2009. <i>Value in Health</i> , 2014, 17, 51-61.	0.1	5
996	Cardiovascular Disease in Diabetes Mellitus. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 25-40.	1.2	43
997	Blood Pressure, Hypertension, RAAS Blockade, and Drug Therapy in Diabetic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 281-286.	0.6	51
998	Preventable Coronary Heart Disease Events from Control of Cardiovascular Risk Factors in US Adults With Diabetes (Projections from Utilizing the UKPDS Risk Engine). <i>American Journal of Cardiology</i> , 2014, 113, 1356-1361.	0.7	30
999	Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD. <i>American Journal of Kidney Diseases</i> , 2014, 63, 869-887.	2.1	31
1001	Type 2 Diabetes Mellitus and Hypertension. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 103-122.	1.2	231
1002	Optimizing Blood Pressure Control in Patients With Nondiabetic Glomerular Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 200-204.	0.6	4
1003	Incident ESRD and Treatment-Resistant Hypertension: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. <i>American Journal of Kidney Diseases</i> , 2014, 63, 781-788.	2.1	46

#	ARTICLE	IF	CITATIONS
1004	Perspective: Time to tackle blood pressure. <i>Nature</i> , 2014, 510, S4-S4.	13.7	1
1005	2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 507.	3.8	6,625
1006	Managing advanced chronic kidney disease: A primary care guide. <i>Cleveland Clinic Journal of Medicine</i> , 2014, 81, 289-299.	0.6	10
1007	Top 10 landmark studies in hypertension. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 437-447.	2.3	7
1009	Prevention and management of co-morbidities in SLE. <i>Presse Medicale</i> , 2014, 43, e187-e195.	0.8	25
1010	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales del American College of Cardiology (Washington D.C., Estados Unidos, 29-31 de marzo de 2014). <i>Revista Espanola De Cardiologia</i> , 2014, 67, 479.e1-479.e7.	0.6	22
1011	Diabetes and age-related demographic differences in risk factor control. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 394-404.	2.3	11
1012	Blood pressure control and perceived health status in African Americans with subclinical hypertensive heart disease. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 321-329.	2.3	7
1016	The J-Curve in Arterial Hypertension: Fact or Fallacy?. <i>Cardiology</i> , 2014, 129, 126-135.	0.6	23
1018	Long Term Complications of Diabetes – A Review. <i>Romanian Journal of Diabetes Nutrition and Metabolic Diseases</i> , 2014, 21, 347-355.	0.3	0
1019	Bayesian Adaptive Trials for Drug Safety. , 2014, , 126-141.		0
1020	When does low normal blood pressure become too low? The J-curve phenomenon. <i>Acta Cardiologica</i> , 2014, 69, 121-129.	0.3	5
1021	Lower systolic blood pressure is associated with poorer survival in long-term survivors of stroke. <i>Journal of Hypertension</i> , 2014, 32, 904-911.	0.3	26
1022	Reflections on vascular ageing and microvascular pulsatility. <i>Journal of Hypertension</i> , 2014, 32, 1907-1908.	0.3	1
1023	Hypertensive urgencies and emergencies. <i>Journal of Hypertension</i> , 2014, 32, 1910-1911.	0.3	2
1024	Have we attained the right control of hypertension? Consequences of the 2013 European Society of Hypertension/European Society of Cardiology and Eighth Joint National Committee recommendations. <i>Journal of Hypertension</i> , 2014, 32, 1906-1907.	0.3	1
1025	Have we attained the right control of hypertension? Consequences of the 2013 European Society of Hypertension/European Society of Cardiology and Eighth Joint National Committee recommendations. <i>Journal of Hypertension</i> , 2014, 32, 1907.	0.3	1
1026	Reflections on vascular ageing and microvascular pulsatility. <i>Journal of Hypertension</i> , 2014, 32, 1908-1910.	0.3	1

#	ARTICLE	IF	CITATIONS
1027	Genetic variation in NEDD4L, salt sensitivity, and hypertension. <i>Journal of Hypertension</i> , 2014, 32, 1905.	0.3	4
1028	Genetic variation in NEDD4L, salt sensitivity, and hypertension. <i>Journal of Hypertension</i> , 2014, 32, 1905-1906.	0.3	3
1029	Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient. <i>Journal of Hypertension</i> , 2014, 32, 1888-1897.	0.3	65
1030	The role of body weight, fat distribution and weight change in ethnic differences. <i>Journal of Hypertension</i> , 2014, 32, 1911-1912.	0.3	1
1031	The role of body weight, fat distribution and weight change in ethnic differences. <i>Journal of Hypertension</i> , 2014, 32, 1912.	0.3	0
1032	Does our understanding of blood pressure targets in diabetics need rethinking?. <i>Diabetes Management</i> , 2014, 4, 215-217.	0.5	0
1033	Hypertensive urgencies and emergencies. <i>Journal of Hypertension</i> , 2014, 32, 1911.	0.3	2
1034	Under or over: still not settled. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 663-664.	2.3	0
1036	US Hypertension Management Guidelines: A Review of the Recent Past and Recommendations for the Future. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	54
1037	Lipids, blood pressure and kidney update 2015. <i>Lipids in Health and Disease</i> , 2015, 14, 167.	1.2	49
1038	Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement. <i>Annals of Internal Medicine</i> , 2015, 163, 861-868.	2.0	253
1039	Type 2 diabetes mellitus. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15019.	18.1	1,308
1040	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan " 2015. <i>Endocrine Practice</i> , 2015, 21, 1-87.	1.1	443
1043	Blood Pressure Management in Patients with Type 2 Diabetes. <i>Internal Medicine</i> , 2015, 54, 2285-2289.	0.3	4
1044	2. Recent Progress of Hypertension Diagnosis and Therapy. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2015, 104, 1750-1760.	0.0	0
1045	2015 Meet-The-Professor: Endocrine Case Management. , 2015, , .		0
1046	Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000122.	1.2	5
1047	Prevalence and Management of Diabetic Nephropathy in Western Countries. <i>Kidney Diseases (Basel,)</i> Tj ETQq1 1 0,784314 rgBT /Ove	1.2	49

#	ARTICLE	IF	CITATIONS
1048	The Korean Society of Hypertension Guidelines for the Management of Hypertension in 2013: Its Essentials and Key Points. <i>Pulse</i> , 2015, 3, 21-28.	0.9	38
1050	Paradox of using intensive lowering of blood glucose in diabetics and strategies to overcome it and decrease cardiovascular risks. <i>Chinese Journal of Integrative Medicine</i> , 2015, 21, 791-800.	0.7	3
1051	Assessment of dipyridamole stress echocardiography for risk stratification of diabetic patients. <i>Cardiovascular Ultrasound</i> , 2015, 13, 35.	0.5	4
1052	Uncontrolled hypertension by the 2014 evidence-based guideline. <i>Journal of Hypertension</i> , 2015, 33, 644-652.	0.3	23
1053	Long-Term Risk of Stroke in Patients With Type 1 and Type 2 Diabetes Following Coronary Artery Bypass Grafting. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	9
1054	Valsartan blocks thrombospondin/transforming growth factor/Smads to inhibit aortic remodeling in diabetic rats. <i>Diagnostic Pathology</i> , 2015, 10, 18.	0.9	16
1055	Association between insufficient medication of antihypertensives and the severity of acute ischemic stroke. <i>Clinical Hypertension</i> , 2015, 22, 11.	0.7	5
1056	Too much blood pressure?. <i>Anaesthesia</i> , 2015, 70, 773-778.	1.8	7
1057	<sc>ADVANCE</sc>: further support for intensive glucose control in type 2 diabetes. <i>Practical Diabetes</i> , 2015, 32, 6-7.	0.1	1
1058	Current and Future Treatment of Hypertension in the SPRINT Era. <i>Methodist DeBakey Cardiovascular Journal</i> , 2015, 11, 206-213.	0.5	7
1059	Fenofibrate and diabetic retinopathy. <i>Clinical and Experimental Ophthalmology</i> , 2015, 43, 297-299.	1.3	2
1060	Cerebral Cortical Microvascular Rarefaction in Metabolic Syndrome is Dependent on Insulin Resistance and Loss of Nitric Oxide Bioavailability. <i>Microcirculation</i> , 2015, 22, 435-445.	1.0	38
1062	Optimal home SBP targets for preventing the progression of diabetic nephropathy in patients with type 2 diabetes mellitus. <i>Journal of Hypertension</i> , 2015, 33, 1853-1859.	0.3	13
1063	Quality of Healthcare Provided to Elderly with Type 2 Diabetes: Data from the AMD* Annals Initiative. <i>Journal of Diabetes & Metabolism</i> , 2015, 06, .	0.2	0
1064	Putting Evidence Based JNC 8 Guideline into Primary Care Practice. <i>Journal of Hypertension: Open Access</i> , 2015, 04, .	0.2	0
1065	Hypertension in Chronic Glomerulonephritis. <i>Electrolyte and Blood Pressure</i> , 2015, 13, 41.	0.6	30
1066	Improvements in the Management of Diabetic Nephropathy. <i>Review of Diabetic Studies</i> , 2015, 12, 119-133.	0.5	65
1067	Diabetic Cardiomyopathy: A New Perspective of Mechanistic Approach. <i>Journal of Diabetes & Metabolism</i> , 2015, 6, .	0.2	5

#	ARTICLE	IF	CITATIONS
1068	Do Perceptions of Empowerment Affect Glycemic Control and Self-Care Among Adults with Type 2 Diabetes?. <i>Global Journal of Health Science</i> , 2015, 7, 80-90.	0.1	19
1069	Adesão ao tratamento do diabetes mellitus e variáveis sociodemográficas, clínicas e de controle metabólico. <i>ACTA Paulista De Enfermagem</i> , 2015, 28, 315-322.	0.1	19
1070	Position paper FADOI sulla prevenzione cardiovascolare nei pazienti complessi a rischio. <i>Italian Journal of Medicine</i> , 2015, 3, 309.	0.2	1
1071	2014 Hypertension Guideline: Recommendation for a Change in Goal Systolic Blood Pressure. , 2015, 19, 64-8.		3
1072	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2015 Executive Summary. <i>Endocrine Practice</i> , 2015, 21, 1403-1414.	1.1	22
1073	Trends in adherence to dietary recommendations among Korean type 2 diabetes mellitus patients. <i>Nutrition Research and Practice</i> , 2015, 9, 658.	0.7	12
1074	Managing hypertension in diabetes. <i>Independent Nurse</i> , 2015, 2015, 22-26.	0.0	1
1075	Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences. <i>Journal of Clinical Medicine</i> , 2015, 4, 1908-1937.	1.0	40
1076	Target Values of Cardiovascular Risk Factors Are Not Associated with All-Cause Mortality in Patients with Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2015, 10, e0124536.	1.1	3
1077	Risk Factors of Coronary Artery Disease in Secondary Prevention—Results from the AtheroGene Study. <i>PLoS ONE</i> , 2015, 10, e0131434.	1.1	26
1078	Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. <i>World Journal of Diabetes</i> , 2015, 6, 1246.	1.3	718
1079	Present and Future in the Treatment of Diabetic Kidney Disease. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-13.	1.0	32
1080	Prevalence of Orthostatic Hypertension in Elderly Patients with Type 2 Diabetes. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-6.	0.6	13
1081	Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2015, 162, 258-265.	2.0	128
1082	In hypertension with high CV risk, BP self-monitoring and medication self-titration reduced BP at 12 months. <i>Annals of Internal Medicine</i> , 2015, 162, JC7.	2.0	3
1083	New Hypertension Guidelines: Progression or a Step Backwards in Hypertension?. <i>Current Hypertension Reports</i> , 2015, 17, 49.	1.5	5
1084	Screening for Type 2 Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2015, 162, 765-776.	2.0	112
1086	Lowering Blood Pressure in Patients With Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2182.	3.8	1

#	ARTICLE	IF	CITATIONS
1087	Twenty-five years of statins: where do we go from here?. <i>Clinical Lipidology</i> , 2015, 10, 33-45.	0.4	2
1088	Systolic Blood Pressure and Mortality After Stroke. <i>Stroke</i> , 2015, 46, 1307-1313.	1.0	30
1089	Hypertension and Dyslipidemia in Patients with Pre-Diabetes. , 2015, , 157-179.		1
1090	Update on Blood Pressure Control and Renal Outcomes in Diabetes Mellitus. <i>Current Diabetes Reports</i> , 2015, 15, 44.	1.7	14
1091	Relationship of Blood Pressure With Mortality and Cardiovascular Events Among Hypertensive Patients aged ≥60 years in Rural Areas of China. <i>Medicine (United States)</i> , 2015, 94, e1551.	0.4	16
1092	Hypertension in African Americans Aged 60 to 79 Years: Statement From the International Society of Hypertension in Blacks. <i>Journal of Clinical Hypertension</i> , 2015, 17, 252-259.	1.0	12
1093	Drug therapies to delay the progression of chronic kidney disease. <i>Clinical Medicine</i> , 2015, 15, 550-557.	0.8	10
1094	Cardiac Benefits of an Intensive Blood Pressure Control in Diabetes Mellitus. <i>Hypertension</i> , 2015, 66, 1104-1105.	1.3	1
1095	How Low Should Systolic Blood Pressure Go? SPRINT Results suggest a Target of 120. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2015, 15, 1.	0.0	0
1096	Spécificité des accidents vasculaires cérébraux chez les diabétiques. <i>Medecine Des Maladies Metaboliques</i> , 2015, 9, 399-405.	0.1	1
1097	Screening asymptomatic patients with type 2 diabetes is recommended. <i>Journal of Nuclear Cardiology</i> , 2015, 22, 1229-1232.	1.4	6
1099	8. Cardiovascular Disease and Risk Management. <i>Diabetes Care</i> , 2015, 38, S49-S57.	4.3	224
1100	No need to change guidelines for diabetic retinopathy and renin-angiotensin system inhibitors. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 231-232.	5.5	2
1101	Interpreting Blood Pressure in Young Adults. <i>Journal of the American College of Cardiology</i> , 2015, 65, 336-338.	1.2	8
1102	Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study. <i>Diabetologia</i> , 2015, 58, 505-518.	2.9	66
1103	Initiation and follow-up of treatment for high blood pressure. <i>BMJ, The</i> , 2015, 350, h167-h167.	3.0	0
1104	Bariatric Surgery can Lead to Net Cost Savings to Health Care Systems: Results from a Comprehensive European Decision Analytic Model. <i>Obesity Surgery</i> , 2015, 25, 1559-1568.	1.1	78
1105	2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension. <i>Journal of the Chinese Medical Association</i> , 2015, 78, 1-47.	0.6	183

#	ARTICLE	IF	CITATIONS
1106	Vascular Complications of Diabetes Mellitus. , 2015, , 1541-1593.		0
1107	Secondary Prevention After Coronary Artery Bypass Graft Surgery. <i>Circulation</i> , 2015, 131, 927-964.	1.6	313
1108	Blood pressure targets for type 2 diabetes should be lower, say researchers. <i>BMJ, The</i> , 2015, 350, h749-h749.	3.0	0
1109	Blood Pressure Lowering in Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 603.	3.8	673
1111	Cardiorenal Metabolic Syndrome and Diabetes in African Americans: Adding to the Risk of Hypertension. , 2015, , 137-150.		0
1112	Cardiovascular outcomes with antihypertensive therapy in type 2 diabetes: an analysis of intervention trials. <i>Journal of Human Hypertension</i> , 2015, 29, 473-477.	1.0	6
1113	Diagnosis and Treatment of Incident Hypertension Among Patients with Diabetes: a U.S. Multi-Disciplinary Group Practice Observational Study. <i>Journal of General Internal Medicine</i> , 2015, 30, 768-776.	1.3	7
1114	Preventing the Progression of Prehypertension to Hypertension: Role of Antihypertensives. <i>Current Hypertension Reports</i> , 2015, 17, 505.	1.5	18
1115	Antihypertensive Therapy and the J-curve: Fact or Fiction?. <i>Current Hypertension Reports</i> , 2015, 17, 6.	1.5	11
1116	Heart Disease and Stroke Statisticsâ€™2015 Update. <i>Circulation</i> , 2015, 131, e29-322.	1.6	5,963
1117	The Elusiveness of Population-Wide High Blood Pressure Control. <i>Annual Review of Public Health</i> , 2015, 36, 109-130.	7.6	69
1118	Prehypertensionâ€™prevalence, health risks, and management strategies. <i>Nature Reviews Cardiology</i> , 2015, 12, 289-300.	6.1	162
1119	Relationship between low blood pressure and renal/cardiovascular outcomes in Japanese patients with chronic kidney disease under nephrologist care: the Gonryo study. <i>Clinical and Experimental Nephrology</i> , 2015, 19, 878-886.	0.7	12
1120	Impact of a Shared Medical Appointment Lifestyle Intervention on Weight and Lipid Parameters in Individuals with Type 2 Diabetes: A Clinical Pilot. <i>Journal of the American College of Nutrition</i> , 2015, 34, 300-309.	1.1	17
1121	Niacin and Progression of CKD. <i>American Journal of Kidney Diseases</i> , 2015, 65, 785-798.	2.1	24
1122	Intensive BP Control, Falls, and Fractures: Response to Jolobe (MS #17620). <i>Journal of General Internal Medicine</i> , 2015, 30, 547-547.	1.3	0
1123	Blood Pressure Goals and Targets in the Elderly. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2015, 17, 394.	0.4	9
1124	Management of hypertension in chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2015, 11, 555-563.	4.1	59

#	ARTICLE	IF	CITATIONS
1125	Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico. <i>Value in Health Regional Issues</i> , 2015, 8, 20-27.	0.5	3
1126	Treatment: special conditions. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 651-654.	2.3	2
1127	Management of Hypertension in the Elderly. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	0.8	0
1128	Understanding drug preferences, different perspectives. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 978-987.	1.1	14
1129	Rate of Change in Renal Function and Mortality in Elderly Treated Hypertensive Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1154-1161.	2.2	21
1130	Implications of the Eighth Joint National Committee Guidelines for the Management of High Blood Pressure for Aging Adults. <i>Hypertension</i> , 2015, 66, 474-480.	1.3	11
1131	Rebuttal of the Con View. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1099.	2.2	4
1132	Effect of Lower On-Treatment Systolic Blood Pressure on the Risk of Atrial Fibrillation in Hypertensive Patients. <i>Hypertension</i> , 2015, 66, 368-373.	1.3	63
1134	Management of chronic kidney disease. <i>Medicine</i> , 2015, 43, 454-461.	0.2	5
1135	The perils of surrogate endpoints. <i>European Heart Journal</i> , 2015, 36, 2212-2218.	1.0	61
1136	Peripheral to central: Organ interactions in stroke pathophysiology. <i>Experimental Neurology</i> , 2015, 272, 41-49.	2.0	28
1137	Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1089-1093.	2.2	40
1138	Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. <i>BMJ, The</i> , 2015, 350, h158-h158.	3.0	117
1139	Update on Blood Pressure Goals in Diabetes Mellitus. <i>Current Cardiology Reports</i> , 2015, 17, 37.	1.3	6
1140	Misconceptions and Facts About Treating Hypertension. <i>American Journal of Medicine</i> , 2015, 128, 450-455.	0.6	7
1141	The value of extracellular miRNA in diabetic kidney disease. <i>Diabetes Management</i> , 2015, 5, 53-56.	0.5	0
1142	Optimal blood pressure targets in 2014 – Does the guideline recommendation match the evidence base?. <i>Hipertension Y Riesgo Vascular</i> , 2015, 32, 71-82.	0.3	0
1143	Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 367-381.	5.5	75

#	ARTICLE	IF	CITATIONS
1144	Effects of RAS inhibitors on diabetic retinopathy. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 315-316.	5.5	3
1145	A perspective on the 2013 US guidelines for hypertension: Where does the so called "Evidence based approach" fall short?. <i>Journal of Indian College of Cardiology</i> , 2015, 5, S10-S14.	0.1	0
1146	Dan-gua Fang (ä,1ç"œæ-1) improves glycolipid metabolic disorders by promoting hepatic adenosine 5â€²-monophosphate activated protein kinase expression in diabetic Goto-Kakizaki rats. <i>Chinese Journal of Integrative Medicine</i> , 2015, 21, 188-195.	0.7	4
1147	Are SGLT2 Inhibitors Reasonable Antihypertensive Drugs and Renoprotective?. <i>Current Hypertension Reports</i> , 2015, 17, 551.	1.5	24
1148	Is Fenofibrate a Reasonable Treatment for Diabetic Microvascular Disease?. <i>Current Diabetes Reports</i> , 2015, 15, 24.	1.7	14
1149	Treatment of hypertension in patients with coronary artery disease. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 453-498.	2.3	47
1150	Blood pressure targets in patients with diabetes â€" a new perspective. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 334-336.	2.3	3
1151	Coronary Artery Disease Screening Using Coronary Computed Tomography Angiographyâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1267.	3.8	1
1152	2013 Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations. <i>Clinical Hypertension</i> , 2015, 21, 3.	0.7	11
1153	2013 Korean Society of Hypertension guidelines for the management of hypertension. Part IIâ€”treatments of hypertension. <i>Clinical Hypertension</i> , 2015, 21, 2.	0.7	30
1156	Coronary Artery Disease Screening Using Coronary Computed Tomography Angiography. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1267.	3.8	1
1157	Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. <i>Kidney International</i> , 2015, 88, 622-632.	2.6	146
1158	Hypertension in the Young Adult. , 2015, , 77-89.		0
1159	Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). <i>Nephrology Dialysis Transplantation</i> , 2015, 30, ii1-ii142.	0.4	113
1160	Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. <i>American Journal of Hypertension</i> , 2015, 28, 995-1009.	1.0	18
1161	Newer targets and therapies for hypertension and dyslipidemia in diabetic patients. <i>Cardiovascular Endocrinology</i> , 2015, 4, 11-16.	0.8	0
1162	Blood pressure control in anticoagulated hypertensive patients. <i>Blood Pressure Monitoring</i> , 2015, 20, 20-26.	0.4	4
1163	Randomized Controlled Trials of Blood Pressure Lowering in Hypertension. <i>Circulation Research</i> , 2015, 116, 1058-1073.	2.0	131

#	ARTICLE	IF	CITATIONS
1164	Lipids, blood pressure and kidney update 2014. <i>Pharmacological Research</i> , 2015, 95-96, 111-125.	3.1	77
1167	Who Would Have Thought It? Surgery Is a Treatment for Diabetes. <i>Annals of Surgery</i> , 2015, 261, 430-431.	2.1	0
1168	The Role of Systemic Blood Pressure in the Progression of Chronic Kidney Disease. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	0.8	15
1169	Treating Hypertension in Patients With Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 573.	3.8	12
1170	Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2015, 162, ITC1-ITC16.	2.0	74
1171	Treatment of Hypertension in Patients With Coronary Artery Disease. <i>Hypertension</i> , 2015, 65, 1372-1407.	1.3	97
1172	New guidelines for hypertension control in cardiac patients “lower may not be better. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 417-419.	2.3	1
1173	Treatment of Hypertension in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1998-2038.	1.2	120
1174	Treatment of Hypertension in Patients With Coronary Artery Disease. <i>Circulation</i> , 2015, 131, e435-70.	1.6	163
1175	Sodium Intake and Cardiovascular Health. <i>Circulation Research</i> , 2015, 116, 1046-1057.	2.0	152
1176	The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy. <i>Hypertension Research</i> , 2015, 38, 367-374.	1.5	25
1177	Benefits of a fixed-dose combination of bisoprolol and amlodipine in the treatment of hypertension in daily practice: results of more than 4000 patients. <i>Current Medical Research and Opinion</i> , 2015, 31, 875-881.	0.9	12
1178	The Utility of Ambulatory Blood Pressure Monitoring for Diagnosing White Coat Hypertension in Older Adults. <i>Current Hypertension Reports</i> , 2015, 17, 86.	1.5	9
1179	BP and Renal Outcomes in Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2159-2169.	2.2	48
1181	Rates of Deintensification of Blood Pressure and Glycemic Medication Treatment Based on Levels of Control and Life Expectancy in Older Patients With Diabetes Mellitus. <i>JAMA Internal Medicine</i> , 2015, 175, 1942.	2.6	137
1182	High B-Type Natriuretic Peptide Hypertensives at Target Blood Pressure. <i>Hypertension</i> , 2015, 66, 927-932.	1.3	3
1183	Management of Hypertension in Patients with Ischemic Heart Disease. <i>Current Cardiology Reports</i> , 2015, 17, 119.	1.3	16
1184	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence. <i>Circulation</i> , 2015, 132, 691-718.	1.6	303

#	ARTICLE	IF	CITATIONS
1185	Advances in stroke prevention. <i>Annals of the New York Academy of Sciences</i> , 2015, 1338, 1-15.	1.8	28
1186	Evidence-based practice guideline for the treatment for diabetes in Japan 2013. <i>Diabetology International</i> , 2015, 6, 151-187.	0.7	65
1187	Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus. <i>Hypertension</i> , 2015, 66, 1123-1129.	1.3	81
1188	Blood pressure target goals from guidelines of 2002â€“2014. <i>Future Cardiology</i> , 2015, 11, 247-250.	0.5	0
1189	A New Proposal for the Target Value for Home BP in Type 2 Diabetes Patients: The J-HOP Study. <i>American Journal of Hypertension</i> , 2015, 28, 971-979.	1.0	3
1190	The Relation Between HbA1c and Cardiovascular Events in Patients With Type 2 Diabetes With and Without Vascular Disease. <i>Diabetes Care</i> , 2015, 38, 1930-1936.	4.3	35
1191	Fundamentals of Clinical Trials. , 2015, , .		603
1192	Updated guidelines from the American Diabetes Association. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 663.	2.3	0
1193	Guiding Hypertension Management Using Central Blood Pressure: Effect of Medication Withdrawal on Left Ventricular Function. <i>American Journal of Hypertension</i> , 2016, 29, 319-325.	1.0	8
1194	Systolic Blood Pressure Control and Mortality After Stroke in Hypertensive Patients. <i>Stroke</i> , 2015, 46, 2113-2118.	1.0	12
1195	Diabetes and chronic kidney disease. <i>Disease-a-Month</i> , 2015, 61, 378-386.	0.4	16
1196	Midlife Blood Pressure and Late-Life GFR and Albuminuria: An Elderly General Population Cohort. <i>American Journal of Kidney Diseases</i> , 2015, 66, 240-248.	2.1	28
1197	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. <i>Diabetes Care</i> , 2015, 38, 1777-1803.	4.3	346
1198	BP Targets in Older Adults with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1501-1503.	2.2	0
1199	The SPRINT trial. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 750-753.	2.3	5
1202	Older people with diabetes â€“ avoiding hospitalization. <i>Diabetes Management</i> , 2015, 5, 311-326.	0.5	2
1203	The 2014 hypertension guidelines: implications for patients and practitioners in Asia. <i>Heart Asia</i> , 2015, 7, 21-25.	1.1	17
1205	Blood-Pressure Control. <i>New England Journal of Medicine</i> , 2015, 373, 2180-2182.	13.9	2

#	ARTICLE	IF	CITATIONS
1206	A Randomized Trial of Intensive versus Standard Blood-Pressure Control. <i>New England Journal of Medicine</i> , 2015, 373, 2103-2116.	13.9	4,880
1207	Redefining Blood-Pressure Targets – SPRINT Starts the Marathon. <i>New England Journal of Medicine</i> , 2015, 373, 2175-2178.	13.9	134
1208	Chronic kidney disease and intensive glyceamic control increase cardiovascular risk in patients with type 2 diabetes. <i>Kidney International</i> , 2015, 87, 649-659.	2.6	158
1209	Blood Pressure in Chronic Kidney Disease. <i>Hypertension</i> , 2015, 65, 27-28.	1.3	0
1210	High-Sensitivity Troponin T and Cardiovascular Events in Systolic Blood Pressure Categories. <i>Hypertension</i> , 2015, 65, 78-84.	1.3	35
1211	Veganism Is a Viable Alternative to Conventional Diet Therapy for Improving Blood Lipids and Glycemic Control. <i>Critical Reviews in Food Science and Nutrition</i> , 2015, 55, 2004-2013.	5.4	11
1212	Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives. <i>Drug Discovery Today</i> , 2015, 20, 332-346.	3.2	74
1213	Health care delivery in type 2 diabetes. A survey in an Italian primary care practice. <i>Primary Care Diabetes</i> , 2015, 9, 9-14.	0.9	7
1214	Canadian Society of Nephrology Commentary on the KDIGO Clinical Practice Guideline for CKD Evaluation and Management. <i>American Journal of Kidney Diseases</i> , 2015, 65, 177-205.	2.1	98
1215	Reducing cardiovascular risk in type 2 diabetes mellitus. <i>Medicine</i> , 2015, 43, 7-12.	0.2	1
1216	Cardiac Drug Therapy. <i>Contemporary Cardiology</i> , 2015, , .	0.0	4
1217	Chronic Kidney Disease and Hypertension. , 2015, , .		0
1218	Approach to Chronic Kidney Disease in the Diabetic Patient. , 2015, , 523-533.		0
1219	Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. <i>Seminars in Dialysis</i> , 2015, 28, 35-47.	0.7	49
1220	Quality of diabetes care in family medicine practices in eastern Bosnia and Herzegovina. <i>Primary Care Diabetes</i> , 2015, 9, 112-119.	0.9	4
1221	Treating hypertension and prehypertension in older people: When, whom and how. <i>Maturitas</i> , 2015, 80, 31-36.	1.0	11
1222	Management of Hypertension in Chronic Kidney Disease. , 2015, , 634-645.		2
1223	The Interdisciplinary Chronic Kidney Disease Clinic. , 2015, , 587-597.		0

#	ARTICLE	IF	CITATIONS
1224	The consequences of failure to achieve targets of guidelines for prevention and treatment of diabetic complications in patients with type 1 diabetes. <i>Acta Diabetologica</i> , 2015, 52, 31-38.	1.2	9
1225	FACTORS ASSOCIATED WITH HYPERTENSION PREVALENCE AND CONTROL AMONG LEBANESE TYPE 2 DIABETIC PATIENTS. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 2016, 8, 153.	0.3	14
1227	Complications of Diabetes Mellitus. , 2016, , 1484-1581.		13
1228	Management of Hypertension in Diabetic Patients. <i>Journal of Korean Diabetes</i> , 2016, 17, 88.	0.1	0
1229	What should the target blood pressure goals be?. <i>Archives of Medical Science</i> , 2016, 6, 1377-1380.	0.4	4
1230	Management of Hypertension: JNC 8 and Beyond. <i>Cardiovascular Innovations and Applications</i> , 2016, 1, .	0.1	2
1231	Impact of Total Risk Management on Coronary Plaque Regression in Diabetic Patients with Acute Coronary Syndrome. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 922-931.	0.9	7
1232	Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management. <i>World Journal of Diabetes</i> , 2016, 7, 101.	1.3	64
1233	Blood Pressure Measurement Biases in Clinical Settings, Alabama, 2010â€“2011. <i>Preventing Chronic Disease</i> , 2016, 13, E01.	1.7	11
1234	Management of Diabetic Nephropathy. <i>Journal of Korean Diabetes</i> , 2016, 17, 102.	0.1	0
1235	Type 2 Diabetes and Heart Failure: Challenges and Solutions. <i>Current Cardiology Reviews</i> , 2016, 12, 249-255.	0.6	53
1236	Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney Disease. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-7.	1.0	171
1237	Improvements in Augmentation Index and Urinary Albumin Excretion With Benidipine in Hypertensive Patients With Chronic Kidney Disease. <i>International Heart Journal</i> , 2016, 57, 53-60.	0.5	7
1238	Timeline of History of Hypertension Treatment. <i>Frontiers in Cardiovascular Medicine</i> , 2016, 3, 3.	1.1	65
1240	Uncontrolled Hypertension and Its Determinants in Patients with Concomitant Type 2 Diabetes Mellitus (T2DM) in Rural South Africa. <i>PLoS ONE</i> , 2016, 11, e0150033.	1.1	67
1241	Target Blood Pressure in Patients with Diabetes: Asian Perspective. <i>Yonsei Medical Journal</i> , 2016, 57, 1307.	0.9	11
1242	Current Challenges in Diabetic Nephropathy: Early Diagnosis and Ways to Improve Outcomes. <i>Endocrinology and Metabolism</i> , 2016, 31, 245.	1.3	53
1244	L'ipotensione. <i>Italian Journal of Medicine</i> , 2016, 4, 1.	0.2	1

#	ARTICLE	IF	CITATIONS
1245	Preventing Cardiovascular Disease in Patients With Diabetes. <i>Journal of Cardiovascular Nursing</i> , 2016, 31, 198-200.	0.6	2
1246	Optimal Blood Pressure Goals in Patients With Hypertension at High Risk for Cardiovascular Events. <i>American Journal of Therapeutics</i> , 2016, 23, e218-e223.	0.5	4
1247	What should the systolic blood pressure be in older diabetics treated for hypertension?. <i>Cardiovascular Endocrinology</i> , 2016, 5, 38-39.	0.8	0
1248	High blood pressure in US diabetic veterans with normal renal function. <i>Journal of Hypertension</i> , 2016, 34, 836-837.	0.3	0
1249	Diabetes and Hypertension: A Comparative Review of Current Guidelines. <i>Journal of Clinical Hypertension</i> , 2016, 18, 95-100.	1.0	94
1250	Synergistic association of combined glycemic and blood pressure level with risk of complications in US veterans with diabetes. <i>Journal of Hypertension</i> , 2016, 34, 907-913.	0.3	18
1251	Effect of Optimal Medical Therapy Before Procedures on Outcomes in Coronary Patients Treated With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2016, 118, 790-796.	0.7	4
1252	Blood pressure and disability-free survival among community-dwelling diabetic and non-diabetic elderly patients receiving antihypertensive treatment. <i>Geriatrics and Gerontology International</i> , 2016, 16, 365-373.	0.7	0
1253	Effects of blood pressure lowering treatment in hypertension. <i>Journal of Hypertension</i> , 2016, 34, 1451-1463.	0.3	69
1254	Vascular Complications of Diabetes. <i>Circulation Research</i> , 2016, 118, 1771-1785.	2.0	262
1255	Hypotension based on office and ambulatory monitoring blood pressure. Prevalence and clinical profile among a cohort of 70,997 treated hypertensives. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 714-723.	2.3	29
1256	Calibrating the impact of dual RAAS blockade on the heart and the kidney - balancing risks and benefits. <i>International Journal of Clinical Practice</i> , 2016, 70, 537-553.	0.8	8
1257	Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT. <i>Journal of Hypertension</i> , 2016, 34, 393-396.	0.3	26
1258	The J-Curve Phenomenon in Hypertension. <i>Pulse</i> , 2016, 4, 49-60.	0.9	1,020
1259	In hypertensive patients with elevated risk of cardiovascular disease, targeting systolic blood pressure to less than 120 mmHg significantly reduces the rate of fatal and non-fatal cardiovascular events as well as death from any cause. <i>Evidence-Based Medicine</i> , 2016, 21, 101-101.	0.6	1
1260	The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2016, 15, 101.	2.7	17
1261	Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm " 2016 EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , 2016, 22, 84-113.	1.1	405
1265	In patients with SBP \geq 130 mm Hg and CV risk, intensive vs standard BP control reduced CV events and mortality. <i>Annals of Internal Medicine</i> , 2016, 164, JC15.	2.0	0

#	ARTICLE	IF	CITATIONS
1268	Diabetes mellitus in the older adult. , 2016, , 421-435.		0
1269	Changes in albuminuria and cardiovascular risk under antihypertensive treatment. Journal of Hypertension, 2016, 34, 1689-1697.	0.3	26
1270	Blood pressure status and the incidence of diabetic kidney disease in patients with hypertension and type 2 diabetes. Journal of Hypertension, 2016, 34, 2090-2098.	0.3	28
1272	From the Editor. Journal of the American Society of Hypertension, 2016, 10, 827.	2.3	0
1273	Relationship among multifaceted factors including blood pressure at discharge and long-term clinical outcome in patients with cardiovascular diseases. Clinical and Experimental Hypertension, 2016, 38, 725-732.	0.5	1
1274	Is diabetes still a state of premature cardiovascular death?. Practical Diabetes, 2016, 33, 285-290.	0.1	1
1275	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2009-2020.	13.9	526
1276	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2032-2043.	13.9	299
1277	“Translational” medicine: transforming SPRINT findings into clinical practice. Journal of the American Society of Hypertension, 2016, 10, 382-386.	2.3	6
1278	Moderator's view: Meta-analysis: the best knowledge but not always shining gold. Nephrology Dialysis Transplantation, 2016, 31, 886-889.	0.4	3
1279	Update in Hypertension Therapy. Medical Clinics of North America, 2016, 100, 665-693.	1.1	7
1280	Low-frequency and very low-intensity ultrasound decreases blood pressure in hypertensive subjects with type 2 diabetes. International Journal of Cardiology, 2016, 215, 147-149.	0.8	5
1281	SPRINT Results in Older Patients. JAMA - Journal of the American Medical Association, 2016, 315, 2669.	3.8	19
1282	Diabetes mellitus and hypertension. Current Opinion in Cardiology, 2016, 31, 402-409.	0.8	38
1283	Is 60 the New 80 in Hypertension?. Journal of General Internal Medicine, 2016, 31, 958-960.	1.3	2
1284	HOPE-3, SPRINT, VALUE and a meta-analysis of trials in patients with diabetes support treatment of hypertension to a target below 140 mmHg. Blood Pressure, 2016, 25, 131-132.	0.7	5
1285	Blood Pressure-Related Outcomes in a Diabetic Population. Hypertension, 2016, 68, 34-35.	1.3	5
1286	Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet, The, 2016, 388, 465-475.	6.3	381

#	ARTICLE	IF	CITATIONS
1287	The results of a survey of physicians about the Japanese Society of Hypertension Guidelines for the Management of Hypertension 2014 and its clinical use. <i>Hypertension Research</i> , 2016, 39, 660-663.	1.5	13
1288	Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: Report from the Swedish National Diabetes Register. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 268-277.	0.9	22
1289	Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2673.	3.8	991
1291	When should we treat hypertension in patients with diabetes?. <i>Nature Reviews Cardiology</i> , 2016, 13, 252-253.	6.1	0
1294	Impactful Clinical Trials of 2015: What Clinicians Need to Know. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1038.e17-1038.e20.	0.8	1
1295	MicroRNA biomarkers in clinical renal disease: from diabetic nephropathy renal transplantation and beyond. <i>Food and Chemical Toxicology</i> , 2016, 98, 73-88.	1.8	28
1297	Hypertension and Diabetic Nephropathy. <i>Endocrine Development</i> , 2016, 31, 97-107.	1.3	8
1298	Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes. <i>American Journal of the Medical Sciences</i> , 2016, 351, 380-386.	0.4	371
1299	Evidence and Perspectives on the 24-hour Management of Hypertension: Hemodynamic Biomarker-Initiated "Anticipation Medicine"™ for Zero Cardiovascular Event. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 262-281.	1.6	116
1300	Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial. <i>Hypertension</i> , 2016, 67, 808-812.	1.3	193
1301	Review of the Systolic Blood Pressure Intervention Trial for Hypertension Management. <i>Stroke</i> , 2016, 47, 1692-1694.	1.0	1
1302	Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2016, 17, 117-127.	2.6	5
1303	MANEJO DE LA HIPERTENSIÓN ARTERIAL EN DIABETES MELLITUS. <i>Revista Médica Clínica Las Condes</i> , 2016, 27, 204-212.	0.2	1
1304	The Continued Quest for Optimal BP Targets in Older Adults with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 753-755.	2.2	0
1308	Cardiovascular Outcomes in Action to Control Cardiovascular Risk in Diabetes: Impact of Blood Pressure Level and Presence of Kidney Disease. <i>American Journal of Nephrology</i> , 2016, 43, 271-280.	1.4	43
1309	LEADER-4. <i>Journal of Hypertension</i> , 2016, 34, 1140-1150.	0.3	13
1310	Diabetic Kidney Disease and Hypertension. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2016, 124, 93-98.	0.6	9
1311	Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years. <i>Hypertension</i> , 2016, 68, 88-96.	1.3	34

#	ARTICLE	IF	CITATIONS
1312	Intensive lowering of blood pressure: Should we SPRINT?. <i>Cmaj</i> , 2016, 188, 1067-1068.	0.9	4
1313	The SPRINT and the HOPE-3 Trial in the Context of Other Blood Pressure“Lowering Trials. <i>JAMA Cardiology</i> , 2016, 1, 857.	3.0	15
1314	Assessing Cardiovascular Risk to Guide Hypertension Diagnosis and Treatment. <i>JAMA Cardiology</i> , 2016, 1, 864.	3.0	29
1315	The Primary Outcome Is Positive “ Is That Good Enough?. <i>New England Journal of Medicine</i> , 2016, 375, 971-979.	13.9	112
1316	Resistant Hypertension. <i>Hypertension</i> , 2016, 68, 1073-1080.	1.3	12
1318	A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. <i>Lancet</i> , The, 2016, 388, 2665-2712.	6.3	670
1319	Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. <i>Diabetes Research and Clinical Practice</i> , 2016, 121, 204-214.	1.1	40
1320	Blood pressure goals in T2DM “ time for a rethink?. <i>Nature Reviews Endocrinology</i> , 2016, 12, 629-630.	4.3	1
1322	Modern Challenges in Treating Hypertension. <i>Clinical Therapeutics</i> , 2016, 38, 2132-2134.	1.1	1
1324	Lower or higher blood-pressure targets for high-risk patients?. <i>Nature Reviews Cardiology</i> , 2016, 13, 637-638.	6.1	5
1325	Treatment of Hypertension: Which Goal for Which Patient?. <i>Advances in Experimental Medicine and Biology</i> , 2016, 956, 117-127.	0.8	8
1326	Different components of blood pressure are associated with increased risk of atherosclerotic cardiovascular disease versus heart failure in advanced chronic kidney disease. <i>Kidney International</i> , 2016, 90, 1348-1356.	2.6	22
1327	Steno-2 “ a small study with a big heart. <i>Nature Reviews Endocrinology</i> , 2016, 12, 692-694.	4.3	6
1328	Effects of tranexamic acid on coagulation indexes of patients undergoing heart valve replacement surgery under cardiopulmonary bypass. <i>International Journal of Immunopathology and Pharmacology</i> , 2016, 29, 753-758.	1.0	6
1329	Hypertension and Comorbidities. <i>Practical Case Studies in Hypertension Management</i> , 2016, , .	0.0	2
1330	The effects of mindfulness-based stress reduction on cardiac patients' blood pressure, perceived stress, and anger: a single-blind randomized controlled trial. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 763-771.	2.3	48
1331	<scp>SPRINT</scp>: The Study Nephrologists Might Take With a Grain of Salt. <i>Journal of Clinical Hypertension</i> , 2016, 18, 1185-1188.	1.0	5
1332	Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?. <i>Kidney International</i> , 2016, 90, 460-462.	2.6	5

#	ARTICLE	IF	CITATIONS
1333	Established and Emerging Strategies in the Treatment of Chronic Kidney Disease. Seminars in Nephrology, 2016, 36, 331-342.	0.6	15
1334	Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An <sc>ACCOMPLISH</sc> Substudy. Journal of Clinical Hypertension, 2016, 18, 299-307.	1.0	26
1335	Psychosocial Factors in Diabetes and Cardiovascular Risk. Current Cardiology Reports, 2016, 18, 95.	1.3	81
1336	BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?. Current Cardiology Reports, 2016, 18, 98.	1.3	6
1337	Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet, The, 2016, 388, 2142-2152.	6.3	357
1338	Should blood pressure reduction be aggressive in patients with hypertension and coronary artery disease?. Lancet, The, 2016, 388, 2061-2062.	6.3	4
1339	What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?. Current Diabetes Reports, 2016, 16, 94.	1.7	2
1340	Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial. Hypertension, 2016, 68, 888-895.	1.3	103
1341	Orthostatic Hypotension in Diabetics in the ACCORD (Action to Control Cardiovascular Risk in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 42	1.3	16
1342	Clinical Case 3: Patient with Diabetes Mellitus. Practical Case Studies in Hypertension Management, 2016, , 41-60.	0.0	0
1343	Cardiovascular Risk in Hypertension in Relation to Achieved Blood Pressure Using Automated Office Blood Pressure Measurement. Hypertension, 2016, 68, 866-872.	1.3	53
1344	Update in Nephrology and Hypertension: Evidence Published in 2015. Annals of Internal Medicine, 2016, 164, W42.	2.0	4
1345	Hypertension in Chronic Kidney Disease. Advances in Experimental Medicine and Biology, 2016, 956, 307-325.	0.8	117
1346	Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes. Diabetes Care, 2016, 39, 2218-2224.	4.3	25
1347	Management of Stable Angina â€“ Current Guidelines: A Critical Appraisal. Cardiovascular Drugs and Therapy, 2016, 30, 419-426.	1.3	37
1348	More Versus Less Blood Pressure Lowering: An Update. Clinical Therapeutics, 2016, 38, 2135-2141.	1.1	11
1349	A Case for Less Intensive Blood Pressure Control: It Matters to Achieve Target Blood Pressure Early and Sustained Below 140/90mmHg. Progress in Cardiovascular Diseases, 2016, 59, 209-218.	1.6	16
1350	Clinical outcomes with a systolic blood pressure lower than 120â€™mmHg in older patients with high disease burden. Renal Failure, 2016, 38, 1364-1369.	0.8	5

#	ARTICLE	IF	CITATIONS
1351	Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to $120/80\text{ mmHg}$ Target?. <i>Circulation</i> , 2016, 134, 1311-1313.	1.6	17
1352	More Versus Less Intensive Blood Pressure Lowering Strategy. <i>Hypertension</i> , 2016, 68, 642-653.	1.3	75
1353	Blood pressure targets for elderly patients: new SPRINT data. <i>Nature Reviews Nephrology</i> , 2016, 12, 450-452.	4.1	2
1354	Specific Blood Pressure Targets for Patients With Diabetic Nephropathy?. <i>Diabetes Care</i> , 2016, 39, S228-S233.	4.3	14
1355	What Should Be the Target Blood Pressure in Elderly Patients With Diabetes?. <i>Diabetes Care</i> , 2016, 39, S234-S243.	4.3	21
1356	Blood Pressure Targets in CKD: Lessons Learned from SPRINT and Previous Observational Studies. <i>Current Cardiology Reports</i> , 2016, 18, 88.	1.3	7
1357	A Tale of 3 Trials: ACCORD, SPRINT, and SPS3. What Happened?. <i>American Journal of Hypertension</i> , 2016, 29, 1020-1023.	1.0	8
1358	Is It Time to Reappraise Blood Pressure Thresholds and Targets?. <i>Hypertension</i> , 2016, 68, 266-268.	1.3	16
1359	Calming down chaos regarding redefining blood pressure targets-the importance of statin-based therapy. <i>International Journal of Cardiology</i> , 2016, 221, 572-574.	0.8	3
1360	Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines. <i>Hypertension</i> , 2016, 68, 318-323.	1.3	21
1361	New blood pressure goals for patients with increased cardiovascular risk. <i>Internal and Emergency Medicine</i> , 2016, 11, 753-754.	1.0	0
1362	Cardiovascular Risk Assessment, Summary of Guidelines for the Management of Hypertension and a Critical Appraisal of the 2014 Expert Panel of the National Institutes of Health Report. , 2016, , 131-150.		0
1366	Managing hypertension in patients with chronic kidney disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2016, 77, 639-644.	0.2	0
1367	Prevalence of Eligibility Criteria for the Systolic Blood Pressure Intervention Trial in US Adults Among Excluded Groups: Age <math>< 50</math> Years, Diabetes Mellitus, or a History of Stroke. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	9
1368	The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2016, 7, 825-845.	1.2	12
1369	Current Consensus and Controversies in Guidelines for Lipid and Hypertension Management in Diabetes. <i>Current Cardiology Reports</i> , 2016, 18, 114.	1.3	3
1370	Interactions between kidney disease and diabetes: dangerous liaisons. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 50.	1.2	108
1371	Treatment Intensification for Hypertension in US Ambulatory Medical Care. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	56

#	ARTICLE	IF	CITATIONS
1372	Total antihypertensive therapeutic intensity score and its relationship to blood pressure reduction. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 906-916.	2.3	33
1373	Lessons in Uncertainty and Humility â€” Clinical Trials Involving Hypertension. <i>New England Journal of Medicine</i> , 2016, 375, 1756-1766.	13.9	21
1374	Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study. <i>BMJ</i> , The, 2016, 354, i4070.	3.0	52
1375	Correlation of global risk assessment with cardiovascular complications in patients with diabetes mellitus living in Puerto Rico. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000279.	1.2	3
1376	Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2016, 34, 1831-1837.	0.3	28
1377	The effect of dietary sodium modification on blood pressure in adults with systolic blood pressure less than 140â€šmmHg. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2016, 14, 196-237.	1.7	9
1378	Use of an electronic health record to identify prevalent and incident cardiovascular disease in type 2 diabetes according to treatment strategy. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000206.	1.2	6
1379	Blood pressure targets in type 2 diabetes: a general perspective. <i>Cardiovascular Endocrinology</i> , 2016, 5, 122-126.	0.8	0
1380	Diabetes and hypertension: too many guidelines, not enough data. <i>Cardiovascular Endocrinology</i> , 2016, 5, 127-132.	0.8	0
1381	What is the truth about renin angiotensin blockers for diabetic patients?. <i>Diabetology International</i> , 2016, 7, 334-337.	0.7	0
1384	Very poor agreement between routine outpatient clinic office and ambulatory blood pressure. <i>Blood Pressure Monitoring</i> , 2016, 21, 340-344.	0.4	2
1385	Management of hypertension and diabetes mellitus by cardiovascular and endocrine physicians. <i>Journal of Hypertension</i> , 2016, 34, 1648-1653.	0.3	23
1386	Hypertension, diabetes and blood pressure targets: ongoing challenges. <i>Cardiovascular Endocrinology</i> , 2016, 5, 120-121.	0.8	0
1387	Identifying the optimal blood pressure target for ideal health. <i>Journal of Translational Internal Medicine</i> , 2016, 4, 1-6.	1.0	7
1388	Treatment of hypertensive patients with diabetes: beyond blood pressure control and focus on manidipine. <i>Future Cardiology</i> , 2016, 12, 435-447.	0.5	1
1389	Hypertension and Brain Damage. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2016, , .	0.1	3
1390	Blood pressure treatment goals in hypertension. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2016, 10, 332-337.	1.0	8
1391	Hypertension Guidelines: Is It Time to Reappraise Blood Pressure Thresholds and Targets?. <i>Hypertension</i> , 2016, 68, 257-262.	1.3	19

#	ARTICLE	IF	CITATIONS
1392	The Future of Clinical Trials in Cardiovascular Medicine. <i>Circulation</i> , 2016, 133, 2662-2670.	1.6	33
1393	Important practice lessons from the SPRINT study beyond the blood pressure goal: all well known and now confirmed. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 613-617.	2.3	6
1394	Medical treatment of stable angina: A tailored therapeutic approach. <i>International Journal of Cardiology</i> , 2016, 220, 445-453.	0.8	36
1395	Effects of blood pressure lowering on outcome incidence in hypertension. <i>Journal of Hypertension</i> , 2016, 34, 613-622.	0.3	254
1396	Target Blood Pressure for Treatment. <i>Hypertension</i> , 2016, 68, 263-265.	1.3	12
1397	Coronary artery disease and diabetes mellitus. <i>Journal of Taibah University Medical Sciences</i> , 2016, 11, 330-338.	0.5	8
1400	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. <i>European Stroke Journal</i> , 2016, 1, 93-100.	2.7	1
1401	Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. <i>Diabetes Care</i> , 2016, 39, 1089-1100.	4.3	119
1402	Hypertension and coronary artery disease: epidemiology, physiology, effects of treatment, and recommendations. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 467-479.	1.0	45
1403	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. <i>Circulation</i> , 2016, 133, 2459-2502.	1.6	766
1404	Recommendations for Intensive Blood Pressure Lowering in High-Risk Patients, the Canadian Viewpoint. <i>Hypertension</i> , 2016, 68, 3-5.	1.3	24
1405	Level of Blood Pressure Control and Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2821-2831.	1.2	30
1406	Managing hypertension in type 2 diabetes mellitus. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 445-454.	2.2	36
1408	Do We Need a New Definition of Hypertension After SPRINT?. <i>American Journal of Hypertension</i> , 2016, 29, 1127-1129.	1.0	16
1409	SPRINT. <i>Hypertension</i> , 2016, 67, 261-262.	1.3	25
1410	Blood pressure and all-cause mortality among patients with type 2 diabetes. <i>International Journal of Cardiology</i> , 2016, 206, 116-121.	0.8	10
1411	Heart Disease and Stroke Statistics—2016 Update. <i>Circulation</i> , 2016, 133, e38-360.	1.6	5,447
1412	Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke. <i>Circulation</i> , 2016, 133, 584-591.	1.6	65

#	ARTICLE	IF	CITATIONS
1413	The SPRINT study: Outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support systolic blood pressure target below 140â€‰mmHg rather than below 120â€‰mmHg. <i>Blood Pressure</i> , 2016, 25, 63-66.	0.7	31
1414	A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. <i>Hospital Practice (1995)</i> , 2016, 44, 9-20.	0.5	1
1415	Hypertension and stroke: an appraisal of the evidence and implications for clinical management. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 609-616.	0.6	13
1416	Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?. <i>Blood Purification</i> , 2016, 41, 139-143.	0.9	22
1417	SPRINT Trial Results. <i>Hypertension</i> , 2016, 67, 263-265.	1.3	79
1418	Treatment of hypertension in diabetes: a contemporary approach with a focus on improving cardiovascular outcomes. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 41-50.	1.2	3
1419	Prognosis after Stroke. , 2016, , 234-252.e10.		1
1420	Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis. <i>American Journal of Hypertension</i> , 2016, 29, 509-518.	1.0	23
1421	Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a <i>post hoc</i> analysis (ORIENT-blood pressure). <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 447-454.	0.4	18
1422	SPRINT: the race for optimal blood pressure control. <i>European Heart Journal</i> , 2016, 37, 937-941.	1.0	8
1423	Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. <i>Blood Pressure</i> , 2016, 25, 93-103.	0.7	90
1424	Treatment of Hypertension in Patients with Coronary Artery Disease. A Case-Based Summary of the 2015 AHA/ACC/ASH Scientific Statement. <i>American Journal of Medicine</i> , 2016, 129, 372-378.	0.6	16
1425	9. Microvascular Complications and Foot Care. <i>Diabetes Care</i> , 2016, 39, S72-S80.	4.3	126
1426	Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure - meta-analyses of randomized trials. <i>Journal of Hypertension</i> , 2016, 34, 373-384.	0.3	75
1427	Importance of sustained and -blood pressure control in patients with high cardiovascular risk. <i>Blood Pressure</i> , 2016, 25, 74-82.	0.7	15
1428	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 374, 1092-1094.	13.9	208
1429	Hypertension in the frail elderly. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 536-541.	2.3	24
1430	Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. <i>Blood Pressure</i> , 2016, 25, 235-240.	0.7	2

#	ARTICLE	IF	CITATIONS
1431	How Does SPRINT (Systolic Blood Pressure Intervention Trial) Direct Hypertension Treatment Targets for CKD?. American Journal of Kidney Diseases, 2016, 68, 15-18.	2.1	13
1432	Ambulatory Blood Pressure Monitoring: New Directions and Uncertainties Arise From the U.S. Preventive Services Task Force Recommendation on the Diagnosis of Hypertension. Journal of Clinical Hypertension, 2016, 18, 172-174.	1.0	7
1433	Which Patients Does the <scp>SPRINT</scp> Study <i>Not</i> Apply To and What Are the Appropriate Blood Pressure Goals in These Populations?. Journal of Clinical Hypertension, 2016, 18, 477-478.	1.0	7
1434	Interventions for Extracranial Carotid Artery Stenosis: An Update. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 34.	0.4	2
1435	Prognostic importance of pretreatment and on-treatment blood pressure: Further analysis of the ACTION database and the effect of nifedipine gastrointestinal therapeutic system. Blood Pressure, 2016, 25, 67-73.	0.7	2
1436	Blood pressure lowering and stroke events in type 2 diabetes: A network meta-analysis of randomized controlled trials. International Journal of Cardiology, 2016, 208, 141-146.	0.8	17
1437	Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. Diabetes Care, 2016, 39, 701-708.	4.3	150
1438	Influence of Blood Pressure and Other Clinical Variables on Long-Term Mortality in a Cohort of Elderly Subjects with Type 2 Diabetes. Canadian Journal of Diabetes, 2016, 40, 12-16.	0.4	8
1439	The role of arterial hypertension in the primary prevention of stroke. Cor Et Vasa, 2016, 58, e279-e286.	0.1	3
1440	Benefits of strict blood-pressure lowering in hypertension. Nature Reviews Cardiology, 2016, 13, 125-126.	6.1	10
1441	SPRINT. Journal of the American College of Cardiology, 2016, 67, 473-475.	1.2	2
1443	Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ, The, 2016, 352, i717.	3.0	288
1444	Cardiovascular benefits of lowering blood pressure. Nature Reviews Nephrology, 2016, 12, 202-204.	4.1	18
1445	Diastolic Hypotension in a Tertiary Care Hypertension Clinic: Have We Gone Too Far?. Canadian Journal of Cardiology, 2016, 32, 695-700.	0.8	5
1446	Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 33.	0.4	41
1447	Patterns and Predictors of Blood Pressure Treatment, Control, and Outcomes among Stroke Survivors in the United States. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 857-865.	0.7	19
1448	No Time to Waste: in Support of Aggressive and Immediate Management of Hypertension. Current Hypertension Reports, 2016, 18, 26.	1.5	3
1450	Treatment Goals in Diabetes. Endocrine Development, 2016, 31, 1-27.	1.3	25

#	ARTICLE	IF	CITATIONS
1451	8. Cardiovascular Disease and Risk Management. Diabetes Care, 2016, 39, S60-S71.	4.3	237
1452	Blood pressure target values: the saga continues. European Heart Journal, 2016, 37, 965-967.	1.0	1
1453	SPRINT, or False Start, Toward a Lower Universal Treated Blood Pressure Target in Hypertension. Hypertension, 2016, 67, 266-267.	1.3	16
1454	Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet, The, 2016, 387, 957-967.	6.3	2,464
1455	Generalizability of SPRINT Results to the U.S. Adult Population. Journal of the American College of Cardiology, 2016, 67, 463-472.	1.2	125
1456	New-onset diabetes in hypertensive patients and mortality: timing is everything. European Heart Journal, 2016, 37, 975-977.	1.0	7
1458	Managing Hypertension in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 40-43.	3.0	21
1459	Ischemic Stroke Therapeutics. , 2016, , .		1
1460	SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a Price. American Journal of Hypertension, 2016, 29, 2-4.	1.0	29
1461	Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. European Heart Journal, 2016, 37, 955-964.	1.0	95
1462	Stroke in women: Where are we in 2015?. Trends in Cardiovascular Medicine, 2016, 26, 89-91.	2.3	1
1463	No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Pressure, 2016, 25, 83-92.	0.7	59
1464	Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet, The, 2016, 387, 435-443.	6.3	792
1465	Lower blood pressure targets: to whom do they apply?. Lancet, The, 2016, 387, 405-406.	6.3	12
1466	Identifying Novel Gene Variants in Coronary Artery Disease and Shared Genes With Several Cardiovascular Risk Factors. Circulation Research, 2016, 118, 83-94.	2.0	52
1467	Effect of Intensive Blood Pressure Lowering on Incident Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial. American Journal of Hypertension, 2016, 29, 1276-1282.	1.0	36
1468	Polypharmacy in Older Adults With Hypertension: A Comprehensive Review. Journal of Clinical Hypertension, 2016, 18, 10-18.	1.0	46
1469	Approach to diabetes management in patients with CVD. Trends in Cardiovascular Medicine, 2016, 26, 165-179.	2.3	38

#	ARTICLE	IF	CITATIONS
1470	Hypertension, Diabetes Type II, and Their Association: Role of Arterial Stiffness. American Journal of Hypertension, 2016, 29, 5-13.	1.0	70
1471	Blood pressure control in type 2 diabetic patients. Cardiovascular Diabetology, 2017, 16, 3.	2.7	77
1472	Blood Pressure Treatment Targets in Adults Aged 60 Years or Older. Annals of Internal Medicine, 2017, 166, 445.	2.0	2
1473	Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta-Analysis of Randomized Trials. American Journal of Medicine, 2017, 130, 707-719.e8.	0.6	142
1474	Beta-blockers for hypertension. The Cochrane Library, 2017, 2017, CD002003.	1.5	205
1475	Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. Nature Reviews Endocrinology, 2017, 13, 365-374.	4.3	29
1476	Lipid and other management to improve arterial disease and survival in end stage renal disease. Expert Opinion on Pharmacotherapy, 2017, 18, 343-349.	0.9	3
1477	Cardiovascular Event Rates and Mortality According to Achieved Systolic and Diastolic Blood Pressure in Patients With Stable Coronary Artery Disease: An International Cohort Study. Journal of Vascular Surgery, 2017, 65, 280.	0.6	1
1479	Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. Current Cardiology Reports, 2017, 19, 7.	1.3	42
1480	Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes and Metabolism, 2017, 43, 99-109.	1.4	41
1481	Blood pressure goals in type 2 diabetes—assessing the evidence. Lancet Diabetes and Endocrinology, 2017, 5, 319-321.	5.5	4
1482	Benefits and Harms of Intensive Blood Pressure Treatment in Adults Aged 60 Years or Older. Annals of Internal Medicine, 2017, 166, 419.	2.0	143
1483	Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians. Annals of Internal Medicine, 2017, 166, 430.	2.0	280
1484	Drug Therapy for Stable Angina Pectoris. Drugs, 2017, 77, 265-284.	4.9	32
1485	Blood pressure and cardiovascular morbidity risk in type 2 diabetes with hypertension over a decade of follow-up: evidence for J-shaped phenomenon. Journal of Human Hypertension, 2017, 31, 415-421.	1.0	3
1486	Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation, 2017, 135, e146-e603.	1.6	7,085
1488	Hypertension in 2017—What Is the Right Target?. JAMA - Journal of the American Medical Association, 2017, 317, 579.	3.8	31
1490	Blood Pressure Management in Hemodialysis Patients: What We Know And What Questions Remain. Seminars in Dialysis, 2017, 30, 203-212.	0.7	19

#	ARTICLE	IF	CITATIONS
1491	Are diabetes guidelines truly evidence based?. Diabetes Research and Clinical Practice, 2017, 127, 70-79.	1.1	5
1492	Optimal Systolic Blood Pressure Levels for Primary Prevention of Stroke in General Hypertensive Adults. Hypertension, 2017, 69, 697-704.	1.3	40
1493	Implications of Blood Pressure Measurement Technique for Implementation of Systolic Blood Pressure Intervention Trial (SPRINT). Journal of the American Heart Association, 2017, 6, .	1.6	104
1494	Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 249-253.	0.9	45
1495	Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet, The, 2017, 389, 1035-1042.	6.3	102
1496	Is it premature to SPRINT?. Cmaj, 2017, 189, E217-E217.	0.9	1
1497	SGLT2 Inhibition in the Diabetic Kidneyâ€”From Mechanisms to Clinical Outcome. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 700-710.	2.2	171
1498	Hypertension treatment in the elderly: a SPRINT to the finish. Future Cardiology, 2017, 13, 99-102.	0.5	1
1499	Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic) Tj ETQq0 0 0 rgBT /Overlock 10 T 2017, 135, 1617-1628.	1.6	96
1500	New evidence for the diastolic Jâ€™curve effect challenges theÂ’safety of intensive blood pressure control. Journal of Clinical Hypertension, 2017, 19, 340-343.	1.0	8
1501	Randomized controlled trial of a coordinated care intervention to improve risk factor control after stroke or transient ischemic attack in the safety net: Secondary stroke prevention by Uniting Community and Chronic care model teams Early to End Disparities (SUCCEED). BMC Neurology, 2017, 17, 24.	0.8	52
1504	Blood pressure treatment levels and choice of antihypertensive agent in people with diabetes mellitus. Journal of Hypertension, 2017, 35, 453-462.	0.3	21
1505	Hypertension in diabetes and the risk of cardiovascular disease. Cardiovascular Endocrinology, 2017, 6, 33-38.	0.8	20
1506	Relationship and associated mechanisms between ambulatory blood pressure and clinic blood pressure with prevalent cardiovascular disease in diabetic hypertensive patients. Medicine (United) Tj ETQq1 1 0.784314 rgB3 /Overlock	1.1	14
1508	Intensive blood pressure lowering in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2017, 26, 197-204.	1.0	2
1509	Practical efficacy of olmesartan versus azilsartan in patients with hypertension. Blood Pressure Monitoring, 2017, 22, 59-67.	0.4	6
1511	A review of chemical therapies for treating diabetic hypertension. Expert Opinion on Pharmacotherapy, 2017, 18, 909-923.	0.9	8
1512	Has the SPRINT trial introduced a new blood-pressure goal in hypertension?. Nature Reviews Cardiology, 2017, 14, 560-565.	6.1	19

#	ARTICLE	IF	CITATIONS
1513	Predictive and explanatory factors of cardiovascular disease in people with adequately controlled type 2 diabetes. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1181-1189.	0.8	12
1514	Wnt signaling, a novel pathway regulating blood pressure? State of the art review. <i>Atherosclerosis</i> , 2017, 262, 171-178.	0.4	24
1515	Blood pressure management in patients with type 2 diabetes mellitus. <i>Hypertension Research</i> , 2017, 40, 721-729.	1.5	7
1516	Learning What We Didn't Know The SPRINT Data Analysis Challenge. <i>New England Journal of Medicine</i> , 2017, 376, 2205-2207.	13.9	36
1517	Side effects and tolerability of combination blood pressure lowering according to blood pressure levels. <i>Journal of Hypertension</i> , 2017, 35, 1318-1325.	0.3	4
1518	Management of Hypertension in Patients with Chronic Kidney Disease. <i>Current Hypertension Reports</i> , 2017, 19, 43.	1.5	22
1519	Low Blood Pressure Is Associated With Greater Risk for Cardiovascular Events in Treated Adults With and Without Apparent Treatment-Resistant Hypertension. <i>Journal of Clinical Hypertension</i> , 2017, 19, 241-249.	1.0	12
1520	SPRINT Blood Pressure. <i>Hypertension</i> , 2017, 69, 15-19.	1.3	45
1521	The J-shaped Curve for Blood Pressure and Cardiovascular Disease Risk: Historical Context and Recent Updates. <i>Current Atherosclerosis Reports</i> , 2017, 19, 34.	2.0	32
1522	Optimal blood pressure target in stroke prevention. <i>Current Opinion in Neurology</i> , 2017, 30, 8-14.	1.8	11
1523	Hypertension: Overly important but under-controlled. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 36-43.	0.8	37
1524	Guidelines on the management of arterial hypertension and related comorbidities in Latin America. <i>Journal of Hypertension</i> , 2017, 35, 1529-1545.	0.3	58
1525	Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 2032-2045.	2.2	1,600
1526	Effects of Intensive BP Control in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2812-2823.	3.0	364
1527	Glucose targets for preventing diabetic kidney disease and its progression. <i>The Cochrane Library</i> , 2017, 2017, CD010137.	1.5	47
1528	Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. <i>American Journal of Cardiology</i> , 2017, 120, S28-S36.	0.7	45
1529	Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. <i>American Journal of Medicine</i> , 2017, 130, S30-S39.	0.6	56
1530	Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality. <i>JAMA Cardiology</i> , 2017, 2, 775.	3.0	515

#	ARTICLE	IF	CITATIONS
1531	Interventions in type 2 diabetes mellitus and cardiovascular mortality—An overview of clinical trials. <i>European Journal of Internal Medicine</i> , 2017, 42, 1-15.	1.0	11
1533	Social epidemiology of hypertension in Buffalo City Metropolitan Municipality (BCMM): cross-sectional study of determinants of prevalence, awareness, treatment and control among South African adults. <i>BMJ Open</i> , 2017, 7, e014349.	0.8	27
1534	Does a blood pressure J curve exist for patients with chronic kidney disease?. <i>Journal of Clinical Hypertension</i> , 2017, 19, 764-770.	1.0	13
1535	Managing Hypertension in the Elderly: What is Different, What is the Same?. <i>Current Cardiovascular Risk Reports</i> , 2017, 11, 1.	0.8	1
1536	Treating to Target in Older Hypertensive Patients: Where Is the Bull's Eye?. <i>American Journal of Kidney Diseases</i> , 2017, 70, 311-314.	2.1	1
1537	Effect of Home Blood Pressure on Inducing Remission/Regression of Microalbuminuria in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Hypertension</i> , 2017, 30, 830-839.	1.0	7
1538	Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	88
1539	Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease. <i>Physiological Reports</i> , 2017, 5, e13228.	0.7	64
1540	Trajectory of systolic blood pressure in a low-income, racial-ethnic minority cohort with diabetes and baseline uncontrolled hypertension. <i>Journal of Clinical Hypertension</i> , 2017, 19, 722-730.	1.0	3
1541	Personalizing the Intensity of Blood Pressure Control. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	37
1542	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>Lancet, The</i> , 2017, 389, 2226-2237.	6.3	263
1543	Hypertension up to date: SPRINT to SPYRAL. <i>Clinical Research in Cardiology</i> , 2017, 106, 475-484.	1.5	18
1544	In the Treatment of Hypertension, Lowering of Diastolic Pressure to <70 mmHg Is Often Unavoidable. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1647-1648.	1.2	0
1545	Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. <i>Journal of Hypertension</i> , 2017, 35, 922-944.	0.3	173
1546	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017, 48, 1218-1225.	1.0	112
1547	Revascularization for Advanced Coronary Artery Disease in Type 2 Diabetic Patients: Choosing Wisely Between PCI and Surgery. <i>Current Cardiology Reports</i> , 2017, 19, 37.	1.3	0
1548	Hypertension in chronic kidney disease after the Systolic Blood Pressure Intervention Trial: targets, treatment and current uncertainties. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, ii219-ii223.	0.4	9
1549	In the Wake of Systolic Blood Pressure Intervention Trial: New Targets for Improving Hypertension Management in Chronic Kidney Disease?. <i>Nephron</i> , 2017, 135, 287-290.	0.9	532

#	ARTICLE	IF	CITATIONS
1550	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary. <i>Endocrine Practice</i> , 2017, 23, 207-238.	1.1	362
1551	Time-Varying Association of Individual BP Components with eGFR in Late-Stage CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 904-911.	2.2	5
1552	Impact of Achieved Blood Pressure on First Stroke in Uncomplicated Grade 1 Hypertension. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	6
1553	The authors respond to –œœ it premature to SPRINT?–œ. <i>Cmaj</i> , 2017, 189, E218-E218.	0.9	0
1554	Cardiovascular inflammation is reduced with methotrexate in diabetes. <i>Molecular and Cellular Biochemistry</i> , 2017, 432, 159-167.	1.4	14
1555	Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 324-327.	2.4	5
1556	Management of Atherosclerotic Cardiovascular Disease Risk Factors in the Older Adult Patient With Diabetes. <i>Diabetes Care</i> , 2017, 40, 476-484.	4.3	9
1557	Precision Medicine for Hypertension Management in Chronic Kidney Disease: Relevance of SPRINT for Therapeutic Targets in Nondiabetic Renal Disease. <i>Canadian Journal of Cardiology</i> , 2017, 33, 611-618.	0.8	7
1558	Should blood pressure goal be individualized in hypertensive patients?. <i>Pharmacological Research</i> , 2017, 118, 53-63.	3.1	12
1559	Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. <i>American Journal of Nephrology</i> , 2017, 45, 136-145.	1.4	13
1560	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2017, 2, 370.	3.0	136
1561	Blood pressure levels and the risk of intracerebral hemorrhage after ischemic stroke. <i>Neurology</i> , 2017, 88, 177-181.	1.5	9
1562	Combined diabetes-renal multifactorial intervention in patients with advanced diabetic nephropathy: Proof-of-concept. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 624-630.	1.2	21
1563	Detecting Heterogeneous Treatment Effects to Guide Personalized Blood Pressure Treatment. <i>Annals of Internal Medicine</i> , 2017, 166, 354.	2.0	35
1564	A Tale of Two Trials: Reconciling Differences in Results by Exploring Heterogeneous Treatment Effects. <i>Annals of Internal Medicine</i> , 2017, 166, 370.	2.0	2
1565	9. Cardiovascular Disease and Risk Management. <i>Diabetes Care</i> , 2017, 40, S75-S87.	4.3	203
1566	10. Microvascular Complications and Foot Care. <i>Diabetes Care</i> , 2017, 40, S88-S98.	4.3	131
1567	Management Strategies for Patients with Diabetic Kidney Disease and Chronic Kidney Disease in Diabetes. <i>Nursing Clinics of North America</i> , 2017, 52, 575-587.	0.7	29

#	ARTICLE	IF	CITATIONS
1568	Clinical Update on Nursing Home Medicine: 2017. Journal of the American Medical Directors Association, 2017, 18, 928-940.	1.2	1
1570	Prehypertension is real and can be associated with target organ damage. Journal of the American Society of Hypertension, 2017, 11, 704-708.	2.3	27
1571	Office blood pressure is lower than awake ambulatory blood pressure at lower targets for treatment. Journal of Clinical Hypertension, 2017, 19, 1210-1213.	1.0	22
1572	Hypertension in African Americans. Current Cardiology Reports, 2017, 19, 129.	1.3	59
1573	Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes and Endocrinology, 2017, 5, 951-964.	5.5	228
1575	A Point-based Mortality Prediction System for Older Adults with Diabetes. Scientific Reports, 2017, 7, 12652.	1.6	10
1576	Chronic Kidney Disease and BP Goals. , 2017, , 403-409.		0
1577	Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. The Cochrane Library, 2017, 10, CD010315.	1.5	33
1578	Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care, 2017, 40, 1733-1738.	4.3	98
1579	Thus Far and No Further: Should Diastolic Hypotension Limit Intensive Blood Pressure Lowering?. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 80.	0.4	2
1580	Blood pressure goal for the elderly Chinese: the findings from the Northern Shanghai Study. Clinical and Experimental Hypertension, 2017, 39, 781-787.	0.5	0
1581	Management of Blood Pressure in Patients with Glaucoma. Current Cardiology Reports, 2017, 19, 109.	1.3	26
1582	Quel est l'objectif tensionnel optimal chez les patients coronariens hypertendus?. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2017, 2017, 21-24.	0.0	0
1583	Hypertension: An Evidence Informed, Case Based Approach. Physician Assistant Clinics, 2017, 2, 557-570.	0.1	0
1584	How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD. Journal of the American College of Cardiology, 2017, 70, 2171-2185.	1.2	59
1585	Do We Need a Patient-Centered Target for Systolic Blood Pressure in Hypertensive Patients With Type 2 Diabetes Mellitus?. Hypertension, 2017, 70, 1273-1282.	1.3	12
1586	Association of central blood pressure and cardiovascular diseases in diabetic patients with hypertension. Medicine (United States), 2017, 96, e8286.	0.4	8
1587	Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older. Annals of Internal Medicine, 2017, 167, 289.	2.0	0

#	ARTICLE	IF	CITATIONS
1588	Intensive Blood Pressure Treatment in Adults Aged 60 Years or Older. <i>Annals of Internal Medicine</i> , 2017, 167, 288.	2.0	3
1589	Intensive Blood Pressure Treatment in Adults Aged 60 Years or Older. <i>Annals of Internal Medicine</i> , 2017, 167, 288.	2.0	2
1590	Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial. <i>International Journal of Clinical Practice</i> , 2017, 71, e12987.	0.8	4
1591	Diabetes and Hypertension: A Position Statement by the American Diabetes Association. <i>Diabetes Care</i> , 2017, 40, 1273-1284.	4.3	462
1592	Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. <i>New England Journal of Medicine</i> , 2017, 377, 745-755.	13.9	157
1593	Comparison of ambulatory blood pressure and clinic blood pressure in relation to cardiovascular diseases in diabetic patients. <i>Medicine (United States)</i> , 2017, 96, e7807.	0.4	8
1594	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. <i>Hypertension</i> , 2017, 70, 907-914.	1.3	12
1595	Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure. <i>Journal of Hypertension</i> , 2017, 35, 2138-2149.	0.3	23
1596	Chronic kidney disease and incident apparent treatment-resistant hypertension among blacks: Data from the Jackson Heart Study. <i>Journal of Clinical Hypertension</i> , 2017, 19, 1117-1124.	1.0	13
1597	Optimal achieved blood pressure for patients with stable coronary artery disease. <i>Scientific Reports</i> , 2017, 7, 10137.	1.6	6
1598	A Practical Approach to Hypertension Management in Diabetes. <i>Diabetes Therapy</i> , 2017, 8, 981-989.	1.2	17
1599	J Curve in Patients Randomly Assigned to Different Systolic Blood Pressure Targets. <i>Circulation</i> , 2017, 136, 2220-2229.	1.6	42
1600	Is cardiovascular risk reduction therapy effective in South Asian, Chinese and other patients with diabetes? A population-based cohort study from Canada. <i>BMJ Open</i> , 2017, 7, e013808.	0.8	7
1601	Hypertension, Diabetes Mellitus, and Excess Cardiovascular Risk. <i>Hypertension</i> , 2017, 70, 882-883.	1.3	6
1602	Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease. <i>Annals of Internal Medicine</i> , 2017, 167, 375.	2.0	78
1603	Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5. <i>JAMA Internal Medicine</i> , 2017, 177, 1498.	2.6	158
1604	Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 459-470.	1.3	4
1605	Blood Pressure Trajectories and the Risk of Intracerebral Hemorrhage and Cerebral Infarction. <i>Hypertension</i> , 2017, 70, 508-514.	1.3	106

#	ARTICLE	IF	CITATIONS
1606	BP Targets in CKD, Mortality, and SPRINT: What Have We Learned?. Journal of the American Society of Nephrology: JASN, 2017, 28, 2561-2563.	3.0	4
1608	Blood pressure parameters are associated with all-cause and cause-specific mortality in chronic kidney disease. Kidney International, 2017, 92, 1272-1281.	2.6	31
1609	The Elusive Search for Optimal Blood Pressure Targets. Current Hypertension Reports, 2017, 19, 63.	1.5	2
1610	Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetologica, 2017, 54, 933-941.	1.2	59
1611	Changing concepts in hypertension management. Journal of Human Hypertension, 2017, 31, 763-767.	1.0	12
1612	Relationships between Medication Adherence and Cardiovascular Disease Risk Factor Control in Elderly Patients with Diabetes. Pharmacotherapy, 2017, 37, 1204-1214.	1.2	9
1613	Managing Hypertension in the Elderly: What is Different, What is the Same?. Current Hypertension Reports, 2017, 19, 67.	1.5	5
1614	Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes. International Journal of Cardiology, 2017, 248, 301-307.	0.8	27
1615	Moving Beyond Office Blood Pressure to Achieve a Personalized and More Precise Hypertension Management. Hypertension, 2017, 70, .	1.3	14
1616	Impact of aortic rather than brachial pulsatile haemodynamics on variations in end-organ measures across the full adult blood pressure range. Journal of Hypertension, 2017, 35, 2443-2453.	0.3	5
1617	Is there a risk in overtreating a hypertensive patient?. Journal of Cardiovascular Medicine, 2017, 18, e50-e53.	0.6	3
1619	Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. Journal of the American College of Cardiology, 2017, 70, 883-893.	1.2	125
1620	Ambulatory blood pressure is superior to clinic blood pressure in relation to ischemic stroke in both diabetic and nondiabetic patients. Blood Pressure Monitoring, 2017, 22, 314-321.	0.4	8
1621	Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care, 2017, 40, 1401-1408.	4.3	68
1622	Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODE) using individual participant data from randomised trials. Lancet Diabetes and Endocrinology, the, 2017, 5, 788-798.	5.5	134
1623	Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older. Annals of Internal Medicine, 2017, 167, 290.	2.0	1
1624	Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older. Annals of Internal Medicine, 2017, 167, 291.	2.0	2
1627	The Tale of an Innocent. Circulation, 2017, 136, 2230-2232.	1.6	4

#	ARTICLE	IF	CITATIONS
1628	Services aimed at achieving desirable clinical outcomes in patients with chronic kidney disease and diabetes mellitus: A narrative review. <i>SAGE Open Medicine</i> , 2017, 5, 205031211774098.	0.7	0
1629	Dynamic treatment selection and modification for personalised blood pressure therapy using a Markov decision process model: a cost-effectiveness analysis. <i>BMJ Open</i> , 2017, 7, e018374.	0.8	7
1630	Relation Between Blood Pressure and Clinical Outcome in Hypertensive Subjects With Previous Stroke. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	6
1631	Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials. <i>Diabetes Care</i> , 2018, 41, 1142-1148.	4.3	37
1632	Systolic Blood Pressure Response in SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD (Action to Control Cardiovascular Risk in Diabetes): A Possible Explanation for Discordant Trial Results. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	16
1633	The New 2017 ACC/AHA Guidelines "Up the Pressure" on Diagnosis and Treatment of Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2083.	3.8	41
1634	Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2132.	3.8	82
1635	Clinical and pathological factors associated with progression of diabetic nephropathy. <i>Nephrology</i> , 2017, 22, 14-19.	0.7	37
1636	Targeted Screening and Improvement of the Medicinal Properties of Oregano and Rhodiola with Chitosan Oligosaccharide and Vitamin C Using in Vitro Assays for Hyperglycemia and Hypertension Linked to Type 2 Diabetes. <i>Journal of Herbs, Spices and Medicinal Plants</i> , 2017, 23, 347-362.	0.5	1
1637	Amelioration of arterial pressure lability: an unmissable target for diabetes management. <i>Hypertension Research</i> , 2017, 40, 629-631.	1.5	1
1638	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2017, 18, 1243-1260.	0.9	35
1641	Clinical Implications of Different Blood Pressure Measurement Techniques. <i>Current Hypertension Reports</i> , 2017, 19, 54.	1.5	12
1643	Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). <i>Pharmacoeconomics</i> , 2017, 35, 375-396.	1.7	24
1644	Applying the Systolic Blood Pressure Intervention Trial Results to Older Adults. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 16-21.	1.3	26
1645	The Case for Low Blood Pressure Targets. <i>American Journal of Hypertension</i> , 2017, 30, 3-7.	1.0	15
1646	Following the LEADER " why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 517-519.	1.2	9
1647	Extended consensus on blood pressure variability beyond blood pressure for management of hypertension. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 6-9.	2.3	0
1648	Heart Failure and Hypertension. <i>Medical Clinics of North America</i> , 2017, 101, 19-28.	1.1	28

#	ARTICLE	IF	CITATIONS
1649	Guidelines for the Management of Hypertension. <i>Medical Clinics of North America</i> , 2017, 101, 219-227.	1.1	46
1650	Personalised treatment targets in type 2 diabetes patients: The Dutch approach. <i>Primary Care Diabetes</i> , 2017, 11, 71-77.	0.9	16
1651	What should the blood pressure be in patients with a prior ischemic stroke or a transient ischemic attack?. <i>Future Cardiology</i> , 2017, 13, 203-206.	0.5	0
1652	Randomized Trial of the Effects of Insulin and Metformin on Myocardial Injury and Stress in Diabetes Mellitus: A Post Hoc Exploratory Analysis. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	7
1653	From "essential" hypertension to intensive blood pressure lowering: the pros and cons of lower target values. <i>European Heart Journal</i> , 2017, 38, 3258-3271.	1.0	13
1655	The impact of antihypertensives on kidney disease. <i>F1000Research</i> , 2017, 6, 611.	0.8	5
1656	The more individualised the blood pressure, the better. <i>Journal of Public Health and Emergency</i> , 2017, 1, 71-71.	4.4	0
1657	Alzheimer's™s: Beyond the Brain. , 2017, , 242-273.		2
1658	The J Curve Phenomenon is Still Valid in the Era of Primary Revascularization. <i>Korean Circulation Journal</i> , 2017, 47, 440.	0.7	0
1659	Progression of Renal Insufficiency in Patients with Essential Hypertension Treated with Renin Angiotensin Aldosterone System Blockers: An Electrocardiographic Correlation. <i>Diseases (Basel)</i> , Tj ETQq1 1 0.784314 rgBT /Overlock		
1660	Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases. <i>Frontiers in Medicine</i> , 2017, 4, 73.	1.2	176
1661	Will the recent hypertension trials change the guidelines?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2017, 18, 147032031771089.	1.0	2
1662	Cost-utility analysis of bariatric surgery compared with conventional medical management in Germany: a decision analytic modeling. <i>BMC Surgery</i> , 2017, 17, 87.	0.6	20
1663	Adequacy of control of cardiovascular risk factors in ambulatory patients with type 2 diabetes attending diabetes out-patients clinic at a county hospital, Kenya. <i>BMC Endocrine Disorders</i> , 2017, 17, 73.	0.9	14
1664	Personalized medicine and Hispanic health: improving health outcomes and reducing health disparities " a National Heart, Lung, and Blood Institute workshop report. <i>BMC Proceedings</i> , 2017, 11, 11.	1.8	22
1665	Association between single nucleotide polymorphism rs9534275 and the risk of coronary artery disease and ischemic stroke. <i>Lipids in Health and Disease</i> , 2017, 16, 193.	1.2	20
1666	FimAsartaN proTeinuriA SusTained reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. <i>Trials</i> , 2017, 18, 632.	0.7	4
1667	Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 53.	1.2	34

#	ARTICLE	IF	CITATIONS
1668	Hypertensive diabetic patients: incidence of cardiovascular and renal outcomes in a historical cohort over 11 years. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 98.	1.2	7
1671	Heterogenous treatment effects: secrets for a reliable treat-to-target trial?. <i>Cardiovascular Research</i> , 2017, 113, e18-e20.	1.8	1
1673	Diabetes mellitus and stroke: A clinical update. <i>World Journal of Diabetes</i> , 2017, 8, 235.	1.3	105
1674	Target goal blood pressure in hypertension management. <i>Journal of the Korean Medical Association</i> , 2017, 60, 819.	0.1	1
1675	Hypertension and blood pressure variability management practices among physicians in Singapore. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 275-285.	1.0	14
1676	Fatores de risco modificáveis e não modificáveis do AVC isquêmico: uma abordagem descritiva. , 2017, 96, 187.	0.0	12
1677	Blood Pressure Management for Stroke Prevention and in Acute Stroke. <i>Journal of Stroke</i> , 2017, 19, 152-165.	1.4	34
1678	Systolic blood pressure target: Have we identified the optimal target yet?. <i>Journal of Public Health and Emergency</i> , 2017, 1, 61-61.	4.4	0
1679	Threshold value of home pulse pressure predicting arterial stiffness in patients with type 2 diabetes: <sc>KAMOGAWA</sc>â€‹<sc>HBP</sc> study. <i>Journal of Clinical Hypertension</i> , 2018, 20, 472-477.	1.0	10
1680	Implications of Recent Clinical Trials and Hypertension Guidelines on Stroke and Future Cerebrovascular Research. <i>Stroke</i> , 2018, 49, 772-779.	1.0	30
1682	Heart failure and the discrepancy between trials of intensive blood pressure management: an analysis of individual patient data. <i>Clinical Research in Cardiology</i> , 2018, 107, 565-569.	1.5	2
1683	Investigation and management of adult hypertension. <i>Heart</i> , 2018, 104, 1543-1551.	1.2	1
1684	Admission Systolic Blood Pressure Predicts the Number of Blood Pressure Medications at Discharge in Patients With Primary Intracerebral Hemorrhage. <i>Neurologist</i> , 2018, 23, 60-64.	0.4	1
1685	The role of KATP channels in cerebral ischemic stroke and diabetes. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 683-694.	2.8	55
1686	Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 555-563.	5.5	81
1687	Target blood pressure and kidney protection. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 521-523.	5.5	5
1688	Treatment Thresholds and Targets in Hypertension. <i>Hypertension</i> , 2018, 71, 966-968.	1.3	11
1689	Blood Pressureâ€œRelated Risk Among Users Versus Nonusers of Antihypertensives. <i>Hypertension</i> , 2018, 71, 1047-1055.	1.3	10

#	ARTICLE	IF	CITATIONS
1690	Effects of different statin types and dosages on systolic/diastolic blood pressure: Retrospective analysis of 24-hour ambulatory blood pressure database. <i>Journal of Clinical Hypertension</i> , 2018, 20, 967-975.	1.0	6
1691	Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus. <i>Annals of Vascular Diseases</i> , 2018, 11, 2-14.	0.2	8
1692	Treatment of hypertension in older people. <i>Journal of Pharmacy Practice and Research</i> , 2018, 48, 92-101.	0.5	2
1693	Low diastolic blood pressure and adverse outcomes in heart failure with preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018, 263, 69-74.	0.8	39
1694	Burden of high blood pressure as a contributing factor to stroke in the Japanese community-based diabetic population. <i>Hypertension Research</i> , 2018, 41, 531-538.	1.5	9
1695	Diabetes in Older People. <i>Canadian Journal of Diabetes</i> , 2018, 42, S283-S295.	0.4	75
1696	Current practice of usual clinic blood pressure measurement in people with and without diabetes: a survey and prospective "mystery shopper" study in UK primary care. <i>BMJ Open</i> , 2018, 8, e020589.	0.8	11
1697	Relation of Aortic Stiffness to Left Ventricular Remodeling in Younger Adults With Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1395-1400.	0.3	36
1698	Is the management of diabetes different in dialysis patients?. <i>Seminars in Dialysis</i> , 2018, 31, 367-376.	0.7	6
1699	Cost-utility analysis of bariatric surgery. <i>British Journal of Surgery</i> , 2018, 105, 1328-1337.	0.1	35
1700	Hypertension in patients with type 2 diabetes mellitus: Targets and management. <i>Maturitas</i> , 2018, 112, 71-77.	1.0	55
1701	Preventive Cardiology. , 2018, , 269-289.		0
1702	Making Sense of Hypertension Guidelines. <i>Journal of Cardiovascular Nursing</i> , 2018, 33, 413-419.	0.6	3
1703	The 2017 high blood pressure clinical practice guideline: The old and the new. <i>Clinical Cardiology</i> , 2018, 41, 279-281.	0.7	2
1704	The new hypertension guideline: logical but unwise. <i>Family Practice</i> , 2018, 35, 528-530.	0.8	1
1705	Usefulness of a Simple Algorithm to Identify Hypertensive Patients Who Benefit from Intensive Blood Pressure Lowering. <i>American Journal of Cardiology</i> , 2018, 122, 248-254.	0.7	5
1706	Chronic Kidney Disease in Diabetes. <i>Canadian Journal of Diabetes</i> , 2018, 42, S201-S209.	0.4	57
1707	Role of autonomic nervous activity, as measured by heart rate variability, on the effect of mortality in disabled older adults with low blood pressure in long-term care. <i>Geriatrics and Gerontology International</i> , 2018, 18, 1153-1158.	0.7	3

#	ARTICLE	IF	CITATIONS
1708	Population impact of the 2017 ACC/AHA guidelines compared with the 2013 ESH/ESC guidelines for hypertension management. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1111-1113.	0.8	21
1709	Treatment of Hypertension. <i>Canadian Journal of Diabetes</i> , 2018, 42, S186-S189.	0.4	15
1710	Type 2 Diabetes and the Reduction of Cardiovascular Risk: Sorting Out the Actors and the Roles. <i>Canadian Journal of Cardiology</i> , 2018, 34, 532-535.	0.8	1
1711	Panvascular risk factor - Diabetes. <i>Cor Et Vasa</i> , 2018, 60, e18-e29.	0.1	8
1712	Personalised blood pressure ranges in type 2 diabetes?. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 761-763.	5.5	1
1713	Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk. <i>European Heart Journal</i> , 2018, 39, 2255-2262.	1.0	45
1714	Hypertension in Adults With Type 2 Diabetes: A Review of Blood Pressure Measurement Methods, Targets and Therapy. <i>Canadian Journal of Diabetes</i> , 2018, 42, 188-195.	0.4	15
1716	Initial Treatment of Hypertension. <i>New England Journal of Medicine</i> , 2018, 378, 636-644.	13.9	43
1717	Natural History of Treated and Untreated Hypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018, , 33-44.	0.1	6
1718	Target home morning SBP be below 125 mmHg in type 2 diabetes patients. <i>Journal of Hypertension</i> , 2018, 36, 1284-1290.	0.3	5
1719	Reduced Long-Term Risk of Aortic Aneurysm and Aortic Dissection Among Individuals With Type 2 Diabetes Mellitus: A Nationwide Observational Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	60
1720	Aggressive systolic blood pressure control in older subjects: benefits and risks. <i>Postgraduate Medicine</i> , 2018, 130, 159-165.	0.9	17
1721	Impact of the SPRINT Trial on Hypertension Management. <i>Annual Review of Medicine</i> , 2018, 69, 81-95.	5.0	6
1722	Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association. <i>Circulation</i> , 2018, 137, e67-e492.	1.6	5,228
1723	Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: A subgroup analysis of high-risk ACCORDION trial participants. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1499-1502.	2.2	36
1724	Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1335-1336.	2.2	5
1725	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 81-96.	1.2	54
1726	Blood Pressure Control and Cardiovascular/Renal Outcomes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 175-184.	1.2	8

#	ARTICLE	IF	CITATIONS
1727	The Evolving Epidemiology of Atherosclerotic Cardiovascular Disease in People with Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 1-32.	1.2	16
1728	Smart Care Based on Telemonitoring and Telemedicine for Type 2 Diabetes Care: Multi-Center Randomized Controlled Trial. <i>Telemedicine Journal and E-Health</i> , 2018, 24, 604-613.	1.6	37
1729	Hypertension with diabetes mellitus complications. <i>Hypertension Research</i> , 2018, 41, 147-156.	1.5	86
1730	Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach. <i>Diabetologia</i> , 2018, 61, 517-525.	2.9	19
1731	Effect of glucose-lowering therapies on heart failure. <i>Nature Reviews Cardiology</i> , 2018, 15, 282-291.	6.1	45
1732	Thresholds and Targets for Hypertension Management in Adults With Type 2 Diabetes Should Remain at 130/80â€mmHg: What's the Evidence?. <i>Canadian Journal of Diabetes</i> , 2018, 42, 166-172.	0.4	3
1733	Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs. <i>International Journal of Cardiology</i> , 2018, 254, 291-296.	0.8	27
1734	Heart Failure. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 117-135.	1.2	17
1735	Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 33-47.	0.4	13
1736	Association between mean systolic blood pressure and cardiovascular outcomes in diabetes mellitus: ACCORD trial. <i>Journal of Human Hypertension</i> , 2018, 32, 167-169.	1.0	0
1737	Risks of High Blood Pressure and Goals for Treatment. , 2018, , 1-38.		1
1739	Attended Versus Unattended Blood Pressure Measurement in a Real Life Setting. <i>Hypertension</i> , 2018, 71, 243-249.	1.3	76
1740	Validation of Risk Equations for Complications of Type 2 Diabetes (RECODE) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S.. <i>Diabetes Care</i> , 2018, 41, 586-595.	4.3	62
1741	Chronic kidney disease and stroke: more observations but no trials. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 367-370.	0.4	2
1742	Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2018, 137, 137-148.	1.1	114
1743	Consensus Document on Improving Hypertension Management in Asian Patients, Taking Into Account Asian Characteristics. <i>Hypertension</i> , 2018, 71, 375-382.	1.3	94
1744	Potential U.S. Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. <i>Journal of the American College of Cardiology</i> , 2018, 71, 109-118.	1.2	283
1745	Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials. <i>Kidney International Supplements</i> , 2018, 8, 8-17.	4.6	7

#	ARTICLE	IF	CITATIONS
1746	Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2018, 20, 323-331.	2.9	23
1747	SPRINT in context. <i>Journal of Hypertension</i> , 2018, 36, 979-986.	0.3	6
1748	Control of glycemia and blood pressure in British adults with diabetes mellitus and subsequent therapy choices: a comparison across health states. <i>Cardiovascular Diabetology</i> , 2018, 17, 27.	2.7	20
1749	Diastolic blood pressure and risk profile in renal and cardiovascular diseases. Results from the SPRINT trial. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 513-523.e3.	2.3	22
1750	Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2131-2139.	2.2	14
1751	Intensive blood pressure lowering reduces adverse cardiovascular outcomes among patients with high-normal glucose: An analysis from the Systolic Blood Pressure Intervention Trial database. <i>Journal of Clinical Hypertension</i> , 2018, 20, 620-624.	1.0	5
1752	More From SPRINT (Systolic Blood Pressure Intervention Trial): A Closer Look at the Price of Intensive Blood Pressure Control. <i>American Journal of Kidney Diseases</i> , 2018, 71, 611-614.	2.1	1
1753	Apparent Treatment Resistant Hypertension, Blood Pressure Control and the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 422-438.	0.9	19
1754	Nuevos objetivos de hipertensi3n arterial, ¿est3n justificados?. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 608-611.	0.6	7
1755	Reliability of single office blood pressure measurements. <i>Heart</i> , 2018, 104, 1173-1179.	1.2	42
1756	Intensive Blood Pressure Targets for Diabetic and Other High-Risk Populations. <i>Hypertension</i> , 2018, 71, 833-839.	1.3	17
1757	Individualizing Blood Pressure Targets for People With Diabetes and Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1319.	3.8	48
1758	Prognostic significance of home pulse pressure for progression of diabetic nephropathy: KAMOGAWA-HBP study. <i>Hypertension Research</i> , 2018, 41, 363-371.	1.5	5
1759	Diabetes and Hypertension: Clinical Update. <i>American Journal of Hypertension</i> , 2018, 31, 515-521.	1.0	16
1760	Blood pressure reduced to new guideline goals in patients with high-normal glucose further reduces cardiovascular events. <i>Journal of Clinical Hypertension</i> , 2018, 20, 625-626.	1.0	1
1761	Long-term outcomes associated with triple-goal achievement in patients with type 2 diabetes mellitus (T2DM). <i>Diabetes Research and Clinical Practice</i> , 2018, 140, 45-54.	1.1	15
1762	Drug treatment of hypertension in older patients with diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 633-642.	0.9	5
1763	Effect of Achieved Systolic Blood Pressure on Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Population-Based Retrospective Cohort Study. <i>Diabetes Care</i> , 2018, 41, 1134-1141.	4.3	25

#	ARTICLE	IF	CITATIONS
1764	What Ever Happened to Cardioprotection With β -Blockers?. Mayo Clinic Proceedings, 2018, 93, 401-403.	1.4	4
1765	Should we adhere to the new diagnostic recommendations for arterial hypertension?. Revista Colombiana De Cardiologia, 2018, 25, e1-e3.	0.1	0
1766	Competing Risk of Death With End-Stage Renal Disease in Diabetic Kidney Disease. Advances in Chronic Kidney Disease, 2018, 25, 133-140.	0.6	12
1767	Patient at intermediate cardiovascular risk. Journal of Cardiovascular Medicine, 2018, 19, e130-e132.	0.6	1
1768	Modern Management and Diagnosis of Hypertension in the United Kingdom: Home Care and Self-care. Annals of Global Health, 2018, 82, 274.	0.8	19
1769	Dual RAAS Blockade with Aliskiren in Patients with Severely Impaired Chronic Kidney Disease. Experimental and Clinical Endocrinology and Diabetes, 2018, 126, 39-52.	0.6	2
1770	Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus. Current Problems in Cardiology, 2018, 43, 68-110.	1.1	22
1771	Genetic Variants in <i>HSD17B3</i> , <i>SMAD3</i> , and <i>IPO11</i> Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. Clinical Pharmacology and Therapeutics, 2018, 103, 712-721.	2.3	30
1772	Blood pressure parameters and morbid and mortal outcomes in nondialysis-dependent chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2018, 27, 16-22.	1.0	2
1773	BP Measurement in Clinical Practice: Time to SPRINT to Guideline-Recommended Protocols. Journal of the American Society of Nephrology: JASN, 2018, 29, 383-388.	3.0	31
1774	Longitudinal Blood Pressure Changes and Kidney Function Decline in Persons Without Chronic Kidney Disease: Findings From the MESA Study. American Journal of Hypertension, 2018, 31, 600-608.	1.0	14
1775	Modelling incremental benefits on complications rates when targeting lower HbA _{1c} levels in people with Type 2 diabetes and cardiovascular disease. Diabetic Medicine, 2018, 35, 72-77.	1.2	17
1776	Aortic stiffness and ambulatory blood pressure as predictors of diabetic kidney disease: a competing risks analysis from the Rio de Janeiro Type 2 Diabetes Cohort Study. Diabetologia, 2018, 61, 455-465.	2.9	26
1777	Cardiovascular Screening and Primary Prevention in Older Adults. Clinics in Geriatric Medicine, 2018, 34, 81-93.	1.0	1
1778	Relationships Between Components of Blood Pressure and Cardiovascular Events in Patients with Stable Coronary Artery Disease and Hypertension. Hypertension, 2018, 71, 168-176.	1.3	41
1779	Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohort. Diabetes, Obesity and Metabolism, 2018, 20, 629-637.	2.2	5
1780	Systolic blood pressure target in systemic arterial hypertension: Is lower ever better? Results from a community-based Caucasian cohort. European Journal of Internal Medicine, 2018, 48, 57-63.	1.0	11
1781	Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease. Journal of Hypertension, 2018, 36, 419-427.	0.3	5

#	ARTICLE	IF	CITATIONS
1782	Patterns of blood pressure response during intensive BP lowering and clinical events: results from the secondary prevention of small subcortical strokes trial. <i>Blood Pressure</i> , 2018, 27, 73-81.	0.7	1
1783	Individualizing treatment choices in the systolic blood pressure intervention trial. <i>Journal of Hypertension</i> , 2018, 36, 428-435.	0.3	7
1784	The optimal cut-off of blood pressure related to left ventricular diastolic dysfunction and remodeling in Asian diabetic patients. <i>Journal of Cardiology</i> , 2018, 71, 16-23.	0.8	3
1785	Achieving target SBP for lowering the risk of major adverse cardiovascular events in persons with diabetes mellitus. <i>Journal of Hypertension</i> , 2018, 36, 101-109.	0.3	13
1786	Association between low diastolic blood pressure and subclinical myocardial injury. <i>Clinical Research in Cardiology</i> , 2018, 107, 312-318.	1.5	13
1787	Effect of nebivolol or atenolol vs. placebo on cardiovascular health in subjects with borderline blood pressure: the EVIDENCE study. <i>Journal of Human Hypertension</i> , 2018, 32, 20-25.	1.0	3
1788	10. Microvascular Complications and Foot Care: <i>Standards of Medical Care in Diabetesâ€™2018</i>. <i>Diabetes Care</i> , 2018, 41, S105-S118.	4.3	269
1789	BP in Dialysis: Results of a Pilot Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 307-316.	3.0	49
1790	Risk of stroke and coronary heart disease among various levels of blood pressure in diabetic and nondiabetic Chinese patients. <i>Journal of Hypertension</i> , 2018, 36, 93-100.	0.3	17
1791	What is the most appropriate target SBP in persons with hypertension and diabetes mellitus?. <i>Journal of Hypertension</i> , 2018, 36, 37-40.	0.3	3
1792	9. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€™2018</i>. <i>Diabetes Care</i> , 2018, 41, S86-S104.	4.3	461
1793	Blood Pressureâ€™Lowering Targets in Patients With Diabetes Mellitus. <i>Canadian Journal of Cardiology</i> , 2018, 34, 644-652.	0.8	1
1794	The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure. <i>Journal of Hypertension</i> , 2018, 36, 916-923.	0.3	4
1795	Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2176-2198.	1.2	138
1796	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2199-2269.	1.2	708
1797	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. <i>Journal of the American College of Cardiology</i> , 2018, 71, e127-e248.	1.2	4,042
1798	Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. <i>Circulation</i> , 2018, 137, 109-118.	1.6	656
1799	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i> , 2018, 71, e13-e115.	1.3	3,332

#	ARTICLE	IF	CITATIONS
1820	Associations Between Triglyceride/High-Density Lipoprotein Cholesterol Ratio and Micro- and Macroangiopathies in Type 2 Diabetes Mellitus. <i>Endocrine Practice</i> , 2018, 24, 615-621.	1.1	13
1821	Documento de consenso de la Sociedad Española de Arteriosclerosis (SEA) para la prevención y tratamiento de la enfermedad cardiovascular en la diabetes mellitus tipo 2. <i>Clínica e Investigación en Arteriosclerosis</i> , 2018, 30, 1-19.	0.4	5
1822	New Challenges for Hypertension Treatment. <i>Archives of Medical Research</i> , 2018, 49, 548-557.	1.5	7
1823	Effect of a Health Coach Intervention for the Management of Individuals With Type 2 Diabetes Mellitus in China: A Pragmatic Cluster Randomized Controlled Trial. <i>Frontiers in Public Health</i> , 2018, 6, 252.	1.3	14
1824	Rationale and design of a pragmatic clinical trial to assess the impact of self-monitoring blood pressure at home and self-titration of antihypertensive medication in poorly controlled hypertension: the ADAMPA study protocol. <i>BMC Family Practice</i> , 2018, 19, 160.	2.9	3
1825	Optimal medical treatment of hypertension in patients with coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 815-823.	0.6	4
1826	Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT. <i>Journal of the American Heart Association</i> , 2018, 7, e009326.	1.6	79
1827	Dangers of Overly Aggressive Blood Pressure Control. <i>Current Cardiology Reports</i> , 2018, 20, 108.	1.3	4
1828	Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. <i>Diabetes Care</i> , 2018, 41, 2404-2413.	4.3	32
1829	Defining Hypertension. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1578-1580.	2.2	6
1830	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>Journal of Hypertension</i> , 2018, 36, 1953-2041.	0.3	2,129
1831	Reaching an ACCORD on Glycemia and Systolic Blood Pressure Targets in Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2018, 7, e010508.	1.6	2
1832	Antihypertensive treatment and renal protection: Is there a J-curve relationship?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1560-1574.	1.0	17
1833	Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses. <i>Vascular Health and Risk Management</i> , 2018, Volume 14, 233-246.	1.0	5
1834	Managing Chronic Coronary Artery Disease in Patients with Diabetes. , 2018, , 355-373.		0
1835	Optimal Blood Pressure Target in Diabetic and Nondiabetic Hypertensive Patients. <i>Circulation Research</i> , 2018, 123, 528-530.	2.0	12
1836	Effect of Hypertension on Aortic Artery Disease-Related Mortality—3.8-Year Nationwide Community-Based Prospective Cohort Study. <i>Circulation Journal</i> , 2018, 82, 2776-2782.	0.7	15
1837	Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1693-1702.	2.2	32

#	ARTICLE	IF	CITATIONS
1838	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2018, 138, e426-e483.	1.6	599
1839	Lowering the systolic blood pressure target in hypertensive patients: current controversies and future outlook. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 889-895.	0.6	2
1840	Sprinting Toward the Optimal Blood Pressure Target for Hypertensive Patients. <i>Circulation Research</i> , 2018, 123, 531-534.	2.0	4
1841	Creatinine Rise During Blood Pressure Therapy and the Risk of Adverse Clinical Outcomes in Patients With Type 2 Diabetes Mellitus. <i>Hypertension</i> , 2018, 72, 1337-1344.	1.3	18
1842	Morning Home Blood Pressure and Cardiovascular Events in Japanese Hypertensive Patients. <i>Hypertension</i> , 2018, 72, 854-861.	1.3	31
1843	Kidney Damage Biomarkers and Incident Chronic Kidney Disease During Blood Pressure Reduction. <i>Annals of Internal Medicine</i> , 2018, 169, 610.	2.0	63
1844	Manidipine: an antihypertensive drug with positive effects on metabolic parameters and adrenergic tone in patients with diabetes. <i>Drugs in Context</i> , 2018, 7, 1-17.	1.0	0
1845	Medical and lifestyle management of peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2018, 68, 1595-1606.	0.6	44
1846	Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009114.	1.6	19
1847	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2018, 138, e484-e594.	1.6	330
1848	Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2018, 138, e595-e616.	1.6	76
1849	Evidence-Based Management of Diabetes in Older Adults. <i>Drugs and Aging</i> , 2018, 35, 1065-1078.	1.3	19
1850	Effect of Intensive Glycemic Control on Risk of Lower Extremity Amputation. <i>Journal of the American College of Surgeons</i> , 2018, 227, 596-604.	0.2	47
1852	Control of blood pressure and cardiovascular outcomes in type 2 diabetes. <i>Open Medicine (Poland)</i> , 2018, 13, 304-323.	0.6	7
1853	Revisiting the Diabetes-Heart Failure Connection. <i>Current Diabetes Reports</i> , 2018, 18, 134.	1.7	10
1854	Prevalence of Hypertension and Cardiovascular Risk According to Blood Pressure Thresholds Used for Diagnosis. <i>Hypertension</i> , 2018, 72, 602-609.	1.3	46
1855	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 579.e1-579.e73.	2.3	126
1856	Blood Pressure Control and Cardiovascular Outcomes: Real-world Implications of the 2017 ACC/AHA Hypertension Guideline. <i>Scientific Reports</i> , 2018, 8, 13155.	1.6	44

#	ARTICLE	IF	CITATIONS
1857	Plasma Leptin Concentration and Sympathetic Nervous Activity in Older Adults With Physical Dysfunction. <i>Journal of the Endocrine Society</i> , 2018, 2, 1040-1049.	0.1	5
1858	The frailty syndrome and outcomes in the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1570-1577.	2.9	106
1859	Primary and Secondary Prevention of Cardiovascular Disease. , 2018, , 63-76.		0
1860	Predictors of glycemic control in type-2 diabetes mellitus: Evidence from a multicenter study in Ghana. <i>Translational Metabolic Syndrome Research</i> , 2018, 1, 1-8.	0.2	20
1861	Hypertension in South Asians. , 2018, , 27-31.		7
1862	Hypertension Management in Diabetes: 2018 Update. <i>Diabetes Spectrum</i> , 2018, 31, 218-224.	0.4	51
1863	Methods of Blood Pressure Assessment Used in Milestone Hypertension Trials. <i>Pulse</i> , 2018, 6, 112-123.	0.9	17
1864	Searching for an Optimal Systolic Blood Pressure Target: A Balance of Benefits and Risks. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1543-1545.	0.8	0
1865	Low Diastolic Blood Pressure Is Associated With Angina in Patients With Chronic Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1227-1232.	1.2	19
1866	Generalizing Intensive Blood Pressure Treatment to Adults With Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1214-1223.	1.2	7
1867	Presence of Diabetes Does Not Mandate Lower Blood Pressure to Reduce Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1224-1226.	1.2	0
1868	Blood pressure level associated with lowest cardiovascular event in hypertensive diabetic patients. <i>Journal of Hypertension</i> , 2018, 36, 2434-2443.	0.3	5
1869	Treatment of Diabetes in Patients with Heart Failure. <i>Current Cardiology Reports</i> , 2018, 20, 97.	1.3	1
1870	The 2018 ESC/ESH hypertension guidelines: Should nephrologists always stop at the lower boundary?. <i>Journal of Nephrology</i> , 2018, 31, 621-626.	0.9	13
1871	2. Diabetische Nephropathie " was ist heute bekannt. , 2018, , 16-35.		0
1872	Increasing SBP variability is associated with an increased risk of developing incident diabetic foot ulcers. <i>Journal of Hypertension</i> , 2018, 36, 2177-2184.	0.3	8
1873	Measuring and Managing Blood Pressure in a Primary Care Setting: A Pragmatic Implementation Study. <i>Journal of the American Board of Family Medicine</i> , 2018, 31, 375-388.	0.8	16
1874	Hypertension guideline update. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2018, 31, 16-22.	0.1	12

#	ARTICLE	IF	CITATIONS
1875	The 2017 U.S. Hypertension Guidelines: What Is Important for Older Adults?. Journal of the American Geriatrics Society, 2018, 66, 1062-1067.	1.3	9
1876	Reevaluating the Evidence for Blood Pressure Targets in Type 2 Diabetes. Diabetes Care, 2018, 41, 1132-1133.	4.3	8
1877	The role of clinic blood pressure for the diagnosis of hypertension. Current Opinion in Cardiology, 2018, 33, 402-407.	0.8	1
1878	Comment on Buckley et al. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care 2017;40:1733-1738. Diabetes Care, 2018, 41, e84-e85.	4.3	1
1879	Estimating the Association of the 2017 and 2014 Hypertension Guidelines With Cardiovascular Events and Deaths in US Adults. JAMA Cardiology, 2018, 3, 572.	3.0	83
1880	Diabetes and Cardiovascular Disease. , 2018, , 823-838.		0
1881	Intensive Blood Pressure Targets and Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1575-1577.	2.2	7
1882	Low-frequency and low-intensity ultrasound increases cardiac parasympathetic neural activity and decreases clinic hypertension in elderly hypertensive subjects with type 2 diabetes. IJC Heart and Vasculature, 2018, 19, 34-36.	0.6	2
1883	Does Intensive Glucose Control Cancel Out Benefits of Systolic Blood Pressure Target <120 mmHg in Patients With Diabetes Mellitus Participating in ACCORD?. Hypertension, 2018, 72, 291-293.	1.3	4
1884	Future Direction for Using Artificial Intelligence to Predict and Manage Hypertension. Current Hypertension Reports, 2018, 20, 75.	1.5	62
1885	Benefits of Intensive Blood Pressure Treatment in Patients With Type 2 Diabetes Mellitus Receiving Standard but Not Intensive Glycemic Control. Hypertension, 2018, 72, 323-330.	1.3	27
1887	Meta-analyses and blood pressure goals. Journal of Clinical Hypertension, 2018, 20, 1149-1152.	1.0	1
1888	Drug Adherence in Hypertension and Cardiovascular Protection. Updates in Hypertension and Cardiovascular Protection, 2018, , .	0.1	5
1889	Impact of the application of the JNC 8 and KDIGO-2013 guidelines on hypertension and lipid control in a nephrology outpatient clinic. Nefrologia, 2018, 38, 373-379.	0.2	0
1890	The optimal blood pressure target in diabetes mellitus: a quest coming to an end?. Journal of Human Hypertension, 2018, 32, 641-650.	1.0	12
1891	Sex Differences of Patients With Systemic Hypertension (From the Analysis of the Systolic Blood) Tj ETQq1 1 0.784314 rgBT 17 Overloc	0.7	17
1892	Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms. Physiology, 2018, 33, 197-210.	1.6	3
1893	Prehypertension increases the risk of atherosclerosis in drug-naïve Japanese patients with type 2 diabetes mellitus. PLoS ONE, 2018, 13, e0201055.	1.1	5

#	ARTICLE	IF	CITATIONS
1894	New antihypertensive medications and clinical implications. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2018, 32, 223-235.	1.7	7
1895	Molecular Actions of PPAR α in Lipid Metabolism and Inflammation. <i>Endocrine Reviews</i> , 2018, 39, 760-802.	8.9	420
1896	Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke. <i>Journal of Stroke</i> , 2018, 20, 145-166.	1.4	39
1897	Hypertension and Diabetes. <i>Endocrinology</i> , 2018, , 1-22.	0.1	0
1898	Hypertension in Ischemic Heart Disease. , 2018, , 288-297.		0
1899	Approach to Difficult to Manage Primary Hypertension. , 2018, , 281-287.		2
1900	Hypertension and Diabetes. , 2018, , 180-185.		2
1901	Impacto de la aplicaci3n del 8. o JNC y de las gu3as KDIGO-2013 en el control de la hipertensi3n arterial y los l3pidos en una consulta de Nefrolog3a. <i>Nefrolog3a</i> , 2018, 38, 379-385.	0.2	2
1902	Combined use of polypill components in patients with type 2 diabetes mellitus. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1523-1531.	0.8	8
1904	Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). <i>Toxins</i> , 2018, 10, 237.	1.5	28
1905	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm " 2018 Executive Summary. <i>Endocrine Practice</i> , 2018, 24, 91-121.	1.1	388
1906	Event simulation and external validation applied in published health economic models for obesity: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 529-541.	0.7	5
1908	Blood pressure variability predicts adverse events and cardiovascular outcomes in <sc>SPRINT</sc>. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1247-1252.	1.0	28
1909	Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study. <i>BMJ: British Medical Journal</i> , 2018, 362, k2357.	2.4	140
1910	Effects of High Blood Pressure on Cardiovascular Disease Events Among Chinese Adults With Different Glucose Metabolism. <i>Diabetes Care</i> , 2018, 41, 1895-1900.	4.3	19
1911	Pharmacological management of hypertension in the elderly and frail populations. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 805-817.	1.3	10
1912	Impact of written information on control and adherence in type 2 diabetes. <i>Revista Da Associa3o M3dica Brasileira</i> , 2018, 64, 140-147.	0.3	17
1913	Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. <i>The Cochrane Library</i> , 2018, 7, CD010315.	1.5	28

#	ARTICLE	IF	CITATIONS
1914	New Targets in Arterial Hypertension, Are They Justified?. Revista Espanola De Cardiologia (English Ed), 2018, 71, 608-611.	0.4	0
1916	Reduced coronary collateralization in type 2 diabetic patients with chronic total occlusion. Cardiovascular Diabetology, 2018, 17, 26.	2.7	55
1917	Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial. American Journal of Hypertension, 2018, 31, 97-107.	1.0	25
1919	Cardiovascular Disease and Diabetic Kidney Disease. Seminars in Nephrology, 2018, 38, 217-232.	0.6	52
1920	Renal function at the time of nephrology referral but not dialysis initiation as a risk for death in patients with diabetes mellitus. CKJ: Clinical Kidney Journal, 2018, 11, 762-768.	1.4	8
1921	Endocrine Hypertension. , 2018, , 390-401.		0
1922	Development and validation of a Health Policy Model of Type 2 diabetes in Chinese setting. Journal of Comparative Effectiveness Research, 2018, 7, 749-763.	0.6	12
1923	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	1.0	6,826
1924	A Comparison of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline and the 2017 American Diabetes Association Diabetes and Hypertension Position Statement for U.S. Adults With Diabetes. Diabetes Care, 2018, 41, 2322-2329.	4.3	40
1925	Determining the Optimal Systolic Blood Pressure for Hypertensive Patients: A Network Meta-analysis. Canadian Journal of Cardiology, 2018, 34, 1581-1589.	0.8	10
1926	Organ memory: a key principle for understanding the pathophysiology of hypertension and other non-communicable diseases. Hypertension Research, 2018, 41, 771-779.	1.5	8
1927	Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. European Heart Journal, 2018, 39, 3855-3863.	1.0	21
1928	The ACC/AHA 2017 Hypertension Guidelines: Both Too Much and Not Enough of a Good Thing?. Annals of Internal Medicine, 2018, 168, 287.	2.0	22
1929	Donor artery stenosis interactions with diastolic blood pressure on coronary collateral flow in type 2 diabetic patients with chronic total occlusion. Cardiovascular Diabetology, 2018, 17, 76.	2.7	7
1930	What Should Be the Target Blood Pressure for This Older Patient With Hypertension?. Annals of Internal Medicine, 2018, 169, 175.	2.0	3
1931	Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. American Journal of Medicine, 2018, 131, 1463-1472.e7.	0.6	16
1932	Intensive blood pressure control may not be safe in subacute ischemic stroke by intracranial atherosclerosis. Journal of Hypertension, 2018, 36, 1936-1941.	0.3	24
1933	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140) mmHg in randomized controlled trials. European Heart Journal, 2018, 39, 3105-3114.	1.0	92

#	ARTICLE	IF	CITATIONS
1934	Nationwide Impact of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines on Stroke Survivors. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	5
1935	<i>Perspective Review</i>: Type 2 Diabetes and Readmission for Heart Failure. <i>Clinical Medicine Insights: Cardiology</i> , 2018, 12, 117954681877958.	0.6	10
1936	SGLT2 inhibitors and the kidney: Effects and mechanisms. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2018, 12, 1117-1123.	1.8	34
1937	Treatment of Hypertension in Chronic Kidney Disease. <i>Current Hypertension Reports</i> , 2018, 20, 64.	1.5	34
1938	Des normes et des cibles chez les patients diabÃ©tiques. <i>Medecine Des Maladies Metaboliques</i> , 2018, 12, 260-267.	0.1	0
1939	Preserving kidney health during intensive blood pressure control. <i>Nature Reviews Nephrology</i> , 2018, 14, 537-538.	4.1	3
1940	Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality. <i>Journal of Hypertension</i> , 2018, 36, 1622-1636.	0.3	77
1941	Current prescription status of antihypertensive drugs in Japanese patients with hypertension: Analysis by type of comorbidities. <i>Clinical and Experimental Hypertension</i> , 2019, 41, 203-210.	0.5	16
1942	Clinical management of chronic kidney disease. , 2019, , 162-168.		0
1943	Pharmacologic treatment of hypertension. , 2019, , 477-482.		3
1945	2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations. <i>Clinical Hypertension</i> , 2019, 25, 19.	0.7	31
1946	2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. <i>Clinical Hypertension</i> , 2019, 25, 20.	0.7	193
1947	Personalized prediction of adverse heart and kidney events using baseline and longitudinal data from SPRINT and ACCORD. <i>PLoS ONE</i> , 2019, 14, e0219728.	1.1	4
1949	Hemodynamic Stress, Pulse Pressure, and Blood Pressure Variability May Be Strong Triggers of Cardiovascular Events in Diabetes. <i>American Journal of Hypertension</i> , 2019, 32, 1045-1047.	1.0	0
1950	Effect of intensive lowering of systolic blood pressure treatment on heart failure events: a meta-analysis of randomized controlled studies. <i>Journal of Human Hypertension</i> , 2019, 33, 648-657.	1.0	6
1951	Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3939-3985.	1.8	42
1952	The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). <i>Hypertension Research</i> , 2019, 42, 1235-1481.	1.5	1,047
1953	Implementing Automated Office Blood Pressure Measurement. <i>Hypertension</i> , 2019, 74, 441-449.	1.3	5

#	ARTICLE	IF	CITATIONS
1954	Diastolic Blood Pressure J-Curve Phenomenon in a Tertiary-Care Hypertension Clinic. <i>Hypertension</i> , 2019, 74, 767-775.	1.3	41
1955	Effect of Baseline Kidney Function on the Risk of Recurrent Stroke and on Effects of Intensive Blood Pressure Control in Patients With Previous Lacunar Stroke: A Post Hoc Analysis of the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). <i>Journal of the American Heart Association</i> , 2019, 8, e013098.	1.6	10
1956	Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , 2019, 42, 2098-2107.	4.3	37
1957	The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes. <i>Endocrinology and Metabolism</i> , 2019, 34, 106.	1.3	14
1958	New Insights Into Mechanisms of Acute Kidney Injury in Heart Disease. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1158-1169.	0.8	12
1959	Hipertensi3n arterial en la enfermedad renal cr3nica. <i>Medicine</i> , 2019, 12, 4772-4778.	0.0	1
1962	Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis. <i>Cost Effectiveness and Resource Allocation</i> , 2019, 17, 13.	0.6	5
1963	Why Do Patients With Well-Controlled Vascular Risk Factors Develop Progressive Chronic Kidney Disease?. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1170-1180.	0.8	7
1964	Current Management of Patients With Acquired Solitary Kidney. <i>Kidney International Reports</i> , 2019, 4, 1205-1218.	0.4	55
1965	Hypertension Management in Chronic Kidney Disease and Diabetes. <i>Cardiology Clinics</i> , 2019, 37, 307-317.	0.9	7
1966	Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?. <i>Nephron</i> , 2019, 143, 100-107.	0.9	13
1967	Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events. <i>American Journal of Hypertension</i> , 2019, 32, 1170-1177.	1.0	2
1968	Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study. <i>Lancet, The</i> , 2019, 394, 663-671.	6.3	34
1969	New American and European Hypertension Guidelines, Reconciling the Differences. <i>Cardiology and Therapy</i> , 2019, 8, 157-166.	1.1	17
1970	Optimal Blood Pressure Thresholds for Minimal Coronary Artery Disease Risk in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1692-1699.	4.3	17
1971	The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection. <i>Future Medicinal Chemistry</i> , 2019, 11, 1285-1303.	1.1	15
1972	Diabetes and Hypertension. , 2019, , 573-585.		2
1973	Risk Factors Management in Diabetic Patients. <i>Journal of Korean Diabetes</i> , 2019, 20, 157.	0.1	1

#	ARTICLE	IF	CITATIONS
1974	Hypertension Treatment in Diabetes. <i>Heart Failure Clinics</i> , 2019, 15, 551-563.	1.0	4
1975	Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. <i>Lancet, The</i> , 2019, 394, 1816-1826.	6.3	228
1976	A nationwide assessment of blood pressure control and the associated factors in Chinese type 2 diabetes mellitus patients. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1654-1663.	1.0	8
1977	Effectiveness of blood pressure lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). <i>Journal of Clinical Hypertension</i> , 2019, 21, 1813-1820.	1.0	10
1978	Potential of Stratified Medicine for High Blood Pressure Management. <i>Hypertension</i> , 2019, 74, 1420-1427.	1.3	4
1979	Risk-Benefit Assessment of Intense Blood Pressure Lowering. <i>Hypertension</i> , 2019, 74, 1302-1304.	1.3	0
1980	Cost-Effectiveness and Challenges of Implementing Intensive Blood Pressure Goals and Team-Based Care. <i>Current Hypertension Reports</i> , 2019, 21, 91.	1.5	11
1981	2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea. <i>Diabetes and Metabolism Journal</i> , 2019, 43, 398.	1.8	176
1982	Cost-Effectiveness of More Intensive Blood Pressure Treatment in Patients with High Risk of Cardiovascular Disease in Saudi Arabia: A Modelling Study of Meta-Analysis. <i>International Journal of Hypertension</i> , 2019, 2019, 1-9.	0.5	8
1983	Thiazide Use and Cardiovascular Events in Type 2 Diabetic Patients With Well-Controlled Blood Pressure. <i>Hypertension</i> , 2019, 74, 1541-1550.	1.3	5
1984	A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. <i>American Journal of Medicine</i> , 2019, 132, S13-S20.	0.6	1
1986	Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. <i>Heart Failure Clinics</i> , 2019, 15, 519-530.	1.0	2
1987	Hypertension in adults: summary of updated NICE guidance. <i>BMJ: British Medical Journal</i> , 2019, 367, l5310.	2.4	57
1988	Controversies in the 2017 ACC/AHA Hypertension Guidelines: Who Can Be Eligible for Treatments Under the New Guidelines? An Asian Perspective. <i>Circulation Journal</i> , 2019, 83, 504-510.	0.7	18
1989	Assessing the applicability of 2017 ACC/AHA hypertension guidelines for secondary stroke prevention in the BOSS study. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1534-1541.	1.0	2
1990	We are far from achieving blood pressure goals in diabetes: Do we really want to do it?. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1664-1665.	1.0	0
1991	Association of Optimal Blood Pressure With Critical Cardiorenal Events and Mortality in High-Risk and Low-Risk Patients Treated With Antihypertension Medications. <i>JAMA Network Open</i> , 2019, 2, e199307.	2.8	11
1992	The right place for Sulphonylureas today: Part of Review the Series: Implications of recent CVOTs in Type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107836.	1.1	23

#	ARTICLE	IF	CITATIONS
1993	Comparison of the 2017 ACC/AHA Hypertension Guideline with Earlier Guidelines on Estimated Reductions in Cardiovascular Disease. <i>Current Hypertension Reports</i> , 2019, 21, 76.	1.5	8
1994	The Reply. <i>American Journal of Medicine</i> , 2019, 132, e624-e625.	0.6	0
1995	Optimal Systolic Blood Pressure Target in Resistant Hypertension. <i>American Journal of Medicine</i> , 2019, 132, e623.	0.6	2
1996	Therapeutic potential of NaoXinTong Capsule on the developed diabetic nephropathy in db/db mice. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109389.	2.5	10
1997	Low on-treatment diastolic blood pressure and cardiovascular outcome: A post-hoc analysis using NHLBI SPRINT Research Materials. <i>Scientific Reports</i> , 2019, 9, 13070.	1.6	8
1998	Association Between Early Hypertension Control and Cardiovascular Disease Incidence in Veterans With Diabetes. <i>Diabetes Care</i> , 2019, 42, 1995-2003.	4.3	5
1999	Prevalence, Awareness, and Treatment of Isolated Diastolic Hypertension: Insights From the China PEACE Million Persons Project. <i>Journal of the American Heart Association</i> , 2019, 8, e012954.	1.6	36
2000	The 2018 ESC/ESH hypertension guideline and the 2019 NICE hypertension guideline, how and why they differ. <i>European Heart Journal</i> , 2019, 40, 3456-3458.	1.0	35
2001	Blood pressure control and impact on cardiovascular events in patients with type 2 diabetes mellitus: A critical analysis of the literature. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2019, 31, 31-47.	0.1	2
2002	Impact of Department of Veterans Affairs Cooperative Studies Program clinical trials on practice guidelines for high blood pressure management. <i>Contemporary Clinical Trials Communications</i> , 2019, 13, 100313.	0.5	3
2003	Cerebral White Matter Hyperintensities, Kidney Function Decline, and Recurrent Stroke After Intensive Blood Pressure Lowering: Results From the Secondary Prevention of Small Subcortical Strokes (SPS3) Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e010091.	1.6	11
2004	Heart Disease and Stroke Statistics�2019 Update: A Report From the American Heart Association. <i>Circulation</i> , 2019, 139, e56-e528.	1.6	6,192
2005	Association of Orthostatic Hypotension Timing With Clinical Events in Adults With Diabetes and Hypertension: Results From the ACCORD Trial. <i>American Journal of Hypertension</i> , 2019, 32, 684-694.	1.0	13
2006	Unanswered Questions Regarding Blood Pressure Management for HF Prevention. <i>Current Hypertension Reports</i> , 2019, 21, 7.	1.5	2
2007	Global vascular guidelines on the management of chronic limb-threatening ischemia. <i>Journal of Vascular Surgery</i> , 2019, 69, 3S-125S.e40.	0.6	841
2008	Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. <i>Current Atherosclerosis Reports</i> , 2019, 21, 32.	2.0	17
2009	Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2218-2227.	1.1	7
2010	Stable Angina Medical Therapy Management Guidelines: A Critical Review of Guidelines from the European Society of Cardiology and National Institute for Health and Care Excellence. <i>European Cardiology Review</i> , 2019, 14, 18-22.	0.7	26

#	ARTICLE	IF	CITATIONS
2011	Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 58, S1-S109.e33.	0.8	741
2012	Stage 1 hypertension defined by the 2017 ACC/AHA Hypertension Guidelines and Risk of Cardiovascular Events: a Cohort Study from Northern China. <i>Hypertension Research</i> , 2019, 42, 1606-1615.	1.5	9
2013	Antihypertensive Medication Nonpersistence and Low Adherence for Adults <65 Years Initiating Treatment in 2007â€“2014. <i>Hypertension</i> , 2019, 74, 35-46.	1.3	35
2014	Antihypertensive therapy and adequacy of blood pressure control among adult hypertensive diabetic patients with chronic kidney disease in a tertiary referral hospital. <i>Hospital Practice (1995)</i> , 2019, 47, 136-142.	0.5	2
2015	The SPRINT Trial Score web calculator. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 2016-2016.	0.8	0
2016	Heart Failure With Preserved Ejection Fraction In Perspective. <i>Circulation Research</i> , 2019, 124, 1598-1617.	2.0	500
2017	Predicting, preventing, and managing cardiovascular and chronic kidney disease progression in people with type 2 diabetes: How to improve on traditional strategies. <i>Journal of Diabetes</i> , 2019, 11, 619-622.	0.8	4
2018	Incidence, prevalence, and predictors of treatmentâ€resistant hypertension with intensive blood pressure lowering. <i>Journal of Clinical Hypertension</i> , 2019, 21, 825-834.	1.0	15
2019	Effect of lifestyle focused text messaging on risk factor modification in patients with diabetes and coronary heart disease: A sub-analysis of the TEXT ME study. <i>Diabetes Research and Clinical Practice</i> , 2019, 153, 184-190.	1.1	11
2020	Personâ€Centered Primary Care and Type 2 Diabetes: Beyond Blood Glucose Control. <i>Journal of Midwifery and Women's Health</i> , 2019, 64, 312-323.	0.7	7
2021	Intensive versus Usual Control of Hypertension in the Prevention of Cardiovascular and Renal Outcomes: A Cumulative Meta-Analysis of Randomized Controlled Trials. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 384-395.	0.9	4
2022	Towards more Accessible Precision Medicine: Building a more Transferable Machine Learning Model to Support Prognostic Decisions for Micro- and Macrovascular Complications of Type 2 Diabetes Mellitus. <i>Journal of Medical Systems</i> , 2019, 43, 185.	2.2	19
2023	Prevalence and Prognosis of Unrecognized Myocardial Infarction in Asymptomatic Patients With Diabetes: A Two-Center Study With Up to 5 Years of Follow-up. <i>Diabetes Care</i> , 2019, 42, 1290-1296.	4.3	23
2025	How Low Do We Go (in the Post-SPRINT Era)?. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 110-116.	0.6	0
2026	Hypertension: A Common but Complex Condition. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 85-86.	0.6	1
2027	Pacing therapy in the management of unexplained syncope: a tertiary care centre prospective study. <i>Open Heart</i> , 2019, 6, e001015.	0.9	11
2028	Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1027-1036.	2.6	60
2029	The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 6-16.	2.2	13

#	ARTICLE	IF	CITATIONS
2030	Incremental risk of cardiovascular disease and/or chronic kidney disease for future ASCVD and mortality in patients with type 2 diabetes mellitus: ACCORD trial. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 468-472.	1.2	12
2031	Mortality Outcomes With Intensive Blood Pressure Targets in Chronic Kidney Disease Patients. <i>Hypertension</i> , 2019, 73, 1275-1282.	1.3	38
2032	Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus. <i>Hypertension</i> , 2019, 73, 1291-1299.	1.3	26
2033	Should Certain Antihyperglycemic Medications Be Preferred Over Antihypertensive Medications for Blood Pressure Control in Special Populations With Diabetes Mellitus?. <i>Circulation</i> , 2019, 139, 2110-2112.	1.6	0
2034	Cause, Consequence or confounding? The kidney in hypertension. <i>Journal of Human Hypertension</i> , 2019, 33, 639-640.	1.0	1
2035	Poor risk factor control in outpatients with diabetes mellitus type 2 in Germany: The DIAbetes COHoRtE (DIACORE) study. <i>PLoS ONE</i> , 2019, 14, e0213157.	1.1	8
2036	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 140, e596-e646.	1.6	1,789
2037	Relationship of patient background with macro- and microvascular complications: a 2-year post-marketing surveillance of vildagliptin in nearly 20,000 Japanese diabetic patients. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1037-1047.	0.9	3
2039	Ginsenoside Rb1 as an Anti-Diabetic Agent and Its Underlying Mechanism Analysis. <i>Cells</i> , 2019, 8, 204.	1.8	173
2040	KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. <i>American Journal of Kidney Diseases</i> , 2019, 73, 437-458.	2.1	24
2041	What constitutes good research?. <i>Journal of Diabetes</i> , 2019, 11, 502-504.	0.8	0
2042	Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1520-1574.	1.8	305
2043	Antihypertensive Agents in Older Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1575-1584.	1.8	11
2044	The Effect of Vegan Diets on Blood Pressure in Adults: A Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Medicine</i> , 2019, 132, 875-883.e7.	0.6	34
2045	Cohort Study Examining the Association Between Blood Pressure and Cardiovascular Events in Patients With Peripheral Artery Disease. <i>Journal of the American Heart Association</i> , 2019, 8, e010748.	1.6	23
2046	Prevalence of Hypertension, Treatment, and Blood Pressure Targets in Canada Associated With the 2017 American College of Cardiology and American Heart Association Blood Pressure Guidelines. <i>JAMA Network Open</i> , 2019, 2, e190406.	2.8	35
2047	Evaluating the feasibility of a pharmacist-guided patient-driven intervention to improve blood pressure control in patients with CKD. <i>Pilot and Feasibility Studies</i> , 2019, 5, 23.	0.5	2
2048	Postprandial Blood Pressure Decrease in Patients with Type 2 Diabetes and Mild or Severe Cardiac Autonomic Dysfunction. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 812.	1.2	7

#	ARTICLE	IF	CITATIONS
2049	A review of the clinical anatomy of hypertension. <i>Clinical Anatomy</i> , 2019, 32, 678-681.	1.5	2
2050	Clinical Value of Predicting Individual Treatment Effects for Intensive Blood Pressure Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005010.	0.9	33
2051	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1376-1414.	1.2	820
2052	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, e177-e232.	1.2	1,038
2053	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 140, e563-e595.	1.6	1,676
2054	Detecting Anomalies Among Practice Sites Within Multicenter Trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e004907.	0.9	2
2055	The Importance and Role of Multiple Risk Factor Control in Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2019, 21, 35.	1.3	14
2056	Target blood pressure level for the treatment of elderly hypertensive patients: a systematic review and meta-analysis of randomized trials. <i>Hypertension Research</i> , 2019, 42, 660-668.	1.5	15
2057	Blood pressure target in diabetics: how low is too low?. <i>European Heart Journal</i> , 2019, 40, 2044-2046.	1.0	2
2058	Use of machine-learning algorithms to determine features of systolic blood pressure variability that predict poor outcomes in hypertensive patients. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 206-212.	1.4	35
2059	Effects of intensive blood pressure lowering on mortality and cardiovascular and renal outcomes in type 2 diabetic patients: A meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0215362.	1.1	28
2061	Arterial stiffness as a risk factor for cardiovascular events and all-cause mortality in people with Type 2 diabetes. <i>Diabetic Medicine</i> , 2019, 36, 1125-1132.	1.2	30
2062	Adherence in Hypertension. <i>Circulation Research</i> , 2019, 124, 1124-1140.	2.0	401
2063	Similarities and Differences Between the ACC/AHA and ESH/ESC Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. <i>Circulation Research</i> , 2019, 124, 969-971.	2.0	7
2064	Diabetic cardiomyopathy: prevalence, determinants and potential treatments. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881983486.	1.4	76
2065	Automated Office-Based Blood Pressure Measurement: an Overview and Guidance for Implementation in Primary Care. <i>Current Hypertension Reports</i> , 2019, 21, 29.	1.5	13
2066	Optimal blood pressure targets for patients with hypertension: a systematic review and meta-analysis. <i>Hypertension Research</i> , 2019, 42, 483-495.	1.5	31
2067	Effect of Blood Pressure on Cardiovascular Diseases at 10-Year Follow-Up. <i>American Journal of Cardiology</i> , 2019, 123, 1654-1659.	0.7	2

#	ARTICLE	IF	CITATIONS
2068	Relationships between blood pressure lowering therapy and cardiovascular events in hypertensive patients with coronary artery disease and type 2 diabetes mellitus: The HIJ-CREATE sub-study. <i>Diabetes Research and Clinical Practice</i> , 2019, 149, 69-77.	1.1	8
2069	Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1277-1290.	2.2	64
2071	Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support. <i>Medical Decision Making</i> , 2019, 39, 239-252.	1.2	8
2072	Blood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics. <i>Neurology</i> , 2019, 92, e1168-e1175.	1.5	45
2073	Seasonal Variations in the Achievement of Guideline Targets for HbA1c, Blood Pressure, and Cholesterol Among Patients With Type 2 Diabetes: A Nationwide Population-Based Study (ABC Study:). <i>Tj ETQq0 0 0.8 BT / Over</i>	0.8	25
2074	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. <i>Endocrine Practice</i> , 2019, 25, 69-101.	1.1	245
2075	Low Diastolic Blood Pressure is Not Related to Risk of First Episode of Stroke in a High-Risk Population: A Secondary Analysis of SPRINT. <i>Journal of the American Heart Association</i> , 2019, 8, e010811.	1.6	14
2076	Management of Hypertension in Chronic Kidney Disease. <i>Drugs</i> , 2019, 79, 365-379.	4.9	196
2077	Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2019, 171, ITC65-ITC80.	2.0	46
2078	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes – 2019. <i>Diabetes Care</i> , 2019, 42, S103-S123.	4.3	676
2079	11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes – 2019. <i>Diabetes Care</i> , 2019, 42, S124-S138.	4.3	337
2080	Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment. <i>BMJ Open</i> , 2019, 9, e028438.	0.8	6
2081	Association of predicted lean body mass and fat mass with cardiovascular events in patients with type 2 diabetes mellitus. <i>Cmaj</i> , 2019, 191, E1042-E1048.	0.9	29
2082	Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease. <i>Cardiovascular Diabetology</i> , 2019, 18, 160.	2.7	14
2083	Hypertensive Heart Failure: Sprinting to the Finish Line to Prevent End-Organ Damage. <i>Heart Failure Clinics</i> , 2019, 15, xiii-xv.	1.0	0
2084	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> , 2019, 42, 2298-2306.	4.3	157
2085	A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. <i>American Journal of Cardiology</i> , 2019, 124, S12-S19.	0.7	15
2086	Rationale and design of a multicenter Chronic Kidney Disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD. <i>BMC Nephrology</i> , 2019, 20, 416.	0.8	12

#	ARTICLE	IF	CITATIONS
2087	Stroke in the elderly. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 393-418.	1.0	27
2088	NICE guideline: the diagnosis and management of hypertension. Trends in Urology & Men's Health, 2019, 10, 10-14.	0.2	1
2089	Evidence for and Against ACC/AHA 2017 Guideline for Target Systolic Blood Pressure of $\leq 130\text{ mmHg}$ in Persons with Type 2 Diabetes. Current Cardiology Reports, 2019, 21, 149.	1.3	9
2090	Pulse Pressure and the Risk of End-Stage Renal Disease Among Chinese Adults in Singapore: The Singapore Chinese Health Study. Journal of the American Heart Association, 2019, 8, e013282.	1.6	8
2091	Long-term clinical outcomes according to the mean observed blood pressure in patients with coronary artery disease after drug-eluting stent implantation. Journal of Hypertension, 2019, 37, 1898-1905.	0.3	1
2092	Differences in prevalence of hypertension subtypes according to the 2018 Korean Society of Hypertension and 2017 American College of Cardiology/American Heart Association guidelines: The Korean National Health and Nutrition Examination Survey, 2007-2017 (KNHANES IV-VII). Clinical Hypertension, 2019, 25, 26.	0.7	14
2094	Hypertension in Cancer Patients and Survivors. JACC: CardioOncology, 2019, 1, 238-251.	1.7	68
2095	Updated management for patients with cardiovascular disease and diabetes. JAAPA: Official Journal of the American Academy of Physician Assistants, 2019, 32, 51-53.	0.1	2
2096	Diabetes and Cardiovascular Disease: an Update. Current Diabetes Reports, 2019, 19, 161.	1.7	53
2097	Blood pressure targets and kidney and cardiovascular disease. Current Opinion in Nephrology and Hypertension, 2019, 28, 245-250.	1.0	15
2098	Does the benefit from treating to lower blood pressure targets vary with age? A systematic review and meta-analysis. Journal of Hypertension, 2019, 37, 1558-1566.	0.3	8
2099	Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. Journal of Hypertension, 2019, 37, 1126-1147.	0.3	29
2100	Blood pressure levels and risk of cardiovascular disease mortality among Japanese men and women. Journal of Hypertension, 2019, 37, 1366-1371.	0.3	12
2101	Reducing Cardiovascular Risk in Diabetes: Insights from Diabetes Trials. Frontiers in Diabetes, 2019, , 119-130.	0.4	0
2102	Serious adverse events in patients with target-oriented blood pressure management. Journal of Hypertension, 2019, 37, 2135-2144.	0.3	13
2103	Influence of baseline systolic blood pressure on the relationship between intensive blood pressure control and cardiovascular outcomes in the Systolic Blood Pressure Intervention Trial (SPRINT). Clinical Research in Cardiology, 2019, 108, 273-281.	1.5	4
2104	J-shaped curve for cardiovascular mortality: systolic or diastolic blood pressure?. Journal of Nephrology, 2019, 32, 347-353.	0.9	5
2105	Research Errors. , 2019, , 537-576.		0

#	ARTICLE	IF	CITATIONS
2106	Lowering systolic blood pressure does not increase stroke risk: an analysis of the SPRINT and ACCORD trial data. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 144-153.	1.7	7
2107	Chronic Kidney Disease in the Elderly. , 2019, , 73-86.e5.		0
2108	Intensive Blood Pressure Treatment for Resistant Hypertension. <i>Hypertension</i> , 2019, 73, 415-423.	1.3	15
2109	Trends in Incidence of ESKD in People With Type 1 and Type 2 Diabetes in Australia, 2002-2013. <i>American Journal of Kidney Diseases</i> , 2019, 73, 300-308.	2.1	33
2110	Chronological renal resistive index increases related to atherosclerotic factors, and effect of renin-angiotensin system inhibitors. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 513-520.	0.7	6
2111	Health Issues and Care System for the Elderly. <i>Current Topics in Environmental Health and Preventive Medicine</i> , 2019, , .	0.1	0
2112	Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study. <i>Heart and Vessels</i> , 2019, 34, 698-710.	0.5	3
2113	Treatment Goals in Diabetic Nephropathy. , 2019, , 435-450.		1
2115	Blood pressure target for the dialysis patient. <i>Seminars in Dialysis</i> , 2019, 32, 35-40.	0.7	10
2116	Arterial Hypertension: What Is the Optimal Goal of Treatment?. , 2019, , 239-252.		0
2117	Methods of Blood Pressure Assessment Used in Milestone Hypertension Trials. , 2019, , 255-267.		0
2118	Medical Biostatistics: Basic Concepts. , 2019, , 19-53.		1
2119	Management of Hypertension in Diabetes Mellitus. , 2019, , 115-133.		0
2120	Hypertension Management in African Americans: The AASK and Other Landmark Trial Application. , 2019, , 145-154.		0
2121	Blood Pressure Goals in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 161-169.	2.2	42
2122	Potential Cardiovascular Disease Events Prevented with Adoption of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. <i>Circulation</i> , 2019, 139, 24-36.	1.6	42
2123	Diabetic Kidney Disease. , 2019, , 42-61.e5.		1
2124	Barriers to blood pressure control initiatives: Regional diversity, inadequate measurement techniques, guideline inconsistencies, and health disparities. <i>Journal of Clinical Hypertension</i> , 2019, 21, 204-207.	1.0	0

#	ARTICLE	IF	CITATIONS
2125	Metas de control de la presión arterial e impacto sobre desenlaces cardiovasculares en pacientes con diabetes mellitus tipo 2: un análisis crítico de la literatura. Clínica e Investigación En Arteriosclerosis, 2019, 31, 31-47.	0.4	2
2126	Cardiovascular outcomes in patients with diabetes when initiating blood pressure lowering at baseline SBP between 130 and 140 mm Hg: A meta-analysis. Journal of Clinical Hypertension, 2019, 21, 220-229.	1.0	4
2127	Reduction in the incidence of myocardial infarction with sodium-glucose linked cotransporter-2 inhibitors: evident and plausible. Cardiovascular Diabetology, 2019, 18, 6.	2.7	9
2128	Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes. Kidney International Reports, 2019, 4, 94-102.	0.4	30
2129	Association of High Levels of Spot Urine Protein with High Blood Pressure, Mean Arterial Pressure and Pulse Pressure with the Development of Diabetic Chronic Kidney Dysfunction or Failure among Diabetic Patients. Statistical Regression Modeling to Predict Diabetic Proteinuria. Current Diabetes Reviews, 2019, 15, 486-496.	0.6	6
2130	Omission Bias. , 2019, , 321-344.		0
2131	Reconsidering the cut-off diastolic blood pressure for predicting cardiovascular events: a nationwide population-based study from Korea. European Heart Journal, 2019, 40, 724-731.	1.0	56
2132	Management of Diabetes Mellitus. Contemporary Cardiology, 2019, , 113-177.	0.0	0
2133	A data-zone scoring system to assess the generalizability of clinical trial results to individual patients. European Journal of Preventive Cardiology, 2019, 26, 569-575.	0.8	9
2134	Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates. Journal of Diabetes and Its Complications, 2019, 33, 69-74.	1.2	3
2135	Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: A secondary analysis of the SPRINT trial. European Journal of Preventive Cardiology, 2019, 26, 238-245.	0.8	19
2136	Effect of Intensive Blood Pressure Lowering on Kidney Tubule Injury: Findings From the ACCORD Trial Study Participants. American Journal of Kidney Diseases, 2019, 73, 31-38.	2.1	47
2137	Effect of intensive versus standard blood pressure control on major adverse cardiac events and serious adverse events: A bivariate analysis of randomized controlled trials. Clinical and Experimental Hypertension, 2019, 41, 160-167.	0.5	10
2138	Gender Differences in Prognostic Markers of All-Cause Death in Patients with Acute Heart Failure: a Prospective 18-Month Follow-Up Study. Journal of Cardiovascular Translational Research, 2020, 13, 97-109.	1.1	5
2139	Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 356-363.	1.4	19
2141	Cardiovascular Disease and Chronic Kidney Disease. , 2020, , 337-353.		0
2142	Management instructions for elderly patients with hypertension. Clinical and Experimental Hypertension, 2020, 42, 295-301.	0.5	1
2143	Prospects for Diminishing the Impact of Nonamyloid Small-Vessel Diseases of the Brain. Annual Review of Pharmacology and Toxicology, 2020, 60, 437-456.	4.2	12

#	ARTICLE	IF	CITATIONS
2144	Heart Failure as a Consequence of Hypertension. , 2020, , 333-346.e6.		0
2145	The Use of Computer Simulation Modeling to Estimate Complications in Patients with Type 2 Diabetes Mellitus: Comparative Validation of the Cornerstone Diabetes Simulation Model. <i>PharmacoEconomics - Open</i> , 2020, 4, 37-44.	0.9	9
2146	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	1.0	2,811
2147	Diabetic Retinopathy Preferred Practice Pattern®. <i>Ophthalmology</i> , 2020, 127, P66-P145.	2.5	341
2148	Approach to Chronic Kidney Disease in the Diabetic Patient. , 2020, , 831-847.		0
2149	Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 12-18.	2.2	0
2150	Prevention and treatment of stroke in patients with chronic kidney disease: an overview of evidence and current guidelines. <i>Kidney International</i> , 2020, 97, 266-278.	2.6	33
2152	Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The International Verapamil SR-Trandolapril Study (INVEST). <i>Journal of Women's Health</i> , 2020, 29, 158-166.	1.5	1
2153	For debate; pharmacological priorities in advanced type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107510.	1.2	2
2154	Waiting List and Kidney Transplant Vascular Risk: An Ongoing Unmet Concern. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 1-27.	0.9	12
2155	2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia Network. <i>Journal of Clinical Hypertension</i> , 2020, 22, 351-362.	1.0	56
2156	Relationship between diastolic blood pressure and the first ischaemic stroke in elderly patients with hypertension. <i>Postgraduate Medical Journal</i> , 2020, 96, 525-529.	0.9	8
2157	Orthostatic Hypotension and Novel Blood Pressure Associated Gene Variants in Older Adults: Data From the TILDA Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 2074-2080.	1.7	0
2159	Systolic blood pressure trajectory and cardiovascular outcomes: An analysis using data in the Systolic Blood Pressure Intervention Trial. <i>International Journal of Clinical Practice</i> , 2020, 74, e13450.	0.8	13
2160	Treating hypertension in older adults: Beyond the guidelines. <i>Journal of the American Association of Nurse Practitioners</i> , 2020, 32, 193-199.	0.5	4
2161	Barriers and Enablers of Older Patients to Deprescribing of Cardiometabolic Medication: A Focus Group Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 1268.	1.6	19
2165	Blood pressure levels and cardiovascular risk according to age in patients with diabetes mellitus: a nationwide population-based cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 181.	2.7	8
2166	Monte Carlo simulation of uncertainty to identify barriers to optimizing blood pressure control. <i>Journal of Hypertension</i> , 2020, 38, 2318-2324.	0.3	2

#	ARTICLE	IF	CITATIONS
2167	Blood Pressure Management in Stroke. <i>Hypertension</i> , 2020, 76, 1688-1695.	1.3	17
2168	Fixed-Dose Combination Medications for Treating Hypertension: A Review of Effectiveness, Safety, and Challenges. <i>Current Hypertension Reports</i> , 2020, 22, 95.	1.5	10
2169	Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 175.	2.7	1
2172	Guidelines on multidisciplinary approaches for the prevention and management of diabetic foot disease (2020 edition). <i>Burns and Trauma</i> , 2020, 8, tkaa017.	2.3	47
2173	The U-shaped association between achieved blood pressure and risk of cardiovascular events and mortality in elderly and younger patients. <i>Journal of Hypertension</i> , 2020, 38, 1559-1566.	0.3	5
2174	Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1926-1936.	1.1	7
2175	Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1121-1128.	2.2	15
2176	Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It?. <i>Diabetes Care</i> , 2020, 43, 1684-1686.	4.3	2
2177	Age-specific Associations Between Systolic Blood Pressure and Cardiovascular Disease: A 10-Year Diabetes Mellitus Cohort Study. <i>Journal of the American Heart Association</i> , 2020, 9, e015771.	1.6	11
2178	This synopsis summarizes key features of a joint VA/DoD guideline on diagnosis and management of hypertension in the primary care setting.. <i>Annals of Internal Medicine</i> , 2020, 173, 904-913.	2.0	14
2179	Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMd dyslipidemia study). <i>Lipids in Health and Disease</i> , 2020, 19, 237.	1.2	8
2180	<p>Practical Strategy for Treating Chronic Kidney Disease (CKD)-Associated with Hypertension</p>. <i>International Journal of Nephrology and Renovascular Disease</i> , 2020, Volume 13, 171-178.	0.8	4
2181	Trends in Antihypertensive Medication Use Among Individuals With a History of Stroke and Hypertension, 2005 to 2016. <i>JAMA Neurology</i> , 2020, 77, 1382.	4.5	28
2182	<p>Systolic Blood Pressure, Cardiovascular Mortality, and All-Cause Mortality in Normoglycemia, Prediabetes, and Diabetes</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 2375-2388.	1.1	5
2183	Intensive BP Control and eGFR Declines: Are These Events Due to Hemodynamic Effects and Are Changes Reversible?. <i>Current Cardiology Reports</i> , 2020, 22, 117.	1.3	3
2184	Optimal blood pressure for the prevention of hypertensive nephropathy in nondiabetic hypertensive patients in Taiwan. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1425-1433.	1.0	7
2185	Risk of Cardiovascular Disease and Chronic Kidney Disease According to 2017 Blood Pressure Categories in Diabetes Mellitus. <i>Hypertension</i> , 2020, 76, 766-775.	1.3	5
2186	Association of Longitudinal Trajectories of Systolic BP with Risk of Incident CKD: Results from the Korean Genome and Epidemiology Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2133-2144.	3.0	11

#	ARTICLE	IF	CITATIONS
2187	RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. International Journal of Diabetes in Developing Countries, 2020, 40, 1-122.	0.3	16
2188	New model of integrated care for uncontrolled type 2 diabetes in a retrospective, underserved adult population in the USA: a study protocol for an effectiveness and cost-effectiveness analysis. BMJ Open, 2020, 10, e038084.	0.8	1
2189	Automated office blood pressure is in agreement with awake and mean 24-hour ambulatory blood pressure at the lower blood pressure range. Journal of Clinical Hypertension, 2020, 22, 1177-1183.	1.0	2
2190	Antihypertensive medication use and blood pressure control among treated older adults. Journal of Clinical Hypertension, 2020, 22, 1406-1414.	1.0	4
2191	Antidiabetic drugs and blood pressure changes. Pharmacological Research, 2020, 161, 105108.	3.1	11
2192	Systolic blood pressure target less than 120 mmHg: the "Chariot Allegory"™ in hypertension?. Journal of Hypertension, 2020, 38, 1462-1463.	0.3	2
2194	Randomized Trials Versus Common Sense and Clinical Observation. Journal of the American College of Cardiology, 2020, 76, 580-589.	1.2	50
2195	Diabetic Kidney Disease. Primary Care - Clinics in Office Practice, 2020, 47, 645-659.	0.7	74
2196	Relationship between blood pressure and kidney diseases in large randomized controlled trials: secondary analyses using SPRINT and ACCORD-BP trials. Journal of Human Hypertension, 2020, 35, 859-869.	1.0	2
2197	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes 2020. Diabetes Care, 2020, 43, S111-S134.	4.3	421
2198	ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE. Nephrology, 2020, 25, 12-45.	0.7	17
2199	A Contemporary Approach to Hypertensive Cardiomyopathy: Reversing Left Ventricular Hypertrophy. Current Hypertension Reports, 2020, 22, 85.	1.5	13
2200	Effect of Intensive Glycemic and Blood Pressure Control on QT Prolongation in Diabetes: The ACCORD Trial. Diabetes, 2020, 69, 2186-2193.	0.3	7
2201	The Story of the Silent Killer. Current Hypertension Reports, 2020, 22, 72.	1.5	31
2202	Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics. Drugs, 2020, 80, 1763-1781.	4.9	39
2203	Diabetes and CVD Risk: Special Considerations in African Americans Related to Care. Current Cardiovascular Risk Reports, 2020, 14, 1.	0.8	8
2204	Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. The Cochrane Library, 2020, 2020, CD010315.	1.5	19
2205	Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. Journal of Hypertension, 2020, 38, 2050-2058.	0.3	9

#	ARTICLE	IF	CITATIONS
2206	Sex differences in the blood pressure level associated with increased risks of cardiovascular events: a Korean nationwide population-based cohort study. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1638-1646.	1.0	5
2207	Changes in the prevalence of measures associated with hypertension among Iranian adults according to classification by ACC/AHA guideline 2017. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 372.	0.7	8
2208	Visit-to-visit blood pressure variability in patients with type 2 diabetes with and without previous history of cardiovascular disease. <i>Journal of Hypertension</i> , 2020, 38, 1737-1744.	0.3	6
2209	Orthostatic hypotension and cardiovascular outcomes: Should we be concerned?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 2161-2162.	1.0	1
2210	Blood pressure targets in adults with hypertension. <i>The Cochrane Library</i> , 2020, 2020, CD004349.	1.5	12
2211	Prevention of Stroke by Lowering Blood Pressure. , 2020, , 289-296.		0
2212	Association between mandatory health examination attendance and diabetes treatment initiation among employees being treated for hypertension. <i>Journal of Occupational Health</i> , 2020, 62, e12183.	1.0	3
2213	Multifaceted strategies to improve blood pressure control in a primary care clinic: A quality improvement project. <i>International Journal of Cardiology: Hypertension</i> , 2020, 7, 100060.	2.2	8
2214	11. Microvascular Complications and Foot Care: <i>Standards of Medical Care in Diabetesâ”2020</i>. <i>Diabetes Care</i> , 2020, 43, S135-S151.	4.3	337
2215	Factors Associated With Failure to Achieve the Intensive Blood Pressure Target in the Systolic Blood Pressure Intervention Trial (SPRINT). <i>Hypertension</i> , 2020, 76, 1725-1733.	1.3	4
2216	Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodiumâ”Glucose Transporter 2 Inhibitors. <i>Diabetes Care</i> , 2020, 43, 1530-1536.	4.3	16
2217	Arterial hypertension treatment in octogenarians with dementia according to ESC/ESH-2018: Three-year follow-up. <i>Medicina ClÃnica (English Edition)</i> , 2020, 154, 301-304.	0.1	0
2219	Prehypertension and risk for all-cause and cardiovascular mortality by diabetes status: results from the national health and nutrition examination surveys. <i>Annals of Translational Medicine</i> , 2020, 8, 323-323.	0.7	6
2220	The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1878-1884.	4.3	31
2221	Blood Pressure Variability and Risk of Heart Failure in ACCORD and the VADT. <i>Diabetes Care</i> , 2020, 43, 1471-1478.	4.3	25
2222	Managing Hypertension in the elderly: Whatâ”s new?. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100001.	1.3	5
2223	Tight versus standard blood pressure control on the incidence of myocardial infarction and stroke: an observational retrospective cohort study in the general ambulatory setting. <i>BMC Family Practice</i> , 2020, 21, 91.	2.9	7
2224	Prevalence of Albuminuria in Cardiology and Endocrinology Departments and Its Influencing Factors: A Multicenter, Real-World Evidence Study in China. <i>International Journal of Hypertension</i> , 2020, 2020, 1-7.	0.5	1

#	ARTICLE	IF	CITATIONS
2225	Current Data Regarding the Relationship between Type 2 Diabetes Mellitus and Cardiovascular Risk Factors. <i>Diagnostics</i> , 2020, 10, 314.	1.3	63
2226	Systolic inter-arm blood pressure difference and risk of cognitive decline in older people: a cohort study. <i>British Journal of General Practice</i> , 2020, 70, e472-e480.	0.7	7
2227	Empagliflozin for Patients With Presumed Resistant Hypertension: A <i>Post Hoc</i> Analysis of the EMPA-REG OUTCOME Trial. <i>American Journal of Hypertension</i> , 2020, 33, 1092-1101.	1.0	23
2228	Unstably controlled systolic blood pressure trajectories are associated with markers for kidney damage in prediabetic population: results from the INDEED cohort study. <i>Journal of Translational Medicine</i> , 2020, 18, 194.	1.8	3
2229	A comparative analysis of current blood pressure management guidelines in people with and without diabetes. <i>Journal of Diabetes</i> , 2020, 12, 781-790.	0.8	3
2230	Achieving blood pressure control targets in hypertensive patients of rural China â€” a pilot randomized trial. <i>Trials</i> , 2020, 21, 515.	0.7	2
2231	Supporting care for suboptimally controlled type 2 diabetes mellitus in general practice with a clinical decision support system: a mixed methods pilot cluster randomised trial. <i>BMJ Open</i> , 2020, 10, e032594.	0.8	11
2232	Diabetic Kidney Disease in Older People with Type 2 Diabetes Mellitus: Improving Prevention and Treatment Options. <i>Drugs and Aging</i> , 2020, 37, 567-584.	1.3	9
2233	Hypertension in the elderly: recent developments and insights. <i>Current Opinion in Cardiology</i> , 2020, 35, 351-356.	0.8	2
2234	Review â€” current opinion in cardiology hypertension in chronic kidney disease. <i>Current Opinion in Cardiology</i> , 2020, 35, 360-367.	0.8	4
2235	Hypertension and diabetes mellitus: highlights of a complex relationship. <i>Current Opinion in Cardiology</i> , 2020, 35, 397-404.	0.8	33
2236	Diabetes and coronary artery disease: not just a risk factor. <i>Heart</i> , 2020, 106, 1357-1364.	1.2	13
2237	Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial. <i>Diabetes Care</i> , 2020, 43, 1920-1928.	4.3	35
2238	Recent advances in the management of secondary hypertension: chronic kidney disease. <i>Hypertension Research</i> , 2020, 43, 869-875.	1.5	9
2239	Aggiornamenti in tema di malattia cerebrovascolare: prevenzione, terapia e riabilitazione. <i>Italian Journal of Medicine</i> , 2020, , 1-174.	0.2	1
2240	<i>PPARA</i> Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. <i>Diabetes</i> , 2020, 69, 771-783.	0.3	28
2241	Diabetes mellitus is associated with high sleep-time systolic blood pressure and non-dipping pattern. <i>Postgraduate Medicine</i> , 2020, 132, 346-351.	0.9	5
2242	Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005â€”2016. <i>Hypertension</i> , 2020, 75, 973-981.	1.3	72

#	ARTICLE	IF	CITATIONS
2243	Determining the Prevalence of Primary Aldosteronism in Patients With New-Onset Type 2 Diabetes and Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1079-1085.	1.8	23
2244	The burden of unrecognised chronic kidney disease in patients with type 2 diabetes at a county hospital clinic in Kenya: implications to care and need for screening. <i>BMC Nephrology</i> , 2020, 21, 73.	0.8	2
2245	Kidney Disease, Intensive Hypertension Treatment, and Risk for Dementia and Mild Cognitive Impairment: The Systolic Blood Pressure Intervention Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2122-2132.	3.0	25
2246	Artificial Intelligence and Hypertension: Recent Advances and Future Outlook. <i>American Journal of Hypertension</i> , 2020, 33, 967-974.	1.0	17
2247	Outcomes in adults with systolic blood pressure between 130 and 139 mmHg in Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial and Systolic Blood Pressure Intervention Trial. <i>Journal of Hypertension</i> , 2020, 38, 1567-1577.	0.3	3
2248	Control of blood pressure levels in patients with premature coronary artery disease: Results from the Genetics of Atherosclerotic Disease study. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1253-1262.	1.0	8
2249	Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. <i>Pharmacological Research</i> , 2020, 160, 105052.	3.1	34
2250	Effect of Lower Blood Pressure Goals on Left Ventricular Structure and Function in Patients With Subclinical Hypertensive Heart Disease. <i>American Journal of Hypertension</i> , 2020, 33, 837-845.	1.0	4
2251	Redefining Resistant Hypertension. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e005979.	0.9	2
2252	Easy-to-use tool for evaluating the elevated acute kidney injury risk against reduced cardiovascular disease risk during intensive blood pressure control. <i>Journal of Hypertension</i> , 2020, 38, 511-518.	0.3	9
2253	Managing the elderly patient with hypertension: current strategies, challenges, and considerations. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 117-125.	0.6	3
2254	A Cross-Sectional Study of Overtreatment and Deintensification of Antidiabetic and Antihypertensive Medications in Diabetes Mellitus: The TEMD Overtreatment Study. <i>Diabetes Therapy</i> , 2020, 11, 1045-1059.	1.2	14
2255	The Growing Epidemic of Diabetes Mellitus. <i>Current Vascular Pharmacology</i> , 2020, 18, 104-109.	0.8	188
2256	Management of Presumed Acute Kidney Injury during Hypertensive Therapy: Stay Calm and Carry on?. <i>American Journal of Nephrology</i> , 2020, 51, 108-115.	1.4	2
2257	Care Team Integration in Primary Care Improves One-Year Clinical and Financial Outcomes in Diabetes: A Case for Value-Based Care. <i>Population Health Management</i> , 2020, 23, 467-475.	0.8	13
2258	Blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes. <i>Journal of Clinical Hypertension</i> , 2020, 22, 212-220.	1.0	14
2259	Hypertension in the Dog and Cat. , 2020, , .		2
2260	Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. <i>Circulation</i> , 2020, 141, e139-e596.	1.6	5,545

#	ARTICLE	IF	CITATIONS
2261	Association of Serum Adiponectin with Intima Media Thickness of Dorsalis Pedis Artery and Macroangiopathy in Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-10.	1.0	4
2262	Diagnosis and management of hypertension in adults: NICE guideline update 2019. <i>British Journal of General Practice</i> , 2020, 70, 90-91.	0.7	109
2263	Low blood pressure and cardiovascular events in diabetic patients with coronary artery disease after revascularization: the CREDO-Kyoto registry cohort-1. <i>Hypertension Research</i> , 2020, 43, 715-723.	1.5	4
2264	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. <i>Current Vascular Pharmacology</i> , 2020, 18, 125-138.	0.8	9
2265	P-wave axis is associated with all-cause mortality in diabetes: The ACCORD trial. <i>Journal of Electrocardiology</i> , 2020, 60, 184-187.	0.4	2
2266	Early Decline in Kidney Function With Intensive Systolic Blood Pressure Lowering. <i>Hypertension</i> , 2020, 75, 1163-1164.	1.3	0
2267	Generalizability of Clinical Trials Supporting the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. <i>JAMA Internal Medicine</i> , 2020, 180, 795.	2.6	17
2268	Blood pressure and long-term mortality in older patients: results of the Fiesole Misurata Follow-up Study. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 2057-2064.	1.4	3
2269	Importance of intensive blood pressure control in type 2 diabetes: Mechanisms, treatments and current guidelines. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 33-42.	2.2	7
2270	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 107-139.	1.1	410
2271	High-Density Lipoprotein Cholesterol in Age-Related Ocular Diseases. <i>Biomolecules</i> , 2020, 10, 645.	1.8	16
2272	Development of a Risk Score for Atrial Fibrillation in Adults With Diabetes Mellitus (from the Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	7
2273	Associations of Systolic Blood Pressure With Incident CKD G3-G5: A Cohort Study of South Korean Adults. <i>American Journal of Kidney Diseases</i> , 2020, 76, 224-232.	2.1	16
2274	How to Manage Hypertension in People With Diabetes. <i>American Journal of Hypertension</i> , 2020, 33, 935-943.	1.0	4
2275	Association of diastolic blood pressure with history of stroke in community hypertensive patients: a cross-sectional study. <i>Journal of Xiangya Medicine</i> , 2020, 5, 5-5.	0.2	0
2276	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020, 141, e779-e806.	1.6	157
2277	Initial Estimated Glomerular Filtration Rate Decline and Long-Term Renal Function During Intensive Antihypertensive Therapy. <i>Hypertension</i> , 2020, 75, 1205-1212.	1.3	33
2278	Heart Failure With Preserved Ejection Fraction: A Comprehensive Review and Update of Diagnosis, Pathophysiology, Treatment, and Perioperative Implications. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 1839-1859.	0.6	30

#	ARTICLE	IF	CITATIONS
2279	Diabetes Mellitus and Noncardiac Atherosclerotic Vascular Diseaseâ€™ Pathogenesis and Pharmacological Treatment Options. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 25-39.	1.0	13
2280	SGLT-2 inhibitors may be targeting higher risk patients with diabetes possibly justifying higher cost: Single center repeated cross-sectional analysis. Journal of Diabetes and Its Complications, 2021, 35, 107761.	1.2	3
2281	Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (<sc>TRSâ€™HF</sub>DM</sub></sc>) in patients in the <sc>ACCORD</sc> trial. Diabetes, Obesity and Metabolism, 2021, 23, 782-790.	2.2	19
2283	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension. Annals of Internal Medicine, 2021, 174, 58-68.	2.0	47
2284	Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events. Journal of the American College of Cardiology, 2021, 77, 559-571.	1.2	31
2285	10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€™2021</i>. Diabetes Care, 2021, 44, S125-S150.	4.3	359
2286	11. Microvascular Complications and Foot Care: <i>Standards of Medical Care in Diabetesâ€™2021</i>. Diabetes Care, 2021, 44, S151-S167.	4.3	247
2287	Effects of the Dietary Approaches to Stop Hypertension Diet and Sodium Reduction on Blood Pressure in Persons With Diabetes. Hypertension, 2021, 77, 265-274.	1.3	8
2288	Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. Diabetology International, 2021, 12, 1-51.	0.7	6
2289	Targeting blood pressure for stroke prevention: current evidence and unanswered questions. Journal of Neurology, 2021, 268, 785-795.	1.8	13
2290	Blood pressure target in patients with hypertension and type-2 diabetes older than 65 years. Is $130/80$â€™mmHg the right target or an excessive objective preventing from achieving the clinical goals we are aiming at?. Blood Pressure, 2021, 30, 79-81.	0.7	0
2291	Aging and Renal Disease: Old Questions for New Challenges. , 2021, 12, 515.		28
2292	Evidence-Experience Gap and Future Perspective on the Treatment of Peripheral Artery Disease. Journal of Atherosclerosis and Thrombosis, 2021, 28, 1251-1259.	0.9	3
2293	Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk. Blood Pressure, 2021, 30, 90-97.	0.7	4
2294	Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension. Blood Pressure, 2021, 30, 82-89.	0.7	4
2295	Randomized Controlled Trials 2: Analysis. Methods in Molecular Biology, 2021, 2249, 213-227.	0.4	0
2296	Diabetes Mellitus and Renal Function: Current Medical Research and Opinion. Current Diabetes Reviews, 2021, 17, e011121190176.	0.6	4
2297	PREVALENCE OF HYPERTENSION AMID PATIENTS WITH TYPE-2 DIABETES MELLITUS- AT A TERTIARY LEVEL HOSPITAL IN CENTRAL INDIA. , 2021, , 57-59.		0

#	ARTICLE	IF	CITATIONS
2298	Blood pressure and cardiovascular diseases in Chinese adults with type 2 diabetes: A prospective cohort study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 7, 100085.	1.3	9
2299	Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. <i>Nature Reviews Nephrology</i> , 2021, 17, 319-334.	4.1	244
2300	Evaluation of Optimal Diastolic Blood Pressure Range Among Adults With Treated Systolic Blood Pressure Less Than 130 mm Hg. <i>JAMA Network Open</i> , 2021, 4, e2037554.	2.8	32
2301	How Should We Measure and Deal with Office Blood Pressure in 2021?. <i>Diagnostics</i> , 2021, 11, 235.	1.3	6
2302	Population impact of different hypertension management guidelines based on the prospective population-based Heinz Nixdorf Recall study. <i>BMJ Open</i> , 2021, 11, e039597.	0.8	3
2303	Four-Year Screening Interval and Vision-Threatening Retinopathy in Type 2 Diabetes Patients With Good Glycemic Control. <i>Mayo Clinic Proceedings</i> , 2021, 96, 322-331.	1.4	5
2304	Kidney, Cardiac, and Safety Outcomes Associated With β -Blockers in Patients With CKD: A Population-Based Cohort Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 178-189.e1.	2.1	21
2305	Insulin Therapy Is Associated With an Increased Risk of Carotid Plaque in Type 2 Diabetes: A Real-World Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 599545.	1.1	12
2306	Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. <i>BMJ, The</i> , 2021, 372, n189.	3.0	58
2307	Blood Pressure and Risk of Cardiovascular Disease in UK Biobank. <i>Hypertension</i> , 2021, 77, 367-375.	1.3	60
2308	Self-Management of Blood Pressure Control at Home in Chronic Kidney Disease: Nursing Interventions and Health Gains. , 0, , .		1
2309	Accuracy of abbreviated protocols for unattended automated office blood pressure measurements, a retrospective study. <i>PLoS ONE</i> , 2021, 16, e0248586.	1.1	2
2310	KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. <i>Kidney International</i> , 2021, 99, S1-S87.	2.6	497
2311	Characteristics of Populations Excluded From Clinical Trials Supporting Intensive Blood Pressure Control Guidelines. <i>Journal of the American Heart Association</i> , 2021, 10, e019707.	1.6	13
2312	Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. <i>Kidney International</i> , 2021, 99, 559-569.	2.6	169
2313	Starting Antihypertensive Drug Treatment With Combination Therapy. <i>Hypertension</i> , 2021, 77, 788-798.	1.3	7
2314	Diretrizes Brasileiras de Hipertensão Arterial â€œ 2020. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 516-658.	0.3	340
2315	Diabetes and Stroke. <i>Journal of Korean Diabetes</i> , 2021, 22, 26-37.	0.1	1

#	ARTICLE	IF	CITATIONS
2316	Association of Stage 1 Hypertension Defined by the ACC/AHA 2017 Guideline With Asymptomatic Coronary Atherosclerosis. <i>American Journal of Hypertension</i> , 2021, 34, 858-866.	1.0	7
2318	Guideline-Driven Management of Hypertension. <i>Circulation Research</i> , 2021, 128, 827-846.	2.0	52
2319	Renin Cells, the Kidney, and Hypertension. <i>Circulation Research</i> , 2021, 128, 887-907.	2.0	25
2320	Blood pressure reduction and anti-hypertensive treatment choice: A post-hoc analysis of the SPRINT trial. <i>Clinical Cardiology</i> , 2021, 44, 665-674.	0.7	3
2321	New Drugs and Interventional Strategies for the Management of Hypertension. <i>Current Pharmaceutical Design</i> , 2021, 27, 1396-1406.	0.9	1
2322	Stroke prevention in patients with arterial hypertension: Recommendations of the Spanish Society of Neurology's Stroke Study Group. <i>Neurología (English Edition)</i> , 2021, 36, 462-471.	0.2	3
2323	Albuminuria increased the risk of left ventricular hypertrophy in type 2 diabetes patients with early renal insufficiency. <i>International Journal of Diabetes in Developing Countries</i> , 2021, 41, 621-627.	0.3	0
2324	Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>European Cardiology Review</i> , 2021, 16, e14.	0.7	4
2325	Effect of Intensive Versus Standard Blood Pressure Control on Stroke Subtypes. <i>Hypertension</i> , 2021, 77, 1391-1398.	1.3	2
2326	Associations between attainment of incentivised primary care diabetes indicators and mortality in an English cohort. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108746.	1.1	9
2327	On-treatment blood pressure and long-term outcomes in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, , .	0.4	4
2328	Application of the American College of Cardiology (ACC/AHA) 2017 Guideline for the Management of Hypertension in Adults and Comparison with the 2014 Eighth Joint National Committee Guideline. <i>Journal of the Saudi Heart Association</i> , 2021, 33, 16-25.	0.2	0
2329	Transporting experimental results with entropy balancing. <i>Statistics in Medicine</i> , 2021, 40, 4310-4326.	0.8	16
2330	Antidiabetic and Other Therapies Used in Subjects with Diabetes and Chronic Kidney Disease in a Hospital-Based Clinic Population in Greece. <i>Journal of Clinical Medicine</i> , 2021, 10, 2104.	1.0	2
2331	Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial. <i>Diabetes Therapy</i> , 2021, 12, 2101-2113.	1.2	6
2332	Hypertension in diabetes care: emerging roles of recent hypoglycemic agents. <i>Hypertension Research</i> , 2021, 44, 897-905.	1.5	13
2334	Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. <i>New England Journal of Medicine</i> , 2021, 384, 1921-1930.	13.9	214
2335	ESO Guideline on covert cerebral small vessel disease. <i>European Stroke Journal</i> , 2021, 6, CXI-CLXII.	2.7	68

#	ARTICLE	IF	CITATIONS
2336	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). Eurasian Heart Journal, 2021, , 6-61.	0.2	9
2337	Associations of Systolic Blood Pressure and Diastolic Blood Pressure With the Incidence of Coronary Artery Disease or Cerebrovascular Disease According to Glucose Status. Diabetes Care, 2021, 44, 2124-2131.	4.3	17
2338	Sample size formula for general win ratio analysis. Biometrics, 2022, 78, 1257-1268.	0.8	12
2339	Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2116-2124.	2.2	79
2340	Development and validation of the CHIME simulation model to assess lifetime health outcomes of prediabetes and type 2 diabetes in Chinese populations: A modeling study. PLoS Medicine, 2021, 18, e1003692.	3.9	9
2341	Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1671-1690.	1.1	5
2342	Blood pressure control in patients with chronic kidney disease. Korean Journal of Internal Medicine, 2021, 36, 780-794.	0.7	6
2343	Evidence-Based Recommendations for Medical Management of Peripheral Artery Disease. Journal of Atherosclerosis and Thrombosis, 2021, 28, 573-583.	0.9	12
2344	Heart Failure Primary Prevention: What Does SPRINT Add?: Recent Advances in Hypertension. Hypertension, 2021, 77, 1804-1814.	1.3	5
2346	Older people's attitudes towards deprescribing cardiometabolic medication. BMC Geriatrics, 2021, 21, 366.	1.1	18
2347	Intensive Home Blood Pressure Lowering in Advanced Chronic Kidney Disease: A Pilot Randomized Controlled Trial Protocol. Open Access Journal of Clinical Trials, 0, Volume 13, 21-29.	1.5	0
2348	Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis. PLoS Medicine, 2021, 18, e1003599.	3.9	16
2349	Hypertension: Diagnosis and management in primary care. InnovAiT, 2021, 14, 534-539.	0.0	0
2350	Importance and efficiency of blood pressure control not only in type 2 diabetes patients. Vnitřni Lekarstvi, 2021, 67, 218-222.	0.1	2
2351	Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018. New England Journal of Medicine, 2021, 384, 2219-2228.	13.9	327
2352	2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association. Diabetes and Metabolism Journal, 2021, 45, 461-481.	1.8	146
2353	The Non-linear Relationship Between Normal Range Systolic Blood Pressure and Cardiovascular or All-Cause Mortality Among Elderly Population. Frontiers in Cardiovascular Medicine, 2021, 8, 677189.	1.1	1
2354	Cardiovascular risk factors associated with acute myocardial infarction and stroke in the MADIABETES cohort. Scientific Reports, 2021, 11, 15245.	1.6	6

#	ARTICLE	IF	CITATIONS
2355	Admission Systolic Blood Pressure and In-hospital Mortality in Acute Type A Aortic Dissection: A Retrospective Observational Study. <i>Frontiers in Medicine</i> , 2021, 8, 542212.	1.2	3
2356	Multivariate approach in analyzing medical data with correlated multiple outcomes: An exploration using ACCORD trial data. <i>Clinical Epidemiology and Global Health</i> , 2021, 11, 100785.	0.9	3
2357	Potential overtreatment of type 2 diabetes therapy in real clinical practice: Omsk Oblast register data. <i>Diabetes Mellitus</i> , 2021, 24, 100-110.	0.5	1
2358	Arterial hypertension. <i>Lancet, The</i> , 2021, 398, 249-261.	6.3	100
2359	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). <i>Archivos De Cardiologia De Mexico</i> , 2021, 92, .	0.1	4
2360	Intensive Blood Pressure Control, APOL1 Genotype, and Kidney Outcomes in Individuals With Type 2 Diabetes: A Post Hoc Analysis of the Action to Control Cardiovascular Risk in Diabetes-Blood Pressure (ACCORD-BP) Trial. <i>Kidney Medicine</i> , 2021, 3, 874-876.	1.0	1
2361	Rapidly progressive diabetic kidney disease: South Asian experience. <i>International Journal of Diabetes in Developing Countries</i> , 0, , 1.	0.3	0
2362	Association of blood pressure and renal outcome in patients with chronic kidney disease; a post hoc analysis of FROM-J study. <i>Scientific Reports</i> , 2021, 11, 14990.	1.6	5
2363	Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 723-732.	2.3	6
2364	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	1.0	2,517
2365	Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rational and protocol. <i>Blood Pressure</i> , 2021, 30, 269-281.	0.7	8
2366	Combining serum 1,5-anhydroglucitol with fasting plasma glucose to detect diabetes mellitus in a community-based population with hypertension. <i>Annals of Palliative Medicine</i> , 2021, 10, 8746-8752.	0.5	2
2367	Impact of DBP on all-cause and cardiovascular mortality: results from the National Health and Nutrition Examination survey, 1999-2014. <i>Journal of Hypertension</i> , 2022, 40, 108-116.	0.3	3
2368	A critical review of chronic kidney disease as a risk factor for coronary artery disease. <i>IJC Heart and Vasculature</i> , 2021, 35, 100822.	0.6	5
2369	Association of Blood Pressure With the Progression of CKD: Findings From KNOW-CKD Study. <i>American Journal of Kidney Diseases</i> , 2021, 78, 236-245.	2.1	39
2370	Association Between Longitudinal Blood Pressure Trajectory and the Progression of Chronic Kidney Disease: Results From the KNOW-CKD. <i>Hypertension</i> , 2021, 78, 1355-1364.	1.3	7
2371	Individual and Combined Cardiometabolic Morbidities and the Subsequent Risk of Cardiovascular Events in Chinese Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e84-e94.	1.8	6
2372	Cardiovascular disease in diabetes, beyond glucose. <i>Cell Metabolism</i> , 2021, 33, 1519-1545.	7.2	87

#	ARTICLE	IF	CITATIONS
2373	Joint testing of overall and simple effects for the two-by-two factorial trial design. <i>Clinical Trials</i> , 2021, 18, 521-528.	0.7	5
2374	A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease. <i>Drugs</i> , 2021, 81, 1491-1511.	4.9	18
2375	Commentary on the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD. <i>Current Cardiology Reports</i> , 2021, 23, 132.	1.3	5
2376	Different impacts of metabolic profiles on future risk of cardiovascular disease between diabetes with and without established cardiovascular disease: the Japan diabetes complication and its prevention prospective study 7 (JDCP study 7). <i>Acta Diabetologica</i> , 2021, , 1.	1.2	1
2377	Nonatherosclerotic Vascular Abnormalities Associated with Chronic Kidney Disease. <i>Cardiology Clinics</i> , 2021, 39, 415-425.	0.9	0
2378	Cardiovascular Disease in Patients with Diabetes: a Comparison of Professional Society Guidelines. <i>Current Diabetes Reviews</i> , 2021, 17, .	0.6	0
2379	Intensive Blood Pressure Control and Diabetes Mellitusâ€Related Limb Events in Patients With Type 2 Diabetes Mellitus: Reanalysis of ACCORD. <i>Journal of the American Heart Association</i> , 2021, 10, e021407.	1.6	0
2380	Association Between Coronary Artery Disease and Plasma Omentin-1 Levels. <i>Cureus</i> , 2021, 13, e17347.	0.2	6
2381	Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies. <i>Current Heart Failure Reports</i> , 2021, 18, 253-263.	1.3	6
2382	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 5-115.	0.8	220
2383	Office, Central, and Ambulatory Blood Pressure for Predicting First Stroke in Older Adults: A Community-Based Cohort Study. <i>Hypertension</i> , 2021, 78, 851-858.	1.3	4
2384	Systolic Blood Pressure and Outcomes in Stable Outpatients with Recent Symptomatic Artery Disease: A Population-Based Longitudinal Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9348.	1.2	6
2385	Targeting the Standardized Blood Pressure: New Guidelines for Blood Pressure Management in Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 1321-1322.	2.0	1
2386	Prevalence, predictors, and outcomes of both true- and pseudo-resistant hypertension in the action to control cardiovascular risk in diabetes trial: a cohort study. <i>Hypertension Research</i> , 2021, 44, 1471-1482.	1.5	7
2387	Impact of 30- Versus 60-Second Time Intervals Between Automated Office Blood Pressure Measurements on Measured Blood Pressure. <i>Hypertension</i> , 2021, 78, 1502-1510.	1.3	5
2388	Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. <i>New England Journal of Medicine</i> , 2021, 385, 1268-1279.	13.9	318
2389	Heart Failure Events in a Clinical Trial on Arterial Hypertension: New Insights Into the SPRINT Trial. <i>Hypertension</i> , 2021, 78, 1241-1247.	1.3	5
2390	Appraisal of Guidelines for the Management of Blood Pressure in Patients with Diabetes Mellitus: The Consensuses, Controversies and Gaps. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 753-764.	1.8	0

#	ARTICLE	IF	CITATIONS
2391	Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2021, 174, 1270-1281.	2.0	41
2393	Association of blood pressure with cardiovascular outcome and mortality: results from the KNOW-CKD study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1722-1730.	0.4	7
2394	2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes. <i>JACC Asia</i> , 2021, 1, 129-146.	0.5	1
2395	Intensive versus standard blood pressure control in type 2 diabetes: a restricted mean survival time analysis of a randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e050335.	0.8	6
2396	SPRINT—A Kidney-Centric Narrative Review: Recent Advances in Hypertension. <i>Hypertension</i> , 2021, 78, 946-954.	1.3	3
2397	SPARTE Study: Normalization of Arterial Stiffness and Cardiovascular Events in Patients With Hypertension at Medium to Very High Risk. <i>Hypertension</i> , 2021, 78, 983-995.	1.3	65
2398	Prognosis After Stroke. , 2022, , 207-220.e11.		0
2399	Preventive Cardiology. , 2022, , 341-375.		0
2400	Treatment of Hypertension in Patients with Diabetes Mellitus: a Contemporary Approach. <i>Current Cardiology Reports</i> , 2021, 23, 14.	1.3	5
2401	N-acetylcysteine inhibits atherosclerosis by correcting glutathione-dependent methylglyoxal elimination and dicarbonyl/oxidative stress in the aorta of diabetic mice. <i>Molecular Medicine Reports</i> , 2021, 23, .	1.1	8
2402	Achievement of guideline targets of glycemic and non-glycemic parameters in North Indian type 2 diabetes mellitus patients: A retrospective analysis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 425-431.	1.8	1
2403	An Analysis of Blood Pressure Situations in Japan Using the Large-Scale Medical Checkup Dataset. <i>Health</i> , 2021, 13, 736-756.	0.1	3
2404	Low-salt low-protein diet and blood pressure control in patients with advanced diabetic kidney disease and heavy proteinuria. <i>International Urology and Nephrology</i> , 2021, 53, 1197-1207.	0.6	3
2406	Effect of chromium picolinate and melatonin either in single or in a combination in high carbohydrate diet-fed male Wistar rats. <i>BioFactors</i> , 2016, 42, 106-114.	2.6	12
2407	Diabetes Care for the Older Patient. , 2012, , .		1
2409	Diabetes Mellitus and Chronic Kidney Disease (Stages 1-5). , 2014, , 103-136.		1
2410	Issues in Data Analysis. , 2015, , 403-462.		2
2411	Hypertension and Atherosclerosis: Pathophysiology, Mechanisms and Benefits of BP Control. , 2016, , 201-216.		6

#	ARTICLE	IF	CITATIONS
2412	The J-Curve Phenomenon in Hypertension. , 2016, , 249-260.		1
2413	Molecular Pathways in Hypertensive Renal Damage. Updates in Hypertension and Cardiovascular Protection, 2018, , 445-463.	0.1	3
2414	Hypertension in Diabetic Kidney Disease. , 2019, , 325-335.		1
2415	Stable Ischemic Heart Disease Stable Ischemic Heart Disease. , 2015, , 2109-2172.		1
2416	Stable Ischemic Heart Disease. , 2014, , 1-70.		1
2417	Evidence in Guidelines for Treatment of Coronary Artery Disease. Advances in Experimental Medicine and Biology, 2020, 1177, 37-73.	0.8	52
2418	A potent risk model for predicting new-onset acute coronary syndrome in patients with type 2 diabetes mellitus in Northwest China. Acta Diabetologica, 2020, 57, 705-713.	1.2	16
2419	Adaptation to Nephron Loss and Mechanisms of Progression in Chronic Kidney Disease. , 2011, , 1918-1971.		5
2420	Cardiovascular Aspects of Kidney Disease. , 2012, , 2059-2080.		5
2421	Complications of Diabetes Mellitus. , 2011, , 1462-1551.		8
2422	Primary and Secondary Prevention of Coronary Heart Disease. , 2012, , 1010-1035.		18
2423	Diabetes and the Cardiovascular System. , 2012, , 1392-1409.		4
2424	Body Mass Index, Sex, and Incident Atrial Fibrillation in Diabetes. JACC: Clinical Electrophysiology, 2020, 6, 1713-1720.	1.3	10
2426	The global epidemiology of hypertension. Nature Reviews Nephrology, 2020, 16, 223-237.	4.1	1,530
2428	Diabetes management in older people: a focus on cardiovascular risk reduction. Postgraduate Medicine, 2017, 129, 169-177.	0.9	3
2429	Pharmacotherapy of hypertension in patients with pre-dialysis chronic kidney disease. Expert Opinion on Pharmacotherapy, 2020, 21, 1201-1217.	0.9	2
2430	Achieving blood pressure targets for prolonged cardiovascular health: a historical perspective. Expert Review of Cardiovascular Therapy, 2017, 15, 517-523.	0.6	3
2431	Quality of Diabetes Care (Current Levels, Distribution, and Trends) and Challenges in Measuring Quality of Care. , 2010, , 373-412.		2

#	ARTICLE	IF	CITATIONS
2432	Diabetic Kidney Disease. , 2019, , 277-286.		1
2434	2019 Chinese guideline for the management of hypertension in the elderly. Journal of Geriatric Cardiology, 2019, 16, 67-99.	0.2	55
2435	Effect of β -blocker therapy in diabetic patients with stable coronary heart disease: a meta-analysis. Journal of Geriatric Cardiology, 2019, 16, 291-297.	0.2	5
2436	2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. Journal of Geriatric Cardiology, 2019, 16, 182-241.	0.2	380
2438	Epidemiology and Primary Prevention of Stroke. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 260-267.	0.4	27
2439	Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes—A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society. Circulation Journal, 2020, 85, 82-125.	0.7	16
2440	Microalbuminuria and cardiorenal risk: old and new evidence in different populations. F1000Research, 2019, 8, 1659.	0.8	15
2441	Update on the Hong Kong Reference Framework for Hypertension Care for Adults in Primary Care Settings—review of evidence on the definition of high blood pressure and goal of therapy. Hong Kong Medical Journal, 2019, 25, 64-7.	0.1	8
2442	Nutritional Health Considerations for Persons with Spinal Cord Injury. Topics in Spinal Cord Injury Rehabilitation, 2017, 23, 188-206.	0.8	33
2443	Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials. PLoS Medicine, 2017, 14, e1002410.	3.9	60
2444	Association of High Blood Pressure with Renal Insufficiency: Role of Albuminuria, from NHANES, 1999–2006. PLoS ONE, 2012, 7, e37837.	1.1	12
2445	Application of Random Forests Methods to Diabetic Retinopathy Classification Analyses. PLoS ONE, 2014, 9, e98587.	1.1	115
2446	The Effects of Comorbidity on the Benefits and Harms of Treatment for Chronic Disease: A Systematic Review. PLoS ONE, 2014, 9, e112593.	1.1	15
2447	Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial. PLoS ONE, 2015, 10, e0125519.	1.1	8
2448	Effect of One-Week Salt Restriction on Blood Pressure Variability in Hypertensive Patients with Type 2 Diabetes. PLoS ONE, 2016, 11, e0144921.	1.1	12
2449	Diabetes mellitus type 2 in adults. Diabetes Mellitus, 2020, 23, 4-102.	0.5	16
2450	Hypertension Treatment ACCORDing to SPRINT. Texas Heart Institute Journal, 2016, 43, 324-327.	0.1	3
2451	Primary Care-Based Investigation of the Effect of Sitagliptin on Blood Pressure in Hypertensive Patients With Type 2 Diabetes. Journal of Clinical Medicine Research, 2017, 9, 188-192.	0.6	10

#	ARTICLE	IF	CITATIONS
2452	Primary Aldosteronism With Type 2 Diabetes Mellitus Requires More Antihypertensive Drugs for Blood Pressure Control: A Retrospective Observational Study. <i>Journal of Clinical Medicine Research</i> , 2018, 10, 56-62.	0.6	6
2453	Cardiovascular outcomes trials with non-statin lipid-lowering drugs in diabetes. <i>British Journal of Diabetes</i> , 2018, 18, 101-105.	0.1	4
2454	New blood pressure levels in Peruvian high altitude populations and the new North American high blood pressure guidelines. <i>Journal of Cardiology & Current Research</i> , 2019, 12, 84-87.	0.1	2
2457	Blood pressure control, hypertension, awareness, and treatment in adults with diabetes in the United States-Mexico border region. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2010, 28, 164-73.	0.6	20
2458	Pharmacotherapy for mild hypertension. <i>Sao Paulo Medical Journal</i> , 2012, 130, 417-418.	0.4	8
2460	Consenso latinoamericano de hipertensi3n en pacientes con diabetes tipo 2 y s3ndrome metab3lico. <i>Revista Med</i> , 2013, 21, 115.	0.1	2
2461	Nomogram for the prediction of diabetic nephropathy risk among patients with type 2 diabetes mellitus based on a questionnaire and biochemical indicators: a retrospective study. <i>Aging</i> , 2020, 12, 10317-10336.	1.4	21
2462	Oscillating blood pressure therapeutic target in type 2 diabetes patients with hypertension. <i>Annals of Translational Medicine</i> , 2016, 4, 422-422.	0.7	5
2463	Blood pressure targets for hypertension in patients with type 2 diabetes. <i>Annals of Translational Medicine</i> , 2018, 6, 199-199.	0.7	9
2464	SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?. <i>Current Medicinal Chemistry</i> , 2019, 26, 5564-5578.	1.2	5
2465	The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia. <i>Current Medicinal Chemistry</i> , 2020, 27, 6682-6702.	1.2	16
2466	The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: An Update. <i>Current Pharmaceutical Design</i> , 2014, 20, 3665-3674.	0.9	38
2467	Diabetes and Vascular Disease: Is It All About Glycemia?. <i>Current Pharmaceutical Design</i> , 2019, 25, 3112-3127.	0.9	14
2468	Metabolic Syndrome and Cardiometabolic Risk Factors. <i>Current Vascular Pharmacology</i> , 2014, 11, 858-879.	0.8	49
2469	Stroke and Hypertension: An Appraisal from Pathophysiology to Clinical Practice. <i>Current Vascular Pharmacology</i> , 2018, 17, 72-84.	0.8	29
2470	Effects of Intensive Blood Pressure Control in Patients with Evident Cardiovascular Disease: An Investigation Using the SPRINT Study Data. <i>Current Vascular Pharmacology</i> , 2019, 17, 298-306.	0.8	1
2471	Pharmacological Management of Diabetic Nephropathy. <i>Current Vascular Pharmacology</i> , 2020, 18, 139-147.	0.8	5
2472	Prevention and Treatment of Diabetic Retinopathy: Evidence from Clinical Trials and Perspectives. <i>Current Diabetes Reviews</i> , 2011, 7, 190-200.	0.6	37

#	ARTICLE	IF	CITATIONS
2473	Recent Advances in Understanding the Pathogenesis of Cardiovascular Diseases and Development of Treatment Modalities. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2019, 19, 19-32.	0.2	12
2474	Usability and Acceptability of a Home Blood Pressure Telemonitoring Device Among Community-Dwelling Senior Citizens With Hypertension: Qualitative Study. <i>JMIR Aging</i> , 2018, 1, e10975.	1.4	15
2475	Telemonitoring and Protocolized Case Management for Hypertensive Community-Dwelling Seniors With Diabetes: Protocol of the TECHNOMED Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2016, 5, e107.	0.5	14
2476	Physician perceptions of blood pressure control in patients with chronic kidney disease and target blood pressure achievement rate. <i>Kidney Research and Clinical Practice</i> , 2017, 36, 349-357.	0.9	4
2477	Protocol of the SPARTE Study: A Strategy for Preventing Cardiovascular and Renal Events based on ARTERial Stiffness. <i>Artery Research</i> , 2020, 26, 250-260.	0.3	10
2479	Spanish Society of Nephrology document on KDIGO guidelines for the assessment and treatment of chronic kidney disease. <i>Nefrologia</i> , 2014, 34, 302-16.	0.2	35
2480	Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment – systematic review and modelling of progression and cost-effectiveness. <i>Health Technology Assessment</i> , 2014, 18, 1-128.	1.3	29
2481	Prevalence of abnormal glycemic and lipidemic status in an urban population of Bangladesh. <i>Journal of Bio-science</i> , 0, 19, 1-6.	0.1	2
2482	Use of spironolactone in the treatment of resistant arterial hypertension. <i>Cor Et Vasa</i> , 2011, 53, 343-347.	0.1	4
2483	Interpreting SPRINT: How low should you go?. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, 187-195.	0.6	6
2484	Blood pressure management in the wake of SPRINT. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, 196-198.	0.6	2
2485	2017 ACC/AHA hypertension guidelines: Toward tighter control. <i>Cleveland Clinic Journal of Medicine</i> , 2018, 85, 771-778.	0.6	8
2486	Hypertension guidelines: Treat patients, not numbers. <i>Cleveland Clinic Journal of Medicine</i> , 2019, 86, 47-56.	0.6	2
2487	Understanding and treating hypertension in diabetic populations. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 353-63.	0.7	11
2488	RESPECT STUDY. Japanese Journal of Clinical Pharmacology and Therapeutics.		
2489	Temporal and Geospatial Trends of Hypertension Management in Korea: a Nationwide Study 2002–2016. <i>Korean Circulation Journal</i> , 2019, 49, 514.	0.7	19
2490	Ideal Target Blood Pressure in Hypertension. <i>Korean Circulation Journal</i> , 2019, 49, 1002.	0.7	24
2491	Control of type 2 diabetes in King Abdulaziz Housing City (Iskan) population, Saudi Arabia. <i>Journal of Family and Community Medicine</i> , 2016, 23, 1.	0.5	18

#	ARTICLE	IF	CITATIONS
2492	RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian Journal of Endocrinology and Metabolism, 2020, 24, 1.	0.2	85
2493	Closing gaps in diabetes care: From evidence to practice. Saudi Journal of Medicine and Medical Sciences, 2018, 6, 68.	0.3	5
2494	Association of Serum Lipids with High Blood Pressure and Hypertension among Diabetic Patients. Mathematical Regression Models to Predict Blood Pressure from Lipids. An Experience from 12-year Follow Up of more than 9000 Patients' Cohort. General Medicine (Los Angeles, Calif), 2017, 05, .	0.2	3
2495	Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence. World Journal of Diabetes, 2019, 10, 291-303.	1.3	14
2497	A collaborative cardiologist-pharmacist care model to improve hypertension management in patients with or at high risk for cardiovascular disease. Pharmacy Practice, 2012, 10, 25-32.	0.8	11
2498	Current status of aggressive blood pressure control. World Journal of Cardiology, 2011, 3, 65.	0.5	19
2499	Treating blood pressure to prevent strokes: The age factor. World Journal of Cardiology, 2013, 5, 22.	0.5	6
2500	Editorial on hemoglobin A1c, blood pressure, and low-density lipoprotein cholesterol goals in diabetics. World Journal of Cardiology, 2013, 5, 119.	0.5	2
2501	Recommendations for the treatment of hypertension in the elderly and very elderly: a scotoma within international guidelines. Swiss Medical Weekly, 2012, 142, w13574.	0.8	11
2502	Uncontrolled arterial hypertension in primary care " patient characteristics and associated factors. Swiss Medical Weekly, 2012, 142, w13693.	0.8	11
2503	The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease. Rambam Maimonides Medical Journal, 2015, 6, e0029.	0.4	3
2504	The implications of blood pressure targets from the 2018 European Society of Cardiology hypertension guidelines in Asian patients: a systematic review and meta-analysis. Annals of Saudi Medicine, 2020, 40, 234-254.	0.5	1
2505	Cardiovascular Risk Factors in Patients with Poorly Controlled Diabetes Mellitus. Medicinski Arhiv = Medical Archives = Archives De MÃ©decine, 2018, 72, 13.	0.4	5
2506	Blood pressure goals: A moving target. World Journal of Hypertension, 2018, 8, 1-4.	0.8	1
2507	24 hour ambulatory blood pressure values corresponding to office blood pressure value of 130/80 mm Hg. Kardiologia Polska, 2013, 71, 675-680.	0.3	2
2508	The Top Articles in Geriatrics 2016"2017*. Canadian Geriatrics Journal, 2018, 21, 210-217.	0.7	3
2510	Blood Pressure Control in Hypertensive Patients in the "Hiperdia Program": A Territory-Based Study. Arquivos Brasileiros De Cardiologia, 2014, 102, 571-8.	0.3	28
2511	Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. Arquivos Brasileiros De Cardiologia, 2019, 113, 787-891.	0.3	102

#	ARTICLE	IF	CITATIONS
2512	The 2017 Focused Update of the Guidelines of the Taiwan Society of Cardiology (TSOC) and the Taiwan Hypertension Society (THS) for the Management of Hypertension. <i>Acta Cardiologica Sinica</i> , 2017, 33, 213-225.	0.1	68
2513	Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial. <i>PeerJ</i> , 2017, 5, e3187.	0.9	11
2514	Current Practice of Hypertension in India: Focus on Blood Pressure Goals. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2016, 10, OC25-OC28.	0.8	5
2515	Characteristics of Scientific Evidence Informing Changed U.S. Preventive Services Task Force Insufficient Evidence Statements. <i>American Journal of Preventive Medicine</i> , 2021, , .	1.6	2
2516	Diabetes, Vascular Aging and Stroke: Old Dogs, New Tricks?. <i>Journal of Clinical Medicine</i> , 2021, 10, 4620.	1.0	13
2517	Average Systolic Blood Pressure and Clinical Outcomes in Patients with Atrial Fibrillation: Prospective Data from COOL-AF Registry. <i>Clinical Interventions in Aging</i> , 2021, Volume 16, 1835-1846.	1.3	5
2518	Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 1575.	2.6	28
2519	On-Treatment Hypertension Control in a Real-World Cohort. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1496-1498.	1.2	0
2520	Association Between Baseline Diastolic Blood Pressure and the Efficacy of Intensive vs Standard Blood Pressure–Lowering Therapy. <i>JAMA Network Open</i> , 2021, 4, e2128980.	2.8	9
2521	On-Treatment Blood Pressure and Cardiovascular Outcomes in Adults With Hypertension and Left Ventricular Hypertrophy. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1485-1495.	1.2	12
2522	Optimizing treatment goals for long-term health outcomes among patients with type 2 diabetes mellitus. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002396.	1.2	4
2523	Diastolic Blood Pressure and the J-Curve—Causal Effect or Confounding?. <i>JAMA Network Open</i> , 2021, 4, e2130031.	2.8	2
2524	Serum Potassium and Mortality in High-Risk Patients: SPRINT. <i>Hypertension</i> , 2021, 78, 1586-1594.	1.3	3
2525	Cerebrovascular Disease in Hypertension. , 2007, , 392-405.		0
2526	Antihypertonika. , 2010, , 389-408.		0
2527	Japanese Journal of Clinical Pharmacology and Therapeutics, 2010, 41, 909		
2529	Targeting Multiple Risk Factors to Reduce Complications of Type 2 Diabetes: Treatment Imperatives. <i>Endocrine Practice</i> , 2010, 16, 21-26.	1.1	0
2531	Risk Reduction in the Diabetic Patient. , 2011, , 281-315.		1

#	ARTICLE	IF	CITATIONS
2532	What are the optimal values of systolic blood pressure in patients with diabetes? The ACCORD Blood Pressure study completed. <i>Cor Et Vasa</i> , 2010, 52, 700-705.	0.1	0
2533	<i>Antihypertonika</i> . , 2011, , 401-420.		0
2534	<i>Nierenerkrankungen und Hypertonie</i> . , 2011, , 1423-1436.		0
2535	<i>Hypertensie en systolische bloeddruk</i> . , 2011, , 109-114.		0
2536	<i>Arterielle Hypertonie</i> . , 2011, , 251-265.		0
2538	Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease. <i>Yearbook of Medicine</i> , 2011, 2011, 389-391.	0.1	0
2540	Stroke Update: Optimal Blood Pressure Management for Stroke Prevention. <i>Korean Journal of Stroke</i> , 2011, 13, 63.	0.1	0
2541	Chapter 4 Hypertension. , 2011, , .		0
2545	â¿fè†“ç—...â¿ç”ç©¶ã©é€²æ©(â¿¼â¿ç’oâ¿™â¿-¿2010â¿1’ã©é€²æ©). <i>Journal of JCS Cardiologists</i> , 2011, 19, 111-116.	0.1	0
2547	<i>Stable Angina</i> . , 2012, , 1-18.		0
2548	<i>Managing Hypertension in Patients with Diabetes</i> . , 0, , .		0
2549	Incidence and features of left ventricular hypertrophy in highly compliant hypertensive patients. <i>Arterial Hypertension (Russian Federation)</i> , 2011, 17, 454-459.	0.1	2
2554	How Low should the Blood Pressure be reduced in Patients with Hypertension and High Risk for Coronary Artery Disease?. <i>Journal of Hypertension: Open Access</i> , 2012, 01, .	0.2	0
2555	Is a systolic blood pressure target <140mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. <i>Yearbook of Cardiology</i> , 2012, 2012, 96-98.	0.0	0
2556	Atrial fibrillation in diabetes: A cause for concern?. <i>Journal of Diabetes Mellitus</i> , 2012, 02, 378-385.	0.1	0
2558	What Should the Optimal Blood Pressure Goal Be in Patients with Diabetes Mellitus?. <i>Journal of Diabetes & Metabolism</i> , 2012, 03, .	0.2	0
2559	Management of Diabetic Nephropathy in the Elderly: Special Considerations. <i>Journal of Nephrology & Therapeutics</i> , 2012, 02, .	0.1	2
2560	<i>The Impact of Diabetes in Older Adults</i> . , 2012, , 453-475.		0

#	ARTICLE	IF	CITATIONS
2561	Antihypertonika. , 2012, , 403-424.		0
2562	Antihypertensive Therapy Benefits: Pleiotropic Versus Blood Pressure-Dependent Mechanisms. , 2012, , 249-266.		0
2563	Peripheral Artery Diseases. , 2012, , 1338-1358.		1
2564	Hypertension in the Older Patient: Practical Clinical Management. Clinical Medicine Reviews in Vascular Health, 0, 4, 29-42.	3.0	0
2566	Stroke Epidemiology and Prevention. , 2012, , 537-559.		0
2567	Risk Markers for Atherothrombotic Disease. , 2012, , 914-934.		6
2568	A Stepped Care Approach to the Management of Chronic Kidney Disease. , 2012, , 2205-2239.		1
2569	é«~è;€âœ\$ç”ç©¶ã®é€²æ©(â³¼³ç’ºâ™”â‡‡2011â¹’ã®é€²æ©). Journal of JCS Cardiologists, 2012, 20, 127-132.	0.1	0
2571	Diuretic use, RAAS blockade and morbidity in elderly patients presenting to the Emergency Department with non-specific complaints. Swiss Medical Weekly, 2012, 142, w13568.	0.8	8
2572	Peripheral Artery Diseases. , 0, , .		0
2573	SECTION III Special Considerations Overview. , 2012, , 173-174.		0
2575	What Should the Systolic Blood Pressure Goal be in Adults with Hypertension?. Journal of Hypertension: Open Access, 2013, 03, .	0.2	0
2576	Cerebrovascular Disease in Hypertension. , 2013, , 303-312.		0
2577	Optimal Blood Pressure Goals in Patients with Hypertension at High Risk for Cardiovascular Events. Journal of Hypertension: Open Access, 2013, 02, .	0.2	1
2578	Diabetes and the Cardiovascular System. , 2013, , 701-714.		0
2580	Antihypertonika. , 2013, , 391-412.		0
2581	Renal Disease in Diabetes Mellitus: Recent Studies and Potential Therapies. Journal of Diabetes & Metabolism, 2013, 01, .	0.2	2
2582	Progression of Chronic Kidney Disease in Patients with Diabetes: Implications for Practice. Endocrine Practice, 2013, 19, 8-13.	1.1	0

#	ARTICLE	IF	CITATIONS
2583	Hemoglobin A1c, Blood Pressure, and Serum Low-Density Lipoprotein Cholesterol Goals in Diabetics. Journal of Clinical & Experimental Cardiology, 2013, 04, .	0.0	0
2584	Screening and Management of Diabetic Nephropathy. Journal of Korean Diabetes, 2013, 14, 19.	0.1	0
2585	Management of the Spectrum of Essential Hypertension: A 2013 Perspective. Cardiovascular Pharmacology: Open Access, 2013, 2, .	0.1	0
2586	Obesity and Diabetes. , 2013, , 39-62.		0
2587	Target Blood Pressure in Diabetes. Journal of Korean Diabetes, 2013, 14, 1.	0.1	1
2588	4. é«~è;€âœ\$æ²»ç™,ã®é€²æ©(â¾¼³ç'â™"â-}2012â¹ã®é€²æ©). Journal of JCS Cardiologists, 2013, 21, 103-107. 0.1	0.1	0
2589	Long-Term Electrolyte Effects during Initiation of Antihypertensive Therapy with Amlodipine or Hydrochlorothiazide in Diabetic Nigerians. American Journal of Medical Sciences and Medicine, 2013, 1, 1-7.	0.1	2
2592	Impact of Diabetes Mellitus and the Metabolic Syndrome on the Female Heart. , 2014, , 265-286.		0
2593	Diabetes and Chronic Kidney Disease. , 2014, , 43-55.		0
2594	Fettstoffwechsel und Hypertonie bei Diabetes. , 2014, , 217-237.		0
2595	Diabetologie fÃ¼r die Pflege. , 2014, , 7-103.		0
2596	Antihypertonika. , 2014, , 445-468.		0
2597	Introduction of Recent Hypertension Guidelines. Korean Journal of Medicine, 2014, 87, 127.	0.1	1
2598	Vascular Complications of Diabetes Mellitus. , 2014, , 1-65.		0
2602	New practice guidelines: Constrained or enhanced by the evidence?. Cleveland Clinic Journal of Medicine, 2014, 81, 136-138.	0.6	0
2603	DIABETES & HYPERTENSION: THE SIAMESE TWINS. Journal of Evidence Based Medicine and Healthcare, 2014, 1, 78-88.	0.0	0
2604	Endocrine Heart Diseases. Contemporary Cardiology, 2015, , 571-591.	0.0	0
2605	Hypertension in African Americans. , 2015, , 233-249.		0

#	ARTICLE	IF	CITATIONS
2606	New Guideline Recommendations on Hypertension: Preventing CVD and Renal Disease with Applications to Blacks. , 2015, , 251-270.		0
2607	Coronary Risk Estimation according to the Framingham-Wilson Score and Impaired Fasting Glucose in Adult Subjects from Maracaibo city, Venezuela. Global Journal of Obesity, Diabetes and Metabolic Syndrome, 2014, 1, 020-029.	0.2	1
2608	Similarities and Differences among Recent Hypertension Guidelines. Hypertension Journal, 2015, 1, 4-12.	0.1	0
2609	Principles of Primary and Secondary Prevention of Cardiovascular Disease. , 2015, , 1627-1664.		0
2610	Antihypertonika. , 2015, , 451-475.		0
2611	Evaluation and Management of the Newly Diagnosed Patient with Type-2 Diabetes. , 2015, , 347-357.		0
2612	Arterial Hypertension. , 2015, , 115-131.		0
2615	The Role Of Elevated NT-ProBNP And Albuminuria As Cardio-Vascular Risk Factors In Type 2 Diabetes Mellitus Patients After Acute Coronary Syndrome. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2015, 22, 141-149.	0.3	0
2616	Features of change of intracardiac hemodynamics and functional state of myocardium under the impact of telmisartan in patients with hypertension.. Medicni Perspektivi, 2016, 21, 26-29.	0.1	0
2617	Blood Pressure Control and Primary Prevention of Stroke: Summary of Clinical Trial Data. , 2016, , 39-59.		0
2618	Optimal target for blood pressure control â€“ how low should we go?. Journal of the Royal College of Physicians of Edinburgh, The, 2016, 46, 21-22.	0.2	0
2619	Traditional Stroke Risk Factor Treatment. , 2016, , 93-98.		0
2620	Hypertension; Grey Zones, Future Perspectives. , 2016, , 361-382.		0
2621	Prevention of Cardiovascular Disease in Diabetes Patients after the SPRINT- and ACCORDIONStudy â€“ and a New Meta Analysis. International Journal of Endocrinology and Metabolic Disorders, 2016, 2, .	0.2	0
2622	Antihypertonika. , 2016, , 335-350.		0
2623	Stable Ischemic Heart Disease. , 2016, , 1-70.		5
2624	Coronary Artery Disease and Cardiomyopathy. , 2016, , 1-21.		0
2625	Blood Pressure, Troponin, and Cardiovascular Function. Hypertension Journal, 2016, 2, 21-27.	0.1	0

#	ARTICLE	IF	CITATIONS
2626	Primary Stroke Prevention. Updates in Hypertension and Cardiovascular Protection, 2016, , 129-142.	0.1	0
2627	Capítulo 8 - Hipertensão e Condições Clínicas Associadas. Arquivos Brasileiros De Cardiologia, 2016, 107, 44-48.	0.3	3
2628	Exploración de la tensión arterial, morbilidades y adherencia en población adulta de Anserma, Caldas, Colombia : estudio SA-TA.. Revista Ciencias Biomédicas (cartagena), 2016, 7, 240-248.	0.0	0
2629	Blood pressure targets (March 2016). Cleveland Clinic Journal of Medicine, 2016, 83, 487.2-488.	0.6	0
2630	CONTEMPORARY PREVENTION AREAS OF DIABETES AND ITS COMPLICATIONS: THE ROLE OF THE FAMILY PHYSICIAN. Problemi Endokrinnoi Patologii, 2016, 57, 60-68.	0.0	0
2632	Experience of Treatment with Noliprel in Hypertensive Patients with Type 2 Diabetes in Ukraine (Research Review). Hypertension, 2016, .	0.2	0
2633	Control of cardiovascular risk in patients with diabetes. Systemic Hypertension, 2016, 13, 42-47.	0.1	2
2634	Hope for primary cardiovascular prevention with the HOPE (Heart Outcomes Prevention Evaluation)-3 trial findings. Global Cardiology Science & Practice, 2016, 2016, e201613.	0.3	0
2636	What should the blood pressure treatment goal be in adults with hypertension in 2016?. Annals of Translational Medicine, 2016, 4, 464-464.	0.7	1
2637	Coronary Artery Disease and Cardiomyopathy. , 2017, , 1-21.		0
2638	Coronary Artery Disease and Cardiomyopathy. , 2017, , 637-657.		0
2639	Diabetes in Older Adults. , 2017, , 1-18.		0
2640	Hypertension in Older Adolescents and Young Adults. , 2017, , 1-12.		0
2642	Controlling Systolic Blood Pressure below 140 mm Hg in Most Hypertensive Patients matches Systolic Blood Pressure Intervention Trial Intensive Treatment: Practical Implications for Patient Care. Hypertension Journal, 2017, 3, 12-19.	0.1	0
2643	Antihypertonika. , 2017, , 335-351.		0
2644	Blood Pressure Targets: Will We Reach Definite Figures? I Currently Have Mine. Arquivos Brasileiros De Cardiologia, 2017, 109, 1-4.	0.3	94
2646	Ramipril in patients with arterial hypertension as monotherapy or in combination with hydrochlorothiazide. Hypertension, 2017, .	0.2	0
2647	STUDY ON AMBULATORY BLOOD PRESSURE MONITORING IN TYPE 2 DIABETIC PATIENTS WITH HYPERTENSION. Journal of Evidence Based Medicine and Healthcare, 2017, 4, 2507-2510.	0.0	1

#	ARTICLE	IF	CITATIONS
2648	Nierenerkrankungen und Hypertonie in der Neurologie. , 2018, , 1-20.		0
2649	Fall 37: Prävention â€“ 47 Jahre, â™, Prädiabetes, familiär gehäufte Schlaganfälle. , 2018, , 145-148.		0
2650	Hypertension in Older Adolescents and Young Adults. , 2018, , 651-662.		0
2651	Empirical Studies of Effects of High Blood Pressure on Medical Costs and Heart Disease: Is the 2017 ACC/AHA Guideline Supported by Enough Evidence?. Health, 2018, 10, 1498-1519.	0.1	5
2652	Fall 20: Spätschäden â€“ 58 Jahre, â™, DM Typ 1, drohende Dialyse. , 2018, , 75-77.		0
2653	Fall 16: Spätschäden â€“ 70 Jahre, â™, DM Typ 1, Albuminurie und Blutdruckspitzen. , 2018, , 59-61.		0
2654	Diabetes Mellitus and Hypertension. Updates in Hypertension and Cardiovascular Protection, 2018, , 695-704.	0.1	1
2655	Fall 17: Spätschäden â€“ 35 Jahre, â™, DM Typ 1, Bluthochdruck. , 2018, , 63-65.		0
2656	Fall 46: Spätschäden â€“ 59 Jahre, â™, DM Typ 2 seit 11 Jahren, erhöhter HbA1c, Bluthochdruck von 145 mm Hg, Nierenwerte erhöht, drohende Dialyse. , 2018, , 183-185.		0
2657	Nurse Led Interventions in Hypertension. Updates in Hypertension and Cardiovascular Protection, 2018, , 237-252.	0.1	0
2658	Patient with coronary artery disease and hypertension. Srce I Krvni Sudovi, 2018, 37, 35-38.	0.1	0
2659	Fall 53: Zielwerte â€“ 68 Jahre, â™, DM Typ 2, Z. n. Herzinfarkt. , 2018, , 211-215.		0
2660	Choosing the Function of Baseline Run-in Data for Use as a Covariate in the Analysis of Treatment Data from Phase III Clinical Trials in Hypertension. ICSA Book Series in Statistics, 2018, , 19-74.	0.0	0
2661	Hypertension and Diabetes. Endocrinology, 2018, , 109-130.	0.1	0
2662	Does High Systolic Blood Pressure Truly Increase Medical Expenditure?â€”An Empirical Analysis of the New 2017 ACC/AHA Hypertension Guideline. Health, 2018, 10, 1044-1065.	0.1	6
2663	The new guidelines of high blood pressure substantially increase prevalence of hypertension in Argentina. International Journal of Family & Community Medicine, 2018, 2, .	0.1	0
2664	Guidelines that are just for guidance. Annals of Clinical Hypertension, 0, , 031-037.	0.7	0
2667	Blood pressure level and arterial stiffness parameters role in prediction of the antihypertensive therapy efficacy escape phenomenon. Systemic Hypertension, 2018, 15, 49-54.	0.1	0

#	ARTICLE	IF	CITATIONS
2668	Cardiovascular risk reduction: Past, present and future in Mexico. <i>Annals of Clinical Hypertension</i> , 0, 038-047.	0.7	2
2669	Diabetes mellitus and cerebral stroke: a modern look at the problem. <i>MÄ¼narodnij EndokrinologÄ½niji Ä½urnal</i> , 2018, 14, 298-309.	0.1	1
2670	Nonproliferative Diabetic Retinopathy. , 2019, , 21-95.		0
2671	Target of Blood Pressure Lowering for Prevention of Cerebrovascular and Cardiovascular Diseases. <i>Health Evaluation and Promotion</i> , 2018, 45, 635-640.	0.0	0
2672	Update on Management of Type 2 Diabetes for Cardiologists. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 14, 273.	0.5	7
2673	Microvascular Damage and Hemodynamic Alterations in Diabetic Nephropathy. , 2019, , 255-276.		0
2674	Blood Pressure and Cardiovascular Disease in theÄ½lderly. <i>Current Topics in Environmental Health and Preventive Medicine</i> , 2019, , 107-119.	0.1	0
2675	Stroke in theÄ½lderly Population. <i>Current Topics in Environmental Health and Preventive Medicine</i> , 2019, , 121-135.	0.1	0
2676	History of Prehypertension: Past and Present, a Saga of Misunderstanding and Neglect. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 17-26.	0.1	0
2677	Hypertension and Diabetes. <i>Endocrinology</i> , 2019, , 1-22.	0.1	0
2678	Commonly Asked Questions. , 2019, , 307-326.		0
2679	An Analysis of the Effects of Blood Pressure and Antihypertensive Drugs on Heart Disease. <i>Health</i> , 2019, 11, 792-816.	0.1	4
2680	Complications cardiovasculaires macro-angiopathiques et insuffisance cardiaque chez le diabÄ½otique. , 2019, , 377-390.		0
2681	Diabetes and Cardiovascular Disease. , 2019, , 709-730.		1
2682	Hypertension in Elderly ä½ Pathogenesis and Treatment. <i>Hypertension Journal</i> , 2019, 5, 109-116.	0.1	0
2683	ThÄ½rapeutique des dÄ½ordres associÄ½s. , 2019, , 253-267.		0
2684	Diabetic Kidney Disease. , 2019, , 15-25.		0
2686	A STUDY OF CLINICAL, METABOLIC AND ANTHROPOMETRIC PROFILE AND POSSIBLE ETIOLOGICAL FACTORS AMONG NEWLY DETECTED TYPE 2 DM IN NORTH KERALA. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2019, 8, 907-914.	0.1	1

#	ARTICLE	IF	CITATIONS
2687	Blood pressure: at what level is treatment worthwhile?. Australian Prescriber, 2019, 42, 127.	0.5	2
2688	Effect of Intensive Blood Pressure Control on Carotid Morphology and Hemodynamics in Chinese Patients with Hyperhomocysteinemia-Type Hypertension and High Risk of Stroke. Medical Science Monitor, 2019, 25, 5717-5726.	0.5	1
2691	Current features of management of comorbid patients with hypertension. Medical Alphabet, 2019, 2, 6-11.	0.0	2
2692	Diabetic Kidney Disease. , 2020, , 33-43.		0
2694	Tratamiento de la hipertensi3n arterial en octogenarios con demencia seg4n ESC/ESH-2018: seguimiento a 3 a4os. Medicina Cl4nica, 2020, 154, 301-304.	0.3	0
2695	What are the blood pressure targets for patients with chronic kidney disease?. Vnitri Lekarstvi, 2020, 66, 200-204.	0.1	0
2696	Type 2 diabetes: basic clinical and laboratory parameters and risk of cardiovascular death. Russian Journal of Cardiology, 2020, 25, 3822.	0.4	2
2697	Significant Neurological Study for Lifestyle Related Diseases Worldwide From Now. , 2020, 1, 50-54.		2
2698	Exercise based assessment of cardiac autonomic function in type 1 versus type 2 diabetes mellitus. Cardiology Journal, 2020, , .	0.5	1
2701	The Peculiarity of Process and Treatment of Arterial Hypertension in Patients with Type 2 Diabetes Mellitus. Rational Pharmacotherapy in Cardiology, 2020, 16, 623-634.	0.3	1
2702	Risk-Based Intensive Blood Pressure Lowering and Prevention of Heart Failure: A SPRINT Post Hoc Analysis. Hypertension, 2021, 78, 1742-1749.	1.3	7
2703	The diastolic blood pressure J-curve revisited: An update. American Heart Journal Plus, 2021, 12, 100065.	0.3	1
2704	Primary Hypertension. , 2020, , 125-133.		0
2705	Blood Pressure and Hypertension Management. Contemporary Cardiology, 2021, , 201-225.	0.0	1
2706	Diabetic Kidney Disease and Cardiovascular Disease. , 2021, , 31-45.		0
2707	Prevention of Heart Failure. Contemporary Cardiology, 2021, , 489-512.	0.0	1
2708	Prevention of Ischemic Stroke. Contemporary Cardiology, 2021, , 581-609.	0.0	0
2709	Heart and kidney disease: a4cardiovascular high-risk constellation. Herz, 2021, 46, 206-211.	0.4	0

#	ARTICLE	IF	CITATIONS
2710	Cardiometabolic: Reducing Risks to Optimize Cardiovascular Disease Outcomes. Contemporary Cardiology, 2021, , 227-248.	0.0	0
2711	Diabetes and cardiovascular disease: inter-relation of risk factors and treatment. Future Journal of Pharmaceutical Sciences, 2020, 6, .	1.1	23
2712	Severity of hypertension as a predictor of initiation of dialysis among study participants with and without diabetes mellitus. Journal of Investigative Medicine, 2021, 69, 724-729.	0.7	1
2713	Metabolic syndrome and kidney disease. , 2022, , 763-777.		0
2714	Association between Blood Pressure and Renal Progression in Korean Adults with Normal Renal Function. Journal of Korean Medical Science, 2020, 35, e312.	1.1	2
2716	Diabetes mellitus and the kidney. , 2020, , 4975-4987.		0
2717	Epidemiology of Hypertension. , 2020, , 67-99.		0
2720	Prevalence and Associated Factors of Diabetic Kidney Disease in Senegalese Patients: A Cross-Sectional Study in Saint-Louis. Open Journal of Nephrology, 2020, 10, 23-33.	0.0	0
2721	Renal Parenchymal Disease. Updates in Hypertension and Cardiovascular Protection, 2020, , 1-19.	0.1	0
2722	Shifting from Pharmacotherapy to Prevention of Hypertension. Cardiovascular Prevention and Pharmacotherapy, 2020, 2, 33.	0.0	1
2723	Hypertension and Diabetes. Endocrinology, 2020, , 109-130.	0.1	0
2724	Medizinische Register im Market Access-Prozess. , 2020, , 361-375.		0
2725	ERKRANKUNGEN DER NIERE. , 2020, , G-1-G14-7.		0
2726	Diabetes in Older Adults. , 2020, , 211-228.		0
2729	Recent Guideline for the Management of Hypertension in Patients with Diabetes. Journal of Korean Diabetes, 2020, 21, 27-35.	0.1	0
2731	Prevalence of hypotension in hypertensive treated patients within the Primary Care setting. The PRESCAP 2010 study. Semergen, 2020, 46, 107-114.	0.2	4
2733	World Kidney Day 2020: Advances in Preventive Nephrology. Annals of the Academy of Medicine, Singapore, 2020, 49, 175-179.	0.2	5
2735	Severe Hypoglycemia and Incident Heart Failure Among Adults With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e955-e962.	1.8	17

#	ARTICLE	IF	CITATIONS
2736	Triglyceride and Glucose Index and Sex Differences in Relation to Major Adverse Cardiovascular Events in Hypertensive Patients Without Diabetes. <i>Frontiers in Endocrinology</i> , 2021, 12, 761397.	1.5	20
2737	Blood Pressure and Cardiovascular Disease in Older Patients With Diabetes: Retrospective Cohort Study. <i>Journal of the American Heart Association</i> , 2021, 10, e020999.	1.6	3
2739	The Impact of Synchronous Telehealth Services With a Digital Platform on Day-by-Day Home Blood Pressure Variability in Patients with Cardiovascular Diseases: Retrospective Cohort Study. <i>Journal of Medical Internet Research</i> , 2022, 24, e22957.	2.1	2
2740	Diabetic Kidney Disease. <i>Nephrology Self-assessment Program: NephSAP</i> , 2020, 19, 110-139.	3.0	1
2741	Management of Diabetes Mellitus in Acute and Chronic Cardiorenal Syndromes. , 2021, , 295-313.		0
2743	Start und Ziele der Blutdrucktherapie. <i>Pharma-Kritik (discontinued)</i> , 2020, 42, .	0.0	0
2745	Hypertension in people with type 2 diabetes: Update on pharmacologic management. <i>Canadian Family Physician</i> , 2011, 57, 997-1002, e347-53.	0.1	37
2746	Appreciating the medical literature: five notable articles in general internal medicine from 2009 and 2010. <i>Open Medicine</i> , 2011, 5, e49-54.	1.5	1
2747	2011 Canadian Hypertension Education Program recommendations: an annual update. <i>Canadian Family Physician</i> , 2011, 57, 1393-7.	0.1	5
2748	Hypertension control in patients with diabetes. <i>Canadian Family Physician</i> , 2012, 58, 31-3.	0.1	1
2749	Diabetes: treating hypertension. <i>Clinical Evidence</i> , 2012, 2012, .	0.2	0
2750	Hypertension revisited. <i>Canadian Family Physician</i> , 2012, 58, 634-6.	0.1	0
2751	What should the optimal blood pressure goal be in patients with diabetes mellitus or chronic kidney disease?. <i>Archives of Medical Science</i> , 2012, 8, 399-402.	0.4	14
2752	Treatment of systemic hypertension. <i>American Journal of Cardiovascular Disease</i> , 2012, 2, 160-70.	0.5	16
2753	Uncertainty about the systolic blood pressure target in people with diabetes. <i>Canadian Family Physician</i> , 2013, 59, 128-31.	0.1	1
2754	The case for intervention bias in the practice of medicine. <i>Yale Journal of Biology and Medicine</i> , 2013, 86, 271-80.	0.2	25
2756	Management of Diabetic Nephropathy in the Elderly: Special Considerations. <i>Journal of Nephrology & Therapeutics</i> , 2012, 2, .	0.1	1
2757	Hypertension in the elderly: new blood pressure targets and prescribing tips. <i>Canadian Family Physician</i> , 2014, 60, 453-6.	0.1	1

#	ARTICLE	IF	CITATIONS
2758	Hypertension and chronic kidney disease: controversies in pathogenesis and treatment. <i>Minerva Urologica e Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2013, 65, 37-50.	3.9	14
2759	Diabetes: treating hypertension. <i>Clinical Evidence</i> , 2014, 2014, .	0.2	0
2760	Diabetic nephropathy for the primary care provider: new understandings on early detection and treatment. <i>Ochsner Journal</i> , 2014, 14, 369-79.	0.5	17
2761	Attainment of multifactorial treatment targets among the elderly in a lipid clinic. <i>Journal of Geriatric Cardiology</i> , 2015, 12, 239-45.	0.2	4
2762	Early and sustained blood pressure control is necessary for stroke prevention. <i>Journal of Thoracic Disease</i> , 2015, 7, 1070-3.	0.6	0
2763	Experts Provide a Glimpse of the New Post-SPRINT Era of Hypertension. <i>P and T</i> , 2017, 42, 118-123.	1.0	1
2764	ADDRESSING HYPERTENSION IN THE PATIENT WITH TYPE 2 DIABETES MELLITUS: PATHOGENESIS, GOALS, AND THERAPEUTIC APPROACH. <i>European Medical Journal Diabetes</i> , 2017, 5, 84-92.	4.0	10
2765	Evidence-based blood pressure reducing actions of electroacupuncture: mechanisms and clinical application. <i>Acta Physiologica Sinica</i> , 2017, 69, 587-597.	0.5	4
2766	Older Age, Polypharmacy, and Low Systolic Blood Pressure Are Associated With More Hypotension-Related Adverse Events in Patients With Type 2 Diabetes Treated With Antihypertensives. <i>Frontiers in Pharmacology</i> , 2021, 12, 728911.	1.6	0
2767	The Impact of Cognitive Function on the Effectiveness and Safety of Intensive Blood Pressure Control for Patients With Hypertension: A post-hoc Analysis of SPRINT. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 777250.	1.1	2
2768	Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial. <i>Diabetes Care</i> , 2022, 45, 241-250.	4.3	6
2769	Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary. <i>Hypertension</i> , 2022, 79, 293-301.	1.3	131
2770	Association of blood pressure and long-term change with chronic kidney disease risk among Chinese adults with different glucose metabolism according to the 2017 ACC/AHA guidelines. <i>Journal of Clinical Hypertension</i> , 2021, , .	1.0	2
2771	The Complement Pathway: New Insights into Immunometabolic Signaling in Diabetic Kidney Disease. <i>Antioxidants and Redox Signaling</i> , 2022, 37, 781-801.	2.5	12
2772	Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. <i>Advances in Therapy</i> , 2022, 39, 148-164.	1.3	41
2773	Association between blood pressure and the risk of chronic kidney disease in treatment-naïve hypertensive patients. <i>Kidney Research and Clinical Practice</i> , 2022, 41, 31-42.	0.9	15
2774	Is the KDIGO Systolic Blood Pressure Target $\leq 120\text{ mmHg}$ for Chronic Kidney Disease Appropriate in Routine Clinical Practice?. <i>Hypertension</i> , 2022, 79, 4-11.	1.3	24
2775	Evaluation of Intensive vs Standard Blood Pressure Reduction and Association With Cognitive Decline and Dementia. <i>JAMA Network Open</i> , 2021, 4, e2134553.	2.8	13

#	ARTICLE	IF	CITATIONS
2776	PrÄvention der diabetischen Nephropathie: Was ist praktisch machbar?. , 0, , .		0
2777	Diabetic Nephropathy and Diabetic Kidney Disease. <i>Journal of Diabetes Mellitus</i> , 2021, 11, 359-377.	0.1	3
2778	Hypertension Management in Patients with Chronic Kidney Disease in the Post-SPRINT Era. <i>Electrolyte and Blood Pressure</i> , 2021, 19, 19.	0.6	4
2781	Update on the pathophysiology and medical treatment of peripheral artery disease. <i>Nature Reviews Cardiology</i> , 2022, 19, 456-474.	6.1	64
2782	Ð Ñ–Ð»ÑŒÐ³⁄₄Ð²Ð, Ð¹ ÑŒÑ–Ð²ÐµÐ¹⁄₂ÑŒ ÐÐç Ð₂ÑŒÐ, Ñ†ÑŒfÐ°ÑŒÐ³⁄₄Ð²Ð³⁄₄Ð¹⁄₄ÑŒf ÐÑ–Ð°Ð±ÐµÑŒ,Ñ– 2Â–Ð³Ð³⁄₄ÑŒ,Ð₂ÑŒfÐ³⁄₄ÑŒ†Ñ–		
2783	Ð–Ð°ÑŒÐ¹⁄₂Ð³⁄₄Ð²Ð°Ð¹⁄₂Ñ– Ð¹⁄₂Ð° Ð³⁄₄Ð°Ð°Ð°Ð°ÑŒ... ÑŒÐµÐ°Ð³⁄₄Ð¹⁄₄ÐµÐ¹⁄₂Ð°ÑŒ†Ñ–Ñ– 2014 ÑŒÐ³⁄₄Ð°ÑŒf Ð· Ð°ÑŒ–Ð°ÑŒfÐ²Ð°Ð¹⁄₂Ð°		
2784	Akutes Koronarsyndrom: Wie geht es nach der Akutphase weiter?. , 0, , .		0
2786	Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021. <i>Kidney International Reports</i> , 2022, 7, 681-687.	0.4	10
2787	KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD. <i>American Journal of Kidney Diseases</i> , 2022, 79, 311-327.	2.1	21
2788	Application of ensemble machine learning algorithms on lifestyle factors and wearables for cardiovascular risk prediction. <i>Scientific Reports</i> , 2022, 12, 1033.	1.6	19
2789	Hypertension and Diabetes. , 2022, , 263-291.		2
2790	Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021. <i>BMC Nephrology</i> , 2022, 23, 9.	0.8	32
2792	Comparing mean and single automated office blood pressure measurement in a US ambulatory care setting. <i>Primary Health Care</i> , 2022, 32, 28-33.	0.0	0
2793	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2022, 145, CIR0000000000001040.	1.6	193
2794	Stage 1 hypertension and risk of cardiovascular disease mortality in United States adults with or without diabetes. <i>Journal of Hypertension</i> , 2022, 40, 794-803.	0.3	16
2796	Heterogeneity of Treatment Effects for Intensive Blood Pressure Therapy by Individual Components of FRS: An Unsupervised Data-Driven Subgroup Analysis in SPRINT and ACCORD. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 778756.	1.1	1
2797	Update in Hypertension. <i>Medical Clinics of North America</i> , 2022, 106, 259-267.	1.1	1
2798	Achieving target blood pressure levels in patients with hypertension combined with comorbid type 2 diabetes after a standard multimodelity therapy. <i>Bukovinian Medical Herald</i> , 2014, 18, .	0.1	0

#	ARTICLE	IF	CITATIONS
2799	Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Systolic Blood Pressure Lowering on the Risk of Stroke. <i>Hypertension</i> , 2022, 79, 785-793.	1.3	8
2800	Hypotension as a marker or mediator of perioperative organ injury: a narrative review. <i>British Journal of Anaesthesia</i> , 2022, 128, 915-930.	1.5	17
2802	Measurement of Blood Pressure in Chronic Kidney Disease: Time to Change Our Clinical Practice - A Comprehensive Review. <i>International Journal of Nephrology and Renovascular Disease</i> , 2022, Volume 15, 1-16.	0.8	3
2803	Methodological Aspects of Meta-Analyses Assessing the Effect of Blood Pressureâ€“Lowering Treatment on Clinical Outcomes. <i>Hypertension</i> , 2022, 79, 491-504.	1.3	11
2804	Is the contemporary care of the older persons with acute coronary syndrome evidence-based?. <i>European Heart Journal Open</i> , 2022, 2, .	0.9	13
2805	10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€”2022</i>. <i>Diabetes Care</i> , 2022, 45, S144-S174.	4.3	282
2806	11. Chronic Kidney Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€”2022</i>. <i>Diabetes Care</i> , 2022, 45, S175-S184.	4.3	168
2807	Sex Differences in Myocardial and Vascular Aging. <i>Circulation Research</i> , 2022, 130, 566-577.	2.0	53
2808	Open-Angle Glaucomatous Optic Neuropathy Is Related to Dips Rather Than Increases in the Mean Arterial Pressure Over 24-H. <i>American Journal of Hypertension</i> , 2022, 35, 703-714.	1.0	5
2809	The apathy, gait impairment, and executive dysfunction (AGED) triad vascular variant. <i>Alzheimer's and Dementia</i> , 2022, 18, 1662-1666.	0.4	5
2810	New Trends in the Diagnosis and Management of Hypertension. <i>Cureus</i> , 2022, 14, e22393.	0.2	2
2812	Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 181-197.	1.8	48
2813	Sex Differences in the Prevalence, Outcomes and Management of Hypertension. <i>Current Hypertension Reports</i> , 2022, 24, 185-192.	1.5	48
2814	Improving outcomes for older hypertensive patients: is more intensive treatment better?. <i>Expert Review of Cardiovascular Therapy</i> , 2022, , 1-13.	0.6	0
2815	STEP to blood pressure management of elderly hypertension: evidence from Asia. <i>Hypertension Research</i> , 2022, 45, 576-582.	1.5	13
2816	Diabetic kidney disease and risk of incident stroke among adults with type 2 diabetes. <i>BMC Medicine</i> , 2022, 20, 127.	2.3	11
2817	The debate over the optimal blood pressure treatment target of less than 130/80 mmHg. <i>Postgraduate Medicine</i> , 2023, 135, 208-213.	0.9	1
2818	Comparison between the world health organization (WHO) and international society of hypertension (ISH) guidelines for hypertension. <i>Annals of Medicine</i> , 2022, 54, 837-845.	1.5	10

#	ARTICLE	IF	CITATIONS
2819	Intensive Blood Pressure Treatment Goals: evidence for cardiovascular protection from observational studies and clinical trials. <i>American Journal of Hypertension</i> , 2022, , .	1.0	0
2820	Long-Term Secondary Prevention: Management of Blood Pressure After a Transient Ischemic Attack or Stroke. <i>Stroke</i> , 2022, 53, 1085-1103.	1.0	6
2821	Prognostic Value of Time in Blood Pressure Target Range Among Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 369-379.	1.9	8
2822	International Guidelines for Hypertension: Resemblance, Divergence and Inconsistencies. <i>Journal of Clinical Medicine</i> , 2022, 11, 1975.	1.0	3
2823	Blood Pressure and Stroke: A Review of Sex- and Ethnic/Racial-Specific Attributes to the Epidemiology, Pathophysiology, and Management of Raised Blood Pressure. <i>Stroke</i> , 2022, 53, 1114-1133.	1.0	13
2824	Benefits of more intensive versus less intensive blood pressure control. Updated trial sequential analysis. <i>European Journal of Internal Medicine</i> , 2022, 101, 49-55.	1.0	9
2825	Demographic and Regional Trends of Mortality in Patients With Aortic Dissection in the United States, 1999 to 2019. <i>Journal of the American Heart Association</i> , 2022, 11, e024533.	1.6	7
2826	Establishing target systolic and diastolic blood pressure in diabetic patients with hypertension: what do we need to consider?. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 993-1003.	0.6	0
2827	Mitochondrial dynamics and diabetic kidney disease: Missing pieces for the puzzle of therapeutic approaches. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 249-273.	1.6	9
2828	Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. <i>New England Journal of Medicine</i> , 2021, 385, 2588-2591.	13.9	4
2829	Association between DBP and major adverse cardiovascular events in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. <i>Journal of Hypertension</i> , 2022, 40, 692-698.	0.3	1
2830	Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts. <i>Nefrologia</i> , 2022, 42, 519-530.	0.2	1
2831	Teaching reproducible research for medical students and postgraduate pharmaceutical scientists. <i>BMC Research Notes</i> , 2021, 14, 445.	0.6	0
2832	Determinants of blood glucose control among people with Type 2 diabetes in a regional hospital in Ghana. <i>PLoS ONE</i> , 2021, 16, e0261455.	1.1	5
2833	SPRINT Revisited: Updated Results and Implications. <i>Hypertension</i> , 2021, 78, 1701-1710.	1.3	9
2834	Cardiovascular risk prevention in clinical medicine: current guidelines in the United States and in Europe. , 2022, , 471-490.		0
2837	Personalizing Medicine. , 2022, , 37-59.		0
2838	Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. <i>Revista Española De Cardiología</i> , 2022, 75, 429.e1-429.e104.	0.6	27

#	ARTICLE	IF	CITATIONS
2839	Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE. <i>International Journal of Cardiology</i> , 2022, 358, 103-109.	0.8	2
2845	Factors associated with blood pressure control in diabetic patients treated in nephrology units. PRESIDIAB Study. <i>Nefrologia</i> , 2011, 31, 313-21.	0.2	5
2846	Older Age, Polypharmacy, and Low Systolic Blood Pressure Are Associated With More Hypotension-Related Adverse Events in Patients With Type 2 Diabetes Treated With Antihypertensives. <i>Frontiers in Pharmacology</i> , 2021, 12, 728911.	1.6	4
2849	Macrovascular Complications. <i>Primary Care - Clinics in Office Practice</i> , 2022, 49, 255-273.	0.7	2
2850	2021 Taiwan Stroke Society Guidelines of blood pressure control for ischemic stroke prevention. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 651-664.	0.6	6
2851	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. <i>Circulation</i> , 2022, 145, 1581-1591.	1.6	13
2852	Time to Clinical Benefit of Intensive Blood Pressure Lowering in Patients 60 Years and Older With Hypertension. <i>JAMA Internal Medicine</i> , 2022, 182, 660.	2.6	26
2853	review on epidemiology, biochemical characteristics, treatment suggestions, and continued studies on diabetes and cardiovascular disease. <i>International Journal of Health Sciences</i> , 0, , 5288-5311.	0.0	1
2854	Antihypertensive therapies. , 2013, , 224-271.		0
2855	Which therapy for which condition?. , 2013, , 463-541.		1
2856	On-Treatment Diastolic Blood Pressure: When Is It Too High?. <i>Korean Circulation Journal</i> , 2022, 52, 475.	0.7	0
2858	Controversies in Hypertension II: The Optimal Target Blood Pressure. <i>American Journal of Medicine</i> , 2022, 135, 1168-1177.e3.	0.6	2
2859	Hypertension and the kidneys. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2022, 83, 1-11.	0.2	8
2860	Potential Impact of 2017 American College of Cardiology/American Heart Association Hypertension Guideline on Contemporary Practice: A Cross-sectional Analysis From NCDR PINNACLE Registry. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	2
2864	Clinical benefit of systolic blood pressure within the target range among patients with or without diabetes mellitus: a propensity score-matched analysis of two randomized clinical trials. <i>BMC Medicine</i> , 2022, 20, .	2.3	2
2865	The Causal Effect of Systolic Blood Pressure Lowering on Vascular Outcomes in Diabetes: A Mendelian Randomization Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2616-2625.	1.8	7
2866	Identifying Distinct Risk Thresholds of Glycated Hemoglobin and Systolic Blood Pressure for Rapid Albuminuria Progression in Type 2 Diabetes From NHANES (1999-2018). <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
2867	Kidney function deterioration is dependent on blood pressure levels: 11.2-year follow-up in diabetic patients. <i>Heart and Vessels</i> , 2022, 37, 1873-1881.	0.5	1

#	ARTICLE	IF	CITATIONS
2868	Does intensive blood pressure control benefit type B aortic dissection patients who undergoing surgical repair?. <i>Perfusion (United Kingdom)</i> , 2023, 38, 1260-1267.	0.5	1
2869	Conservative versus aggressive blood pressure reduction: Do we have a winner?. <i>European Journal of Internal Medicine</i> , 2022, 101, 39-40.	1.0	0
2870	Glucose-lowering drug use, glycemic outcomes, and severe hypoglycemia: 18-Year trends in 9 million adults with Diabetes in Hong Kong (2002-2019). <i>The Lancet Regional Health - Western Pacific</i> , 2022, 26, 100509.	1.3	12
2871	Cardiometabolic: Newer Pharmacologic Strategies for Reducing Cardiovascular Disease Risks. <i>Canadian Journal of Physiology and Pharmacology</i> , 0, , .	0.7	0
2872	Target Blood Pressure and Combination Therapy: Focus on Angiotensin Receptor Blockers Combination with either Calcium Channel Blockers or Beta Blockers. <i>Current Hypertension Reviews</i> , 2022, 18, .	0.5	0
2873	The 2021-2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	3
2874	Management of CKD. <i>Nephrology Self-assessment Program: NephSAP</i> , 2022, 21, 146-167.	3.0	0
2876	Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors. <i>Kidney Research and Clinical Practice</i> , 2022, 41, 682-698.	0.9	4
2877	Care Endpoints in Adults With Type 2 Diabetes: Screening and Therapeutic Targets at a Canadian Tertiary Diabetes Care Centre. <i>Canadian Journal of Diabetes</i> , 2023, 47, 31-37.e2.	0.4	1
2878	Control of Blood Pressure and Risk of Cardiovascular Disease and Mortality in Elderly Chinese: A Real-World Prospective Cohort Study. <i>Hypertension</i> , 2022, 79, 1866-1875.	1.3	3
2879	Isolated Diastolic Hypertension and Risk of Cardiovascular Disease: Controversies in Hypertension - Pro Side of the Argument. <i>Hypertension</i> , 2022, 79, 1563-1570.	1.3	9
2881	Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 645-654.	5.5	33
2882	Quality of care and prescription patterns among patients with diabetic kidney disease—a large-scale cohort study from Taiwanese clinics. <i>PeerJ</i> , 0, 10, e13636.	0.9	2
2883	Glycemic status and the association of change in blood pressure with incident cardiovascular disease. <i>American Heart Journal</i> , 2022, 254, 48-56.	1.2	2
2884	Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy. <i>Drugs</i> , 2022, 82, 1165-1177.	4.9	5
2885	Control and complications of diabetes in urban primary care units in Thailand: a cross-sectional study. , 2022, 23, .		0
2886	Maximum home blood pressure and cardiovascular outcomes in patients with type 2 diabetes: KAMOGAWA-HBP study. <i>Journal of Hypertension</i> , 0, Publish Ahead of Print, .	0.3	1
2887	Revisiting ACCORD: Should blood pressure targets in people with and without type 2 diabetes be different?. <i>American Journal of Medicine</i> , 2022, , .	0.6	0

#	ARTICLE	IF	CITATIONS
2888	Integrating Health Data-Driven Machine Learning Algorithms to Evaluate Risk Factors of Early Stage Hypertension at Different Levels of HDL and LDL Cholesterol. <i>Diagnostics</i> , 2022, 12, 1965.	1.3	6
2889	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. <i>Endocrine Practice</i> , 2022, 28, 923-1049.	1.1	146
2890	Clinical implications of central blood pressure measured by radial tonometry and automated office blood pressure measured using automatic devices in cardiovascular diseases. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
2891	Relationship between orthostatic blood pressure changes and intensive blood pressure management in patients with hypertension. <i>Heart</i> , 2023, 109, 111-118.	1.2	1
2892	Intensive vs. conventional blood pressure goals in older patients with type 2 diabetes: a systematic review and meta-analysis. <i>Endocrine</i> , 0, , .	1.1	0
2894	Joint effect of visit-to-visit variability in LDL-cholesterol, HDL-cholesterol and HbA1c on cardiovascular and total mortality in patients with diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	1
2895	Effect of intensive blood pressure control on cardiovascular mortality in patients with type 2 diabetes: a meta-analysis. <i>Endokrynologia</i> , 2022, 53, 101-107.	1.1	0
2896	Association of an Automated Blood Pressure Measurement Quality Improvement Program With Terminal Digit Preference and Recorded Mean Blood Pressure in 11 Clinics. <i>JAMA Network Open</i> , 2022, 5, e2229098.	2.8	4
2898	Blood Pressure Target in Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 667-674.	1.8	8
2899	Examining the Linear Association Between Blood Pressure Levels and Cardiovascular Diseases in the Absence of Major Risk Factors in China. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, .	0.9	3
2900	Considerations for Optimal Blood Pressure Target of Hypertension. , 0, Publish Ahead of Print, .		1
2901	Day-by-Day Home Blood Pressure Monitoring as a Biomarker in Diabetes. <i>Biomarkers in Disease</i> , 2023, , 705-727.	0.0	0
2902	Diabetic kidney disease treatment: new perspectives. <i>Kidney Research and Clinical Practice</i> , 2022, 41, S63-S73.	0.9	8
2903	Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, .	0.9	5
2905	Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study. <i>Nature Medicine</i> , 2022, 28, 2056-2065.	15.2	29
2906	Influence of Baseline Diastolic Blood Pressure on the Effects of Systolic Blood Pressure Lowering on Cognitive Function in Type 2 Diabetes Mellitus. <i>American Journal of Hypertension</i> , 2023, 36, 120-125.	1.0	1
2907	Heart diseases, hypertension and effects of antihypertensive medications: Is hypertension a true risk factor of heart diseases?. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
2908	Systolic Blood Pressure Time in Target Range and Major Adverse Kidney and Cardiovascular Events. <i>Hypertension</i> , 2023, 80, 305-313.	1.3	11

#	ARTICLE	IF	CITATIONS
2910	Blood Pressure Control Targets and Risk of Cardiovascular and Cerebrovascular Events After Intracerebral Hemorrhage. <i>Stroke</i> , 2023, 54, 78-86.	1.0	3
2911	Cardiac autonomic dysfunction and risk of incident stroke among adults with type 2 diabetes. <i>European Stroke Journal</i> , 2023, 8, 275-282.	2.7	3
2913	Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials. <i>The Lancet Digital Health</i> , 2022, 4, e796-e805.	5.9	17
2914	Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes. <i>Biochemical Pharmacology</i> , 2022, 206, 115304.	2.0	5
2915	Editorâ€™s Pick: Addressing Hypertension in the Patient with Type 2 Diabetes Mellitus: Pathogenesis, Goals, and Therapeutic Approach. <i>European Medical Journal Diabetes</i> , 0, , 84-92.	4.0	1
2916	Feasibility of Precision Medicine in Hypertension Managementâ€™Scope and Technological Aspects. <i>Journal of Personalized Medicine</i> , 2022, 12, 1861.	1.1	3
2917	Hypertension Across a Womanâ€™s Life Cycle. <i>Current Hypertension Reports</i> , 2022, 24, 723-733.	1.5	8
2918	Treatment of Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 1849.	3.8	77
2919	Hypertension management in patients with cardiovascular comorbidities. <i>European Heart Journal</i> , 2023, 44, 2066-2077.	1.0	24
2920	Randomized controlled trials of biomarker targets. <i>Clinical Trials</i> , 0, , 174077452211318.	0.7	0
2921	The Global Burden of Cardiovascular Diseases and Risk. <i>Journal of the American College of Cardiology</i> , 2022, 80, 2361-2371.	1.2	348
2922	Effect of Immediate Antihypertensive Treatment on Clinical Outcomes in Acute Ischemic Stroke Patients With Different Renal Function Status. <i>Hypertension</i> , 2023, 80, 204-213.	1.3	0
2923	Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, , .	1.2	3
2925	Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	6
2927	Pharmacotherapy for Essential Hypertension: A Brief Review. <i>Methodist DeBaakey Cardiovascular Journal</i> , 2022, 18, 5-16.	0.5	4
2928	A new approach to the consideration of hypertension in chronic kidney disease through the prism of the last KDIGO guide 2021. <i>Timocki Medicinski Glasnik</i> , 2022, 47, 84-95.	0.0	0
2929	Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. <i>Nature Reviews Endocrinology</i> , 2023, 19, 151-163.	4.3	21
2930	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetesâ€™2023. <i>Diabetes Care</i> , 2023, 46, S158-S190.	4.3	156

#	ARTICLE	IF	CITATIONS
2932	Rationale and design of the Effects of intensive Systolic blood Pressure lowering treatment in reducing Risk of vascular evenTs (ESPRIT): A multicenter open-label randomized controlled trial. American Heart Journal, 2023, 257, 93-102.	1.2	2
2934	Analysis of lifestyle modifications and antihypertensive therapy in patients with arterial hypertension and chronic kidney disease (data from the national registry). Systemic Hypertension, 2022, 19, 39-46.	0.1	0
2935	Associations between visceral adiposity index and incident nephropathy outcomes in diabetic patients: Insights from the ACCORD trial. Diabetes/Metabolism Research and Reviews, 2023, 39, .	1.7	3
2936	Interaction of Blood Pressure and Glycemic Status in Developing Cardiovascular Disease: Analysis of a Nationwide Realâ€World Database. Journal of the American Heart Association, 2023, 12, .	1.6	2
2937	Benefits of intensified reductions in blood glucose and in blood pressure for patients with type 2 diabetes. Presse Medicale, 2023, 52, 104160.	0.8	1
2938	Effects of intensive blood pressure lowering in patients with diabetes: A pooled analysis of the <sc>STEP</sc> and <sc>ACCORDâ€BP</sc> randomized trials. Diabetes, Obesity and Metabolism, 2023, 25, 796-804.	2.2	1
2939	11. Chronic Kidney Disease and Risk Management: <i>Standards of Care in Diabetesâ€™2023</i>. Diabetes Care, 2023, 46, S191-S202.	4.3	97
2940	Blood Pressure-Lowering Treatment and Macrovascular Events. Updates in Hypertension and Cardiovascular Protection, 2023, , 305-326.	0.1	0
2941	Blood Pressure Control in Patients with Diabetic Kidney Disease. Electrolyte and Blood Pressure, 2022, 20, 39.	0.6	0
2942	Long-Term Risk of Cardiovascular Disease Among Type 2 Diabetes Patients According to Average and Visit-to-Visit Variations of HbA1c Levels During the First 3 Years of Diabetes Diagnosis. Journal of Korean Medical Science, 2023, 38, .	1.1	2
2943	Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 1. Contemporary Cardiology, 2023, , 1-65.	0.0	0
2944	Blood Pressure Lowering and Microvascular Complications of Diabetes. Updates in Hypertension and Cardiovascular Protection, 2023, , 327-335.	0.1	0
2945	Blood Pressure Thresholds for Initiation of Drug Treatment: Blood Pressure Targets in Diabetes. Updates in Hypertension and Cardiovascular Protection, 2023, , 377-387.	0.1	0
2946	Hypertension and Type 2 Diabetes. Updates in Hypertension and Cardiovascular Protection, 2023, , 39-56.	0.1	0
2947	How low should blood pressure be in patients with chronic coronary and cerebrovascular diseases. European Journal of Internal Medicine, 2023, , .	1.0	0
2948	Blood pressure in heart failure management and prevention. Hypertension Research, 2023, 46, 817-833.	1.5	15
2949	Time in Target Range: the Future of Assessing Adequacy of Blood Pressure Control?. Hypertension, 2023, 80, 314-315.	1.3	1
2950	Conventional office blood pressure measurements and unattended automated office blood pressure compared with home self-measurement and 24-h ambulatory blood pressure monitoring. Blood Pressure Monitoring, 2023, 28, 59-66.	0.4	1

#	ARTICLE	IF	CITATIONS
2951	Treatment of hypertension in elderly. <i>Journal of Medicine and Life Science</i> , 2022, 19, 79-89.	0.1	0
2952	Efficacy and safety of intensive versus conventional glucose targets in people with type 2 diabetes: a systematic review and meta-analysis. <i>Expert Review of Endocrinology and Metabolism</i> , 2023, 18, 95-110.	1.2	0
2953	Impact of metabolic control on all-cause mortality in a nationwide cohort of patients with diabetes from Colombia. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
2954	Incidence of severe hypokalaemia in patients taking indapamide. <i>Internal and Emergency Medicine</i> , 2023, 18, 549-557.	1.0	2
2955	Intensive BP Control in Patients with CKD and Risk for Adverse Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2023, 34, 385-393.	3.0	7
2956	Trends in obesity prevalence and cardiometabolic risk factor control in US adults with diabetes, 1999â€“2020. <i>Obesity</i> , 2023, 31, 841-851.	1.5	8
2957	Combined effects of blood pressure and glycemic status on risk of heart failure: a population-based study. <i>Journal of Hypertension</i> , 0, Publish Ahead of Print, .	0.3	1
2958	Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts. <i>Nefrologia</i> , 2022, 42, 519-530.	0.2	2
2959	Impact of diabetic status and contribution of office and home blood pressure across diabetic status for cardiovascular disease: the J-HOP study. <i>Hypertension Research</i> , 2023, 46, 1684-1693.	1.5	3
2960	Heart failure and diabetes: Clinical significance and epidemiology of this two-way association. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 3-14.	2.2	4
2961	Diabetes Mellitus and the Kidneys. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2023, 53, 565-580.	0.5	1
2962	A low-salt diet with candesartan administration is associated with acute kidney injury in nephritis by increasing nitric oxide. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114484.	2.5	1
2963	Mean systolic blood pressure above the control threshold in people with treated uncontrolled hypertension: a pooled, cross-sectional analysis of 55 national health surveys. <i>EClinicalMedicine</i> , 2023, 57, 101833.	3.2	0
2964	A Protocol for Developing Chinese Clinical Practice Guidelines of Hypertension. , 0, Publish Ahead of Print, .		0
2965	Hypertension in Chronic Kidney Disease: An Update on Diagnosis and Management. <i>Southern Medical Journal</i> , 2023, 116, 237-244.	0.3	1
2966	Body Position and Orthostatic Hypotension in Hypertensive Adults: Results from the Syst-Eur Trial. <i>Hypertension</i> , 2023, 80, 820-827.	1.3	3
2967	Trends in using of antihypertensive medication among US CKD adults, NHANES 2001â€“2018. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	2
2968	Treating the Diabetic Hypertensive: Consensus and Differences. , 0, , 98-104.		0

#	ARTICLE	IF	CITATIONS
2969	Effects of Intensive Systolic Blood Pressure Lowering on End-Stage Kidney Disease and Kidney Function Decline in Adults With Type 2 Diabetes Mellitus and Cardiovascular Risk Factors: A Post Hoc Analysis of ACCORD-BP and SPRINT. <i>Diabetes Care</i> , 2023, 46, 868-873.	4.3	1
2972	The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension. <i>Clinical Hypertension</i> , 2023, 29, .	0.7	27
2973	Intensive versus standard blood pressure control in older persons with or without diabetes: a systematic review and meta-analysis of randomised controlled trials. <i>Journal of the Royal Society of Medicine</i> , 2023, 116, 133-143.	1.1	5
2974	Systolic blood pressure, low-density lipoprotein cholesterol levels, and adverse kidney outcome: results from KNOW-CKD. <i>Hypertension Research</i> , 2023, 46, 1395-1406.	1.5	2
2975	Longer time in blood pressure target range improves cardiovascular outcomes among patients with Type 2 diabetes: A secondary analysis of a randomized clinical trial. <i>Diabetes Research and Clinical Practice</i> , 2023, 198, 110600.	1.1	2
2976	Randomised controlled trials of antihypertensive therapy: does exclusion of orthostatic hypotension alter treatment effect? A systematic review and meta-analysis. <i>Age and Ageing</i> , 2023, 52, .	0.7	1
2977	Intensive blood pressure control in older patients with hypertensionâ€”a STEP in the right direction?. <i>Postgraduate Medical Journal</i> , 2023, 99, 47-49.	0.9	0
2978	Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. <i>Lancet, The</i> , 2023, 401, 928-938.	6.3	14
2979	Superior stroke prevention with angiotensin receptor blockers compared with other antihypertensive drugs. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 125-131.	1.0	0
2980	Association Between Magnitude of Differential Blood Pressure Reduction and Secondary Stroke Prevention. <i>JAMA Neurology</i> , 2023, 80, 506.	4.5	4
2982	Hypothetical intervention of targeted systolic blood pressure control of ± 120 mmHg on renal prognosis for persons with stage 3â€“4 chronic kidney disease: an application of parametric g-formula using health checkup data in Japan. <i>Clinical and Experimental Nephrology</i> , 0, , .	0.7	0
2983	Development and Progression of Chronic Kidney Disease. , 2018, , 466-475.e1.		0
2984	Pathogenesis, Pathophysiology, and Treatment of Diabetic Nephropathy. , 2018, , 252-265.e1.		0
2985	Evaluation and Management of Hypertension. , 2018, , 616-628.		0
2986	Intrarenal Renin-Angiotensin System Activation Alters Relationship Between Systolic Blood Pressure and Progression of Chronic Kidney Disease. <i>Hypertension</i> , 2023, 80, 1024-1034.	1.3	1
2987	Blood Pressure in CKD. , 2023, , 115-129.		0
2988	Machine-learning-based high-benefit approach versus conventional high-risk approach in blood pressure management. <i>International Journal of Epidemiology</i> , 2023, 52, 1243-1256.	0.9	3
2989	Diabetic Kidney Disease. <i>Medical Clinics of North America</i> , 2023, 107, 689-705.	1.1	12

#	ARTICLE	IF	CITATIONS
2990	Prevention of Cardiovascular Events in Patients With Chronic Kidney Disease. <i>Annals of Pharmacotherapy</i> , 0, , 106002802311657.	0.9	2
2991	Chronic Kidney Disease Management in Developing Countries. , 2023, , 1-146.		0
2992	Intensive blood pressure control for patients aged over 60: A meta-analysis of the SPRINT, STEP, and ACCORD BP randomized controlled trials. <i>Maturitas</i> , 2023, 172, 52-59.	1.0	0
3000	Recent understandings about hypertension management in type 2 diabetes: What are the roles of SGLT2 inhibitor, GLP-1 receptor agonist, and finerenone?. <i>Hypertension Research</i> , 2023, 46, 1892-1899.	1.5	4
3002	Managing Stable Coronary Artery Disease in Diabetes. <i>Contemporary Cardiology</i> , 2023, , 655-681.	0.0	0
3005	Diabetes and Cardiovascular Disease. , 2023, , 813-835.		0
3006	Diabetes and Hypertension. , 2023, , 627-643.		0
3011	Adjunct Drug Treatment to Reduce Vascular Disease in People with Diabetes. <i>Contemporary Diabetes</i> , 2023, , 779-819.	0.0	0
3027	Tight Control of Diabetes in Adult Patients (ACCORD)-2008. , 2023, , 83-86.		0
3028	Diabetes and Cerebrovascular Disease. <i>Contemporary Cardiology</i> , 2023, , 551-576.	0.0	0
3047	Hypertension in diabetes. <i>Pediatric Nephrology</i> , 0, , .	0.9	0
3056	Diabetes Mellitus:. , 2024, , 439-455.		0
3073	Diabetic Kidney Disease: Increasing Hope with Transformative Therapies. , 2023, , 41-53.		0
3110	Treating Hypertension Complicated with Heart Failure: Going Beyond the Numbers. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 339-355.	0.1	0
3112	Age-related disease: Kidneys. , 2024, , 91-117.		0
3117	Multimodale kardiovaskuläre Prävention. <i>Springer Reference Medizin</i> , 2023, , 1-13.	0.0	0